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Abstract  
Streptococcus pneumoniae is a major cause of morbidity and mortality in HIV infected 
individuals. Mortality rates remain high despite modern antibiotics, therefore, successful 
vaccination is key to preventing infection. Vaccination strategies against pneumococcus 
include a pure polysaccharide vaccine, Pneumovax® (PPV-23), and a polysaccharide-
conjugate vaccine, Prevenar-13 ®(PCV-13). PCV-13 is given as part of three vaccine series in 
infants but is currently recommended only as a single vaccine in adults. The evidence base 
for either vaccine in adults is limited and guidelines vary. In 2009, national guidelines 
recommended PPV-23 vaccination but a PCV-13+PPV-23 schedule is now recommended 
(BHIVA, 2008 & 2015). 
The Assessment of Immune Responses to Routine Immunisations (AIR) is an observational study 
that has examined the immune response to UK recommended vaccinations in adults with 
HIV.  Firstly, the AIR study went on to examine the impact of HIV-infection on 
pneumococcal vaccination with PPV-23, as assessed by pre- and post- vaccine IgG 
antibodies against 12 pneumococcal (Pn) serotypes (Pn 1, 3, 4, 5, 6B, 7F, 9V, 14,18C, 19A, 19F, 
and 23F at the WHO (World Health Organization) protective threshold 0.35µg/mL in  ≥ 
8/12 serotypes threshold using a 19-plex Luminex-based assay. HIV-infected patients 
responded poorly to a single dose of PPV-23 compared to HIV-negative controls.  
AIR then established that PCV-13 could increase the percentage of patients that reach WHO 
protective thresholds compared to a single dose of PPV-23 and that immune responses to 
PCV-13 could be maintained for a longer period compared to PPV-23. Response rates could 
be further improved by booster doses of PCV-13.  
Low antigen-specific IgG concentrations are associated with impaired opsonophagocytic 
killing against pneumococcus, thus a novel opsonophagocytic assay was developed in order 
to further understand the relationship between the quantity and opsonic functionality of Pn-
specific antibody.   
Furthermore, assessing responses to pneumococcal vaccination is important in determining 
immunogenicity. Thus, this thesis also explored the whole vaccine and serotype IgG 
subclass (IgG1-IgG4) response to PPV-23 and PCV-13 by developing novel Pn-specific IgG 
subclass assays. Lastly, HIV-infection is characterised by a dysregulated humoral system, 
therefore, we have examined the impact on different B cell populations at baseline and 
relationships with total and Pn- specific antibody post-vaccination with PCV-13 are 
described.  
In summary, this study aimed to examine the impact of HIV-infection on pneumococcal 
vaccination by investigating the quantity and quality of the Pn-specific IgG response, IgG 
subclass responses, and the effects of a dysfunctional humoral system on total and Pn-
specific antibody.  Findings would be informative in developing vaccination strategies in 
HIV-infected adults in the UK.  
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Chapter 1. Introduction 
1.1 Overview 
The overview of this report is the investigation of the immune response to pneumococcal 
vaccination in the context of HIV-infection. Pneumococcal (Pn)-specific opsonic antibody is 
essential for effective phagocytosis and bacterial killing. The quantity and quality of specific 
Pn-antibody required for immunity to pneumococcus in HIV-infected adults is investigated. 
Thus, this report will primarily focus on B-cell responses to pneumococcal vaccination as 
dysregulation of the humoral immune system is characterised in HIV-infection.  This 
chapter will discuss Streptococcus pneumoniae and the epidemiology of pneumococcal 
infections, particularly in HIV-infected individuals. The virulence factors of S. pneumoniae  
and the host immune response to these factors will be investigated.  Pneumococcal 
treatment and vaccine options will also be discussed. Furthermore, a section on HIV 
immunology including CD4 counts, viral loads, and antiretroviral (ARV) treatment will be 
presented. The AIR (Assessment of Immune Responses to Routine Immunisation) study will 
also be introduced. 
1.2. Streptococcus pneumoniae 
Streptococcus pneumoniae (S. pneumoniae), a bacterium also known as a pneumococcus, is a 
major cause of pneumonia, sepsis and meningitis. Mortality rates remain high despite 
modern antibiotics, so successful vaccination is key to preventing infection.   
S. pneumoniae is a gram-positive diplococcus with a polysaccharide capsule that is known to 
contribute to its virulence.  
1.2.1 Taxonomy 
The genus Streptococcus is a member of the Streptococcaceae family, which is divided into 
alpha-haemolytic and beta-haemolytic species. S. pneumoniae is an alpha-haemolytic species.  
1.3 Epidemiology of pneumococcal infection 
1.3.1 Pneumococcal infections in the HIV population 
HIV-infected patients are at a higher risk of developing pneumococcal infection than the 
general population. The annual incidence of IPD is 2.5 per 1000 HIV population (aged 15-  
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44), which is fifty times higher than the general population (1). Furthermore, IPD was higher 
amongst those individuals who were not on antiretroviral therapy (ART) (2.8 per 1000) and 
severely immunosuppressed (5.6 per 1000) (1). IPD has increased 50-fold in HIV 15-44 year 
olds and 25 fold in 45-64 year olds in England and Wales (2000-2009) even in patients who 
have received ARV treatment and those with higher CD4 counts. (2).  
Approximately 1.5% of adults living with HIV in the UK have suffered one or more episodes 
of invasive pneumococcal disease (IPD) (1), invasive disease includes meningitis and 
septicaemia. Bacterial pneumonia is the most common infection in HIV positive individuals 
and 70% of these pneumonias are caused by S. pneumoniae (3). 
1.3.2 Pneumococcal serotype distribution in carriage, colonisation, 
infection, and disease 
1.3.2.1 PCV-7 and PCV-13 effectiveness in the UK  
Since the introduction of PCV-7 (in September 2006) and PCV-13 (in April 2010) to the 
childhood vaccine schedule in England and Wales in the UK, there has been a general 
reduction in vaccine serotype-related IPD; however, there has also been an increase in non-
vaccine serotype replacement causing IPD including pneumococcal serotypes 7F and 19A 
(4). Following 4 years post-introduction of PCV-7 in the UK with coverage greater than 90%, 
vaccine-type IPD had decreased by 86% in all age groups, but there was still a substantial 
increase in non-vaccine serotype IPD in children < 5 years and in adults 65 years and older 
(5). PCV-13 replaced PCV-7 with high coverage of over 94.4% coverage in England and 
95.5% coverage in Wales with the expectation that carriage of pneumococcal serotypes in the 
nasopharynx would change slightly and that colonisation of IPD-causing serotypes would 
be substantially reduced (4,6,7). An observational cohort study performed in 2013/14 by 
Public Health England found that there was an increased incidence of non-vaccine serotype 
disease since the introduction of PCV-13 and an overall decrease in IPD caused by vaccine 
serotypes across all age groups (4). Most notably, there was a significant decrease in vaccine 
serotypes 1, 6A, 7F, and 19A across all age groups, but a significant increase in non-PCV-13 
serotypes including 8, 9N, 10A, 12F, 15A, 16F, 24F, 33F, and 35B in individuals over the age 
of 5 in 2013/14 (4). Although there has been serotype replacement disease, IPD has 
decreased by 56% in the UK compared to 2006 before the introduction of PCV-7 (4). 
Furthermore, nasopharyngeal carriage of any of the additional 6 serotypes in PCV-13 that 
were not included in PCV-7 in children had increased by 38%, but decreased by 95% 2 years 
post-introduction of PCV-13 replacement of PCV-7 (8). There was a 19% increase of non-
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vaccine serotypes in all age groups after the introduction of PCV-7 and a 25% increase in 
non-PCV-13 vaccine serotypes 4 years post-PCV-7 replacement (4,5).  
Interestingly, in individuals older than 45 years old, non-PCV-13 vaccine serotypes causing 
IPD were the largest and only small reductions were seen within PCV-13 vaccine-type IPD 
in 2016-17, which suggests that potentially PCV-13 should be given to this age group as 
individuals may not be protected from the herd effects from the childhood PCV-13 
vaccination scheme (9).  
As of 2016-17, non-PCV-13 vaccine serotypes  caused 78-88% of IPD cases across all age 
groups in the UK, in particular: <2 years old (y.o.), 2-4 y.o., 15-44 y.o.,45-64 y.o., and >65 y.o, 
but an overall decrease in 5-14 y.o. (9). These serotypes include 8, 9N, 12F, 15A, 22F, and 33F. 
Two PCV-13 serotypes still causing IPD across all age groups include 3 and 19A as of 2016-
17 and they were still detected in nasopharyngeal carriage in children as 2015-16 (9,10). 
Furthermore, carriage of serotypes 3, 19A, and 19F has also been found 3 to 4 years post-
introduction of PCV-13 to the childhood vaccination schedule in Massachusetts in the USA 
(11). 
 Common serotypes amongst children in the UK with lower respiratory infections (LRTIs) 
include serotype 3, 19A, 12F, 22F, and 33F (12). Common serotypes in children that are 
responsible for meningitis included 10A, 12F, 15B/C, 22F, and 33F (12). Serotypes causing 
septicaemia cases included 12F, 15B/C, 22F, 23B, and 33F (12). 
 Worryingly, serotype 3 is still causing 65% of IPD cases in adults over 65 years of age and 
24% of IPD cases in 45-64 year olds in England and Wales as of 2016-17 (9). Serotypes 8, 9N, 
and 12F are classed as emerging serotypes as their prevalence has increased rapidly over the 
last 3 years and has caused over 40% of total IPD cases. Surprisingly, serotype 8 has caused 
over 20% of IPD cases in 2016-17. Furthermore, 8 of the 10 most prevalent serotypes that 
have contributed to IPD cases in 2016-17 are included in the PPV-23 vaccine (9). 
Furthermore, the increase of these serotypes were prevalent in adults over the age of 65 
years old despite the national UK PPV-23 vaccination programme in this patient cohort 
having been in place since 2003 (9). Even though non-PCV-13 vaccine serotypes have been 
causing IPD in the UK as of 2016-17, there was no increase in non-PCV-13 vaccine serotypes 
in the USA until 2015 (13). Interestingly, the emergence of non-PCV-13 vaccine serotypes 
may have been caused by a wide array of factors including the high incidence of influenza 
cases during the winter of 2014-15. This was caused by antigenic and genetic mismatch 
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between the prevalent influenza viruses and the influenza vaccine (14). Furthermore, the UK 
introduced the live attenuated influenza vaccine for young children in 2013-14, which may 
have led to the alteration of the nasopharyngeal microbiome thus impacting the carriage of 
pneumococcus and subsequent disease (15).  
Higher valency pneumococcal vaccines may help to reduce IPD infections in some of the 
emerging non-PCV-13 serotypes including PCV-15, which will include all of the original 
serotypes included in PCV-13, plus 22F and 33F (16). However,  vaccine serotype 
replacement could still be problematic in the future even with higher valency vaccines, thus, 
it would be advantageous to find a highly conserved protein present on all 93 pneumococcal 
serotypes. Some of the best protein candidates include: iron transport lipoproteins, histidine 
triad proteins, pneumolysin, pneumococcal surface protein A, pneumococcal surface protein 
C, and pneumococcal surface antigen A, although these pneumococcal protein vaccine 
candidates are probably at least 5 years away from clinical efficacy trials (16).  
1.4 Risk factors for pneumococcal disease 
1.4.1.Environmental risk factors 
Pneumococcus mainly affects the young, elderly, and immunocompromised, notably those 
with HIV-infection. A bimodal distribution of pneumococcal infection is apparent with 
children less than 2 years and adults who are 65 years and older carrying the majority of 
disease (17,18). Other risk factors include alcoholism, cochlear implants, cerebrospinal fluid 
(CSF) leaks, chronic heart disease, chronic kidney disease (CKD), chronic liver disease,  
smoking, asplenia, deficiencies in complement and immunoglobulin, diabetes mellitus,  
influenza, liver and lung disease, sickle cell disease, other respiratory diseases, as well as 
other immunocompromised states including HIV  (12,19–22).  
This high susceptibility to pneumococcal infection has a major impact both in terms of 
quality of life  for the patient and significant healthcare service costs , such as lengthy 
hospital stays,  treatment , as well as the possibility of increased mortality due to antibiotic 
resistance  In a Dutch analysis that involved cost-effectiveness of PCV-13, it was found that 
vaccination with PCV-13 would cost €85.3 million, but would prevent an average of 9850 
cases of outpatient community acquired pneumonia ( CAP), 1850 cases of inpatient CAP,  
2050 episodes of IPD, ,and 630 deaths in the cohort. During the lifetime of the cohort, 
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patients would gain 5500 life years and 4850 quality adjusted life-years (QALY).  Vaccination 
with PCV-13 would thus save approximately €43.2 million (23).  
1.5 Clinical presentation 
Pneumococcal pneumonia manifests itself as acute community acquired pneumonia  (CAP). 
Pneumococci colonise the lower airway, but can be expelled via antimicrobial peptides, 
cough, innate immune defences,  and mucociliary clearance (24). If these initial innate 
immune defences fail, then infection will be established in the host.  
Presenting symptoms would include chills, cough, fever, dyspnoea (shortness of breath), 
and malaise (24).  A chest radiograph may indicate pneumococcal pneumonia. Bacterial 
sepsis is the most common presentation in children less than 5 years of age. However, 
pneumococcal pneumonia is the most common presentation for adults (18).  
If the infection is left untreated,  patients may develop blood-tinged and/or brownish  
purulent  sputum, in addition to acute respiratory failure, septicaemia, and multi-organ 
failure that can lead to death within a short period of days following the onset of clinical 
symptoms (24).  
Patients that present with recurrent pneumococcal pneumonia should be further 
investigated as this may indicate an undiagnosed immunocompromised condition such as 
HIV, congenital or acquired B-cell disorders, lymphoreticular disorders, multiple myeloma, 
and ciliary dyskinesia (defects in the cilia lining of the respiratory tract) (24,25).  
1.5.1 Diagnosis 
Pneumococci are -haemolytic and can be cultured on blood agar base plates (BAB) in a 
37°C CO2  incubator. Pneumococci are identified as gram stain positive diplococci (Figure 
1.3). Cultures could be sampled from the blood and sputum, as well as other tissue sites 
before any antibiotics are administered to the patient.   
Pneumococcal infection can be detected by urinary antigen secretion of the C-polysaccharide 
that originates in the pneumococcal cell wall. This assay is an immune-chromatographic test 
called Binax NOW® (26). This rapid-test also can be used for detecting nasopharyngeal 
carriage.  
A more highly specific- identification of infectious pneumococcal strains would be DNA-
sequencing or PCR assays, which are rapid and non-culture based methods.  
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1.5.2 Treatment 
Historically, pneumococcal infection has been treated with penicillin since the late 1940s 
(24,27). However, penicillin-resistant strains of S. pneumoniae have emerged globally since 
the middle of the 1970s due to structurally modified penicillin binding proteins that allow 
for peptidoglycan synthesis (24,25). It is suggested that resistance mechanisms can be 
overcome by administering high doses of penicillin to patients with resistant strains of 
pneumococci (24,25). Patients that have confirmed cases of mon-meningeal pneumococcal 
strains can be treated with high dose, β-lactam antibiotics, which may include penicillins, 
and second or third generation cephalosporins (24).  
Pneumococci have developed resistance to antibiotics such as: fluroquinolones, macrolides, 
trimethroprim, vancomycin, in addition to other various antibiotics (24). This is thought to 
have arisen partially as a result of aberrant prescription and usage of broad-spectrum 
antibiotics that do not completely clear pneumococci from the infected patient. Thus, 
prevention through vaccination is a way of overcoming antibiotic resistance.  
1.6 S. pneumoniae as a pathogen 
There are over 90+ different types of S. pneumoniae, which are known to cause various types 
of non-invasive and invasive illnesses. Pneumococcal serotypes are defined by distinct 
variabilities in the structures of their polysaccharide capsules. The various serotypes can be 
identified by the quellung reaction, which is a serum-based test (28). Some serotypes may be 
closely related, antigenically,  and may be placed in a group ie 6A and 6B (29). There are also 
non-encapsulated pneumococci that are referred to as non-typeable. The different serotypes 
possess the ability to cause either asymptomatic carriage or various types of illnesses and 
infections (30).  
Such illnesses can include but are not limited to pneumonia, meningitis, sepsis, acute otitis 
media, etc. It is also important to note that mortality against pneumococcus has not changed 
since the 1950s. Currently, pneumonia is the sixth leading cause of death in the UK and S. 
pneumoniae is the most common cause of pneumonia (31). It mainly affects the young, 
elderly, and immunocompromised.  
1.6.1 Mode of Infection  
Pneumococci infect the host by entering the lower airway. Pneumococcal disease 
subsequently follows asymptomatic colonisation of the host in the mucosal surfaces of the 
upper respiratory tract.  
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S. pneumoniae can be spread via nasopharyngeal carriage via inhalation of aerosols via 
asymptomatic carriers or a patient with pneumococcal disease. It occurs naturally in 
approximately 100% of healthy pre-school children at some time and 30% of healthy older 
children and adults (32).  Colonisation declines with age in approximately 10% of adults 
(33).  
Colonisation can progress to invasive (bacteraemia) or non-invasive infections (acute otitis 
media). Pneumococcal infection can also lead to acute conjunctivitis, arthritis, empyema, 
meningitis, osteomyelitis, peritonitis, and pneumonia (34).  
1.7 S. pneumoniae and resistance to killing 
1.7.1 Virulence factors  
 S. pneumoniae possesses a number of physical structures that contribute to its virulence and 
subsequent evasion of the host species.  
1.7.1.1 The capsule  
S. pneumoniae is an encapsulated bacteria. The capsule is composed of a polysaccharide layer 
which is approximately 200-400 nm thick. This structure is considered one of the main 
virulence factors of the pneumococcus and can be considered as anti-phagocytic (35). The 
capsule restricts access to cell-bound complement and may also reduce the amount of 
complement deposited on its surface dependent upon its variable thickness. Therefore, 
polysaccharide capsule coat thickness is associated with increased colonisation capabilities  
nd immune evasion.  
The C-type lectin, SIGN-R1, expressed by macrophages binds capsular polysaccharide from 
various serotypes and is essential to pneumococcal clearance (36,37).  
Currently, the capsule is a vaccine target. As mentioned before, capsules distinguish various 
serotypes from one another (29). Thus, vaccinations have been developed to include  
polysaccharides from multiple serotypes in order to cover invasive strains within the 
population. In the future, it is more likely that that vaccine targets will include more 
conserved molecules that cover multiple serotypes. The capsule is essential for colonisation 
and consequently for its dissemination in the host. Thus, it is an extremely important 
virulence factor. It is known to escape clearance in the host by its secretion of mucous once 
invasive disease is established within the host (24,38).  
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1.7.1.2 The cell wall 
Additionally, the cell wall is an important virulence factor as it facilitates attachment of the 
pneumococcus to activated lung cells. The cell wall consists of phosphorylcholine that binds 
to the platelet-activating factor (PAF). which is upregulated during inflammation and viral 
infections, such as HIV (35).  
1.7.1.3 Pneumolysin 
Pneumolysin, a pore-forming protein, is a toxin that establishes the production of 
inflammatory products such as TNF- , IL-1β, NO, and IL-8, prostaglandins, and 
leukotrienes (35). IL-8 (Interleukin 8 or CXCL8), a chemokine produced by monocytes, 
macrophages, fibroblasts, endothelial, and epithelial cells, recruits and activates innate 
immune cells such as neutrophils to sites of infection (39).  Pneumolysin, is also known as 
haemolysin due to its ability to lyse red blood cells. It is toxic to pulmonary endothelial and 
epithelial cells. It also has mechanisms that can contribute to the evasion of the immune 
system, including the inhibition of appropriate lymphocyte and phagocyte function, in 
addition to interfering with the complement pathway (35). Pneumolysin is an important 
virulence factor with regards to the pathogenesis of meningitis as it  can cause damage and 
induce apoptosis in neural cells (35,40,41). It also can bind Toll-like receptor 4 (TLR4), which 
protects mice from invasive pneumococcal disease (IPD) (35,42). In humans, TLR defects 
such as IRAK-4 (interleukin-1 receptor-associated kinase 4) deficiency causes recurrent 
systemic pneumococcal disease in children (43). IRAK-4 deficiency inhibits appropriate TLR-
signaling and function, thus abrogating the innate immune response to pneumococcus , 
which can lead to fatal pneumococcal disease such as meningitis despite prophylactic 
vaccination and subcutaneous or intravenous immunoglobulin therapy (44,45). Often IRAK-
4 deficiency is undetected in patients as they exhibit normal immunological profiles 
including T, B-cell , and neutrophil responses, normal total IgG, IgA, and IgM levels, and 
complement activity (45,46).  
Pneumolysin also facilitates protection from complement-mediated clearance. A study 
found that absence of complement in genetic knock-out mice reduces the need for 
pneumolysin as an essential virulence factor and that it acts via the classical pathway as 
opposed to the alternative pathway (36,47).  Pneumolysin also acts as a decoy toxin as it is 
released into the host environment and thus, directs complement activation away from the 
pneumococcal cell surface, thus allowing pneumococcal survival (36). Increased 
29 | P a g e  
 
complement activation as opposed to inhibition may induce even host-tissue damage, thus 
contributing even more to pneumococcal pathogenesis.  
1.7.1.4  Capsular Surface Proteins 
The pneumococcus possesses three families of capsular surface proteins including choline-
binding proteins, LPXTG-anchored proteins, and lipoproteins, which may also serve as 
potential vaccine targets as they are conserved regions.  
Choline-binding proteins are attached to the cell wall via non-covalent bonds of the 
carboxy-terminal end of the protein with the phosphorylcholine of the cell wall. The 
proteins that are particularly virulent include autolysin (LytA), pneumococcal surface 
protein A (PspA), and pneumococcal surface protein C (PspC). Interestingly, PspA is 
expressed by many clinically important pneumococcal serotypes (35), which presents a 
potential vaccine target. It is known to inhibit complement activation and the deposition of 
C3b in addition to the alternative pathway component C3 convertase. These contributing 
factors therefore reduce clearance of various pneumococcal serotypes. PspC is involved in 
the adhesion of pneumococci to the nasopharynx and some forms of PspC may be involved 
in the binding of the complement-control protein factor H (35).  
LPXTG proteins are composed of hyaluronidase and neuraminidase enzymes. 
Hyaluronidase leads to the breakdown of mammalian connective tissue and extracellular 
matrix and is secreted by most clinical isolates. Neuraminidase (of which there are three) 
cleaves N-acetyl-neuraminic acid from glycolipids, lipoproteins, and oligosaccharides that 
originate on cell surfaces  in body fluids (35). For example, neuraminidase A is involved in 
nasopharyngeal colonisation. These two proteins are involved in colonisation and facilitate 
the attachment of pneumococci to various host cells.  
Lipoproteins are adhesins that are involved in the adhesion of pneumococci to the host cells. 
An example is pneumococcal surface antigen A (PsaA). PsaA resides in the ABC transporter 
system and is involved in the transport of manganese. PavA is another adhesion that is 
involved in the binding of pneumococci to fibronectin, which is a host-cell glycoprotein that 
is involved in cell adhesion.  
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1.8 Immunity to S. pneumoniae 
1.8.1 The Spleen 
The spleen is a secondary lymphoid organ found in the upper left quadrant of the abdomen 
that filters the blood. Its primary function is to remove opsonised bacteria and respond to 
blood-borne pathogens (48). It also destroys dead erythrocytes  (48). It also provides a 
reservoir of antigen-specific B-cells that respond to bacterial pathogens in the absence of T-
cell help (48). The spleen is a highly-structured organ that is  composed of the red pulp and 
white pulp.  The red pulp contains macrophages and red blood cells. The white pulp, which 
is distributed along the central arterioles of the spleen, contains the B and T-cell areas. T-cells 
are mainly distributed in the periarteriolar lymphoid sheath (PALS) around the central 
arterioles. B-cells are found primarily in the primary (no germinal centre) and secondary 
lymphoid tissues (with germinal centres) (48,49). Secondary lymphoid follicles tend to 
generate activated B-cells. The marginal zone forms the outer region of the PALS, which 
contains slowly recirculating B-cells in addition to macrophages, which present T-
independent antigen to B-cells (49).  
1.8.1.1 Germinal Centers 
Germinal centers are structures that develop in the B-cell follicles of the secondary lymphoid 
tissues in response to T-cell dependent antibody reactions within the first three weeks after 
initial exposure to an antigen (50,51). They will reappear after a repeated encounter with the 
same antigen and are also involved with the clonal expansion of B-cells, somatic 
hypermutation in B-cell Ig v-region genes, and positive selection of B-cells that can respond 
to antigen-specific signals (50). Germinal center B-cells express high affinity antibodies, 
which subsequently develop and differentiate into antibody-secreting plasma cells and 
memory B-cells that provide long-term protection against pathogens (52). Furthermore, 
CD40 is expressed by B-cells and increases B-cell proliferation, Ig class switching, and 
somatic hypermutation. Subsequent binding of CD40 to CD40 ligand (expressed on helper 
T-cells) also helps to drive resting B-cells to become activated in response to T-dependent 
antigens. Furthermore, absence or blockade of CD40 ligation via protein antigens inhibits 
germinal center formation, thus inhibiting the capacity for high affinity antibody to be 
generated in an individual (53,54). 
1.8.2 Antibody 
Antibodies, also known as immunoglobulins, are proteins that are produced in response to 
specific antigens (48).  They are instrumental in the immune response because they 
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neutralise antigens by binding to their surfaces (55). Antibodies are important in the 
immune response to pneumococcus because they neutralise the shielding effect of the 
polysaccharide capsule by opsonisation for ingestion and destruction by phagocytes (56). 
Some serotypes are more likely to cause IPD, thus these serotypes are covered in the 
multivalent vaccines. There is cross-protective antibody between vaccine serotypes groups 
including Pn serotype 6A and 6B, and Pn serotype 19A and 19F (57). However, there is no 
cross-protective antibody between different serotype groups, which is why it is important to 
measure each pneumococcal-specific antibody.  
1.8.3 Phagocytes 
1.8.3.1 Macrophages 
Alveolar macrophages are  phagocytic cells that kill pneumococci in the lung (24). They also 
phagocytose neutrophils that have undergone apoptosis as a result of clearing pneumococci. 
Macrophages also undergo apoptosis themselves in order to kill phagocytosed pneumococci 
(24,58). 
1.8.3.2 Neutrophils 
Galectin-3 is a host adhesion molecule expressed and secreted by human monocytes and  
macrophages that recruits neutrophils in response to pneumococcal infection (59). It is also 
involved in activating the innate immune response such as degranulation of mast cells and 
oxidative burst via neutrophils  (59) An influx of neutrophils to the site of infection during 
pneumococcal pneumonia can be due to α- chemokines, as well as many other 
chemoattractants including CXCL8, most notably induced by pneumolysin  (60,61). 
1.8.4 Complement 
It binds C1q to antibody- polysaccharide complexes or C-reactive protein (CRP) binding to 
phosphocholine molecules of pneumococci. Pneumococci are opsonised by the complement 
fragments (C3b, C4b, and C5a) as generated by the complement cascade. In turn, this 
opsonisation promotes phagocytosis via binding receptors expressed via phagocytic cells. 
The classical pathway and the induction of natural IgM antibodies are the most important 
with regards to the clearance of pneumococcus (62).  
The complement system is a group of serum molecules that control inflammation and is 
activated by the innate and adaptive immune system. Complement facilitates the disposal of 
immune complexes and mediates lysis of pathogens or cells that are opsonised by antibody.  
Furthermore, this system is comprised of the classical, alternative, and lectin pathways.   
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Complement may be able to destroy other microbes through lysis via the membrane attack 
complex (MAC), but it cannot destroy pneumococcus alone. Opsonisation with 
pneumococcal-specific antibody is needed (36). Thus, this binding of antibody and 
complement lead to opsonophagocytosis and killing.   
The complement system bridges the two arms of an immune response: the innate and 
adaptive immune systems. There are three pathways, which include: the classical, the lectin, 
and the alternative pathway (63).  
1.8.5 Cytokines  
Cytokines are small proteins that are secreted and released by body cells that induces 
interactions and communication between cells in an autocrine, paracrine, or endocrine 
action (64). Upon entrance of pneumococci into the host respiratory tract, anti-inflammatory 
and pro-inflammatory cytokines are generated as part of the innate immune response (24). 
TNF-  is an important cytokine that is produced in response to pneumococcal infection as it 
inhibits and/or eliminates the growth and spread of pneumococci  (65). Interleukin-1 also 
protects against pneumococcus (66). Interleukin-17 (IL-17) is an important cytokine that is 
produced by CD4+T-cells or Th17 cells that has been described as being important for the 
clearance of pneumococcus in the context of carriage and colonization (67,68). 
1.8.6 Toll-like receptors (TLRs)  
Toll-like receptors are pattern recognition receptors that are important in pneumococcal 
infection. Pattern recognition receptors comprise a part of the innate immune system. They 
are located on the host cell surface. Their primary function is to establish inflammation, 
which will ultimately lead to the destruction of the bacterial pathogen (36). There are 10 TLR 
genes expressed in humans which recognise distinct sets of molecular patterns that are 
derived from Gram-positive and Gram-negative bacteria, fungi, protozoa, and viruses (69).  
Human genetic defects in TLR-signalling are associated with an increased susceptibility to 
pneumococcal infection. TLR-4 is essential in the recognition and innate immune response to 
gram-negative bacteria; however, it does recognise TLR-4 on macrophages via pneumolysin 
secretion (42). Furthermore, pneumolysin directly interacts with TLR-4 (70).  Malley et al. 
(2003) found when comparing wild-type (WT) and TLR-4 KO mice in a nasopharyngeal 
carriage model that TLR4 mice were much more heavily colonised by pneumococcus and 
much more likely to develop IPD.  TLR4 recognises pneumolysin and thus, limits the extent 
of pneumococcal proliferation within the nasopharynx (42) . TLR9 is required for the 
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detection of general bacterial DNA and optimal phagocytosis and  killing of pneumococci 
via macrophages that reside in the lung (24).  
1.8.7 T-cells  
CD4+T-cells are an important component of the adaptive immune response; however, they 
have also been shown to play a role in the early response to pneumococcal infection (71). 
CD4+T-cells have been shown to migrate towards pneumococcus in vitro and pneumolysin 
was shown to play a role in this migration . TLR4 is also expressed on T-cells, which may 
play a role in T-cell migration towards pneumococcus (72). Malley et al (2005) found that 
CD4+T-cells play an essential role in antibody-independent acquired immunity to 
pneumococcal colonisation (73).  
Ƴδ-T-cells, which are present in respiratory tissues, play an important role in the resolution 
of pneumococcal infection by the maintenance and regulation of inflammatory cell 
populations such as alveolar macrophages and  pulmonary dendritic cells that may form 
granulomas, which may contribute to pneumococcal pathogenesis and a delay in the 
resolution of inflammation (74).  
1.9 Vaccines against S. pneumoniae 
National guidelines published by BHIVA in 2008 (75) recommend HIV patients receive 
immunisation with polysaccharide pneumococcal vaccine (PPV-23; Pneumovax) (76).  
However, these guidelines have been established with a limited evidence base. PPV-23 
responses in adults with many comorbid illnesses (such as CLL, renal disease, etc.)  have a 
limited response to vaccination and any response is short-lived due no memory B-cells being 
generated. Polysaccharides stimulate B-cells via cross-linkage of the B-cell receptor (BCR), 
which drives the production of immunoglobulin (18). No new memory B-cells are generated 
and the former memory B-cell pool is decreased, which has an effect on subsequent immune 
responses to booster vaccines. In other words, the memory B-cell pool is terminally 
differentiated to plasma cells (77).This is a medical challenge as PPV does not stimulate T-
cell activation so no long-term memory cells are generated. If patients are re-vaccinated with 
PPV-23, before 5 years, they get a much lower immune response called hyporesponsiveness. 
This leaves a number of years where patients are not protected. However, it is important to 
note that most vaccination studies have been performed at a short duration and further 
evidence is needed to elucidate whether hyporesponsiveness can last beyond 5 years post-
vaccination with PPV-23. A study performed in Fiji in 2016 found that PPV-23 boosting of 
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children previously vaccinated with PCV-7 did results in hyporesponsiveness; however, 
there were no clinical consequences of this and after 5 years, immune responses to PCV-13 
vaccination were considered normal (78). 
 It has been suggested that  hyporesponsiveness is caused by the large amount of Pn 
polysaccharide that is contained within the PPV-23 vaccine (approximately 575 µg compared 
to less than 20 µg in Prevenar-7 (PCV-7)) and repeated antigen exposure and stimulation, 
which leads to B-cell exhaustion or depletion including memory B-cell and B1b cell subsets 
that are important for protection against pneumococcal serotypes (79).  
In contrast, the conjugate vaccine, Prevnar-13 (PCV-13), which works by stimulating T cells, 
generates a memory response which can be augmented with repeat vaccination, as 
undertaken in infants in the UK vaccination schedule. The carrier protein from the conjugate 
vaccine is presented to a polysaccharide-specific B-cell and is then is internally processed. 
Carrier protein peptides are then presented to specific T-cells, which then induce T-cell help 
for the production of plasma and long-lived memory B-cells (18).  
 PCV-13 covers approximately 61% of the serotype distribution amongst people co-infected 
with IPD and HIV (1). In fact, three out of every 5 IPD episodes among HIV-positive adults 
could be prevented by successful vaccination with PCV-13 (1).  
In 2015, the British HIV Association (BHIVA) suggested that HIV-infected adults should be 
vaccinated with a single-dose of PCV-13 irrespective of CD4 count, viral load, and ARV 
therapy without any booster doses(80). This had changed from the previously 
recommended single-dose of PPV-23. Most individuals (approximately 80%) who receive 
PPV-23 develop antibodies within 2-3 weeks, but in immunocompromised individuals such 
as HIV-patients, these responses decline rapidly or are absent entirely. Furthermore, 
boosting with PPV-23 is not recommended if previously vaccinated due to issues of 
hyporesponsiveness (81). HIV-patients have already shown a diminished antibody response 
to PPV-23, as well as PCV-13, particularly in the AIR  (Assessment of Immune Responses to 
Routine Immunisations) study that has been established at the Queen Elizabeth Hospital 
HIV Service in collaboration with the University of Birmingham Clinical Immunology 
Service (CIS). About 50% of patients did not respond to a single-dose of PCV-13, which 
showed a need for the additional boosters. 
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Prevention of pneumococcal infection is key with the ever increasing threat of antibiotic 
resistance. Thus, vaccination with PCV-13 is essential as it covers many of the resistant 
strains.  
In 2012, the JCVI (Joint Committee on Vaccination and Immunisation) reviewed the impact 
and cost-effectiveness of vaccination with PCV-13 (82). It rejected the implementation of a 
vaccination programme that would offer PCV-13 to some clinical risk groups and older 
adults (over 65 years old) in the UK on grounds of the lack of cost-effectiveness and that 
indirect immunity would offer protection against PCV-13 serotypes across the population. 
The JCVI considered that the following clinical risk groups would benefit from vaccination 
with PCV-13 including: patients receiving bone marrow transplants, patients with acute and 
chronic leukaemia, multiple myeloma, and patients with genetic disorders that severely 
suppress the immune system (including, IRAK-4, NEMO (NF-kappa B essential modulator), 
and complement deficiency) (82).  NEMO deficiency is caused by a hypomorphic mutation 
in the NEMO gene, which leads to impaired NFκB activation, thus leading to a decreased 
activation of mature naïve B cells (83). Consequently, this decreased activation of mature 
naïve B cells leads to impaired antibody class switch recombination and antibody synthesis 
(83).  
Currently, the Green Book advises that clinical risk groups include individuals with: 
asplenia, chronic respiratory disease, chronic heart disease, chronic kidney disease, chronic 
liver disease, diabetes, immunosuppression, cochlear implants, cerebrospinal fluid leaks, 
who undergo bone marrow transplantation, and those with genetic deficiencies (84). As of 
November 2015, the JCVI  have not changed their position with regards to the advice of 
adult pneumococcal vaccination and still support PPV-23 vaccination in adults (85)    
There is no cross-protection between serotypes (however, this is not the case within serotype 
groups such as 6A/6B and 19A/19F) when individuals are vaccinated with pneumococcal 
vaccines. This is why vaccines need to include multiple serotypes (Figure 1.1). Also, 
different serotypes cause different types of disease (29,86,87). For instance, certain serotypes 
may be more likely to cause IPD and other types of pneumococcal disease.  
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1.9.1 Measuring antibody responses to pneumococcal vaccination  
Quantification of the IgG response to pneumococcal vaccination assesses protective 
antibody levels and can be used to monitor high-risk or immunocompromised patients 
when their protective levels drop below WHO threshold levels. Two ways that one can 
measure vaccine-induced antibodies to pneumococcus is through the quantity of capsular 
polysaccharide-specific antibody produced and the quality or ability of the antibody to 
opsonise and promote phagocytosis of the pneumococcal serotypes.  
1.9.1.1 Quantification of pneumococcal-specific IgG- pneumococcal immunoassays 
The earliest method for measuring the antibody response to pneumococcus was a 
radioimmunoassay, which was then replaced by enzyme-linked immunosorbent assays 
(ELISAs) (88).  
The World Health Organization (WHO) established a pneumococcal-serotype specific IgG 
ELISA method, which was standardised for use in clinical and research laboratories around 
the world in 2002 (89). Although this method could still generate serotype-specific IgG 
results, the assay would need to be run multiple times in tandem. Thus, an alternative 
method using a multiplex microsphere assay using pneumococcal polysaccharide coated 
Luminex beads allows for the simultaneous measurement of IgG against a wide array of 
pneumococcal serotypes in one assay (90). This method requires a substantially smaller 
Table 1.1. Serotypes included in available pneumococcal vaccines 
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volume of patient serum and is much less time-consuming. The dynamic range of the 
multiplex immunoassay is much greater than the standard ELISA, thus allowing for greater 
sensitivity and the subsequent removal of additional sample dilutions for patient samples 
where there is a high concentration of pneumococcal serotype-specific IgG.  
The development of the pneumococcal multiplex immunoassays has increased significantly 
over the last 15 years with the establishment of a nonaplex assay developed at Public Health 
England in Manchester, 14-plex assay established at the University of Utah School of 
Medicine in Salt Lake City, USA, and a 19-plex assay established at the University of 
Birmingham, Clinical Immunology Service, in Edgbaston, UK (91–95). The most important 
requirement of the multiplex assay is that the results compare to the ELISA technique. Some 
studies have shown that there is variability between the correlation of the ELISA and 
multiplex method for some pneumococcal serotypes; however, there are other studies that 
have demonstrated a robust correlation between the two methods, thus making multiplex 
immunoassays a reliable alternative to the WHO ELISA method (92,94,96).  
1.10 Immunity against HIV  
HIV infection induces immune suppression and chronic inflammation, which ultimately 
leads to the  exhaustion of the immune system (97). Due to this significant dysregulation of 
the immune system, HIV-infected patients are particularly vulnerable to acute respiratory 
infections including pneumococcal disease (76).  
HIV is characterised by the progressive loss of CD4+T-cells. Normally, these lymphocytes 
upon stimulation with antigen release B-cell growth factors, IL-2, and interferons that 
regulate the growth, maturation, and activation of cytotoxic T-cells, macrophages, and 
natural killer T-cells (NKT) (98). During the initial weeks of HIV-infection, there may be a 
small increase in the rise of CD8+T-cells that may be in the peripheral circulation; however, 
during the asymptomatic stages of the disease, many individuals will have normal levels of 
circulating CD8+T-cell subsets (98). Another hallmark of infection in progressive HIV-
infection would be polyclonal B-cell activation that would result in a dramatic increase in 
serum immunoglobulin levels (98).  
Normally, during the adaptive immune response, an acute infection will be cleared within 4-
7 days (22).  
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However, during acute HIV infection, CD4+T-cells are depleted dramatically within the first 
2 to 6 weeks of infection. This acute phase of infection is usually accompanied by a flu-like 
illness also known as seroconversion , in about 80% of HIV-infected individuals (100). High 
titres of HIV virus are present in the blood during this period. Furthermore, an increased 
number of CD8+T-cells are found in the peripheral blood (98).  Following this period, the 
adaptive immune response is established and CD4+T-cells are restored. However, viral load 
is not reduced (asymptomatic phase). During the symptomatic phase, as CD4+T-cell counts 
fall to around 500 cells per µl, opportunistic infections begin to overwhelm the immune 
system (1200 cells per µl is normal). This period can last anywhere between 6 months and 
20+ years post-primary infection. A person is said to have AIDS when CD4+T-cell counts fall 
below the 200 cells per µl threshold. Most individuals will develop AIDS unless the HIV 
viral load is suppressed for a lifetime with anti-retroviral treatment (ARV).  
If HIV-infection is left untreated, AIDS can develop within the patient. An untreated patient 
can survive for up to 6-12 months following opportunistic infections, 9-12 months following 
Pneumocystis jirovecii pneumonia, and 20-30 months following Kaposi’s sarcoma (34).  
1.10.1 CD4 counts and Viral load (VL)  
HIV-infected CD4+T-cells located within the plasma have a short half-life of approximately 2 
days (101). The majority of detectable virus (approximately 95%) within the plasma is 
thought to be derived from these CD4+T-cells. CD4+T-cells found within the T-cell zones of 
lymphoid tissue may become infected as a result of activation during an immune response 
(102). HIV may lie dormant within memory CD4+T-cells and macrophages, which are 
reservoirs of infection (103).  
Survival for HIV-infected patients will vary depending on whether or not they have 
initiated ARV treatment, previous treatment and viral resistance, viral load, HLA type, and 
viral mutation rate (98).  
1.10.2 B-cells and HIV 
HIV infection is characterised by dysregulated humoral immune responses, which include 
hypergammaglobulinemia or hyper IgM syndrome that may induce inhibitory, blocking 
antibody. Hypergammaglobulinemia is a B-cell class switching defect where patients have a 
normal B and T-cell repertoire with normal to high levels of IgM in their serum. Typically, 
patients mount poor antibody responses to antigens that require T-cell help and only 
produce other immunoglobulin isotypes in minute amounts (104). It has been established 
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that  memory B-cell populations are dramatically reduced and hyperactivated naïve B-cells 
are very common in the context of HIV-1 infection (105). Furthermore, the loss of memory B-
cells may be due to overexpression of CD70 on activated T-cells, which can lead to terminal 
differentiation into plasma cells and/or spontaneous apoptosis (105–108).  Activated naive B 
–cells have been suggested as the causative agent of hypergammaglobulinemia  in HIV-1 
infected patients  (106). This cell population presents viral antigens via a BCR-independent 
mechanism (109). Furthermore, activated naïve B-cells from HIV-1 infected patients have the 
ability to secrete abnormal IgG due to reduced numbers of memory B-cells in circulation 
(106). Inhibitory, blocking antibody inhibits complement and antigen-specific antibody 
deposition, thus affecting effective opsonisation and subsequent phagocytic killing, 
particularly with regards to S. pneumoniae.   
HIV-infection is also characterised by hyperactivation, which causes cytokines and growth 
factors to trigger the activation of B-cells, which is known to inhibit effective B and T-cell 
interactions. This could potentially lead to impaired responses to both pneumococcal 
vaccines.   
Hypergammaglobulinemia and high spontaneous antibody production occur in the early 
stages of HIV-infection before the depletion of fully functional CD4+T-cells (110–114). This 
results in the production of excessive, but non-functional antibodies.  
In addition to impaired B-cell responses, CD4+T-cell responses are reduced during HIV-
infection since HIV infects this cell type. Subsequently, infected CD4+T-cells are killed via 
viral cytopathic effects or indirectly by activation-induced apoptosis (115). Thus, B-cell 
responses are essential with regards to regulating opportunistic infections that accompany 
HIV infection.  However, due to the dependency on B- cells in the context of controlling 
infection, B-cells become exhausted.  Also, in cases of chronic viraemia, B-cells lose their 
function even when patients are on antiretroviral treatment. As a result of HIV-infection, B-
cell polyclonal activation occurs and antibodies are generated in abundance, although, they 
may not be fully functional (116).  
Past research suggests that there is a correlation between invasive pneumococcal disease 
(IPD) and dysfunctional B-cell responses.  It has been suggested that effective ARV 
treatment cannot reconstitute B-cell function (110). Low antigen-specific IgG concentrations 
are found in serum and there is evidence of poor opsonophagocytic killing against various 
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serotypes of S. pneumoniae, which suggests that the quality and number of antigen-specific 
antibodies is impaired (110).  
After antigen stimulation by specific pneumococcal capsular polysaccharides, naïve B-cells 
can differentiate into IgM+ memory B-cells, which can produce pneumococcal-specific IgM 
without T-cell help. Later, during hypermutation and class-switching, pneumococcal 
specific IgM B-cells will differentiate into pneumococcal specific IgG or IgA memory B cells 
or plasma cells  (110). 
HIV+ patients may experience a decline in CD27+ memory B-cells (IgD+IgM+CD27+). 
Patients deficient in this cell phenotype experience are more vulnerable to lethal 
pneumococcal infections, particularly in the elderly population. IgM defects may impact B-
cell maturation and the production of antigen-specific IgG or IgA and function. Thus, this 
leads to dysfunctional late humoral responses which cause severe bacterial infections. 
Therefore, IgM is essential in order to mount a successful immune response against 
pneumococcal infection. Also, patients with low levels of IgM memory B-cells have 
impaired immunity to pneumococcal infections and often develop recurrent respiratory 
infections.  
IgA is also important in the humoral defence against pneumococcal infection, but more 
specifically at the mucosa, including the nasal and salivary mucosal sites (110). Patients with 
IgA deficiency mount impaired vaccine responses to pneumococcal vaccination, thus, they 
have high rates of recurrent infection and bronchiectasis (110).  
Patients should mount an IgM+ memory B-cell response post-vaccination after 6-7 days; 
however, IgM+ memory B-cells are depleted and pneumococcal-specific antibody responses 
to vaccination are impaired in HIV-patients (even those that have received long-term ARV 
therapy).  
A reduced number of CD4+T-cells, especially follicular helper CD4+T-cells, may also  
account for the impaired immune response to pneumococcal vaccination (110). 
Additionally, there is a marked increase in spontaneous B-cell apoptosis and an impaired 
proliferation response to T-cell independent B-cell antigens in HIV-infection.   
HIV leads to chronic immune activation via ongoing viral replication (117).  Before effective 
ARV regimes came into effect, B-cell hyperactivation and impaired antibody responses were 
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widely reported in HIV-infected individuals. B-cells in the peripheral blood of healthy 
controls are phenotypically resting naïve or memory B-cells that are characterised by either a 
switched (IgA, IgG, or IgE) or unswitched (IgM or IgD) antibody isotype  (117). However, in 
HIV-infected individuals, there are several additional B-cell subpopulations that reside in 
the peripheral blood including immature transitional B-cells, exhausted B-cells, activated 
mature B-cells, and plasmablasts due to the dysregulation caused by the disease (117–120).  
 Additionally, HIV-induced lymphopenia leads to the production of immature transitional 
B-cells in HIV infected individuals (117).  
High viral loads associated with HIV-infection may lead to the expansion of several aberrant 
B-cell sub-populations, including immature transitional, hyperactivated, and exhausted B-
cells, which collectively contribute to impaired humoral responses to vaccination (117) .  
Loss of CD21 expression of peripheral blood B cells is a reliable marker of ongoing HIV 
replication and disease progression. Furthermore, CD21 lo B-cells consist of two 
heterogeneous populations including:  CD27+ B-cells (as a result of HIV-induced activation 
and differentiation into plasmablasts) and CD10+ B-cells (immature transitional B-cells that 
are generated in response to the low numbers of T-cells that accompany HIV-infection . 
Thus, an exhausted B-cell subpopulation results.  
Many patients in the AIR cohort will have initiated ARV treatment; however, ARV 
treatment may not actually assist the memory B-cell population. It has been evidenced that 
B-cell deficiencies persist even after several years of effective ARV treatment (117,121,122).  
However, it has been documented that there are some B-cell abnormalities that are 
decreased by ARV treatment including hypergammaglobulinaemia and HIV-induced 
chronic immune cell activation, which is a key feature of HIV pathogenesis. There is an 
increased rate of B-cell death during ongoing viral replication, which leads to an overall net 
loss of B-cells. An increase in CD4+T-cell counts following the reduction in HIV viraemia by 
ART is associated with a decrease in the frequency of immature transitional B-cells. 
However, some B-cell deficiencies are not reversed by ARV treatment including the loss of 
memory B-cells and the decrease in memory B-cell function in chronically-HIV infected 
individuals.  
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Conversely, ARV treatment has been shown to increase the numbers of CD27+ resting 
memory B-cells following treatment; however, this reconstitution is slow and incomplete 
(117).  
 Studies have evidenced that the loss of responsiveness to pneumococcal vaccination was 
not reversed by ARV therapy  (123,124). Furthermore, loss of memory function is associated 
with a decreased frequency of IgM+ memory B-cells, which makes individuals more 
susceptible to pneumococcal infection. However, early initiation of ART does seem to 
reverse the low frequency of IgM+ memory B-cells, which is a major defect of chronic HIV 
infection (125).  
1.11 HIV treatment 
Despite antibiotic treatment and preventative pneumococcal vaccination, the burden of 
pneumococcal disease is approximately 35-fold higher in HIV-infected patients when 
compared to age-matched HIV-uninfected individuals (2). Thus, it is essential that ARV 
treatment is given to patients as it has been shown to decrease rates of IPD in the HIV-
infected population (126). 
Current and potential therapies have been established as a result of investigating the way 
that HIV gains entry to the host cell and replicates inside the cell (98). Vaccines to induce the 
production of neutralising antibodies have not been as successful due to viral syncytium 
formation and its facilitation of cell-to-cell spread of the virus (98). However, fusion 
inhibitors such as enfuvirtide, inhibits entry of the virus via cell-to-cell transmission by 
blocking viral gp41 fusion with the host cell membrane (98).  Maraviroc, an entry inhibitor, 
is an example of an allosteric co-receptor entry inhibitor that binds to the CCR5 co-receptor. 
Viral replication can also be inhibited by blocking the activity of the reverse transcriptase 
e.g. zidovudine. Zidovudine, the first drug approved to treat HIV, is a thymidine analogue 
that leads to the production of inactive proviral DNA (98). Protease inhibitors can also be 
used to block the assembly of new HIV virions (98). However, many infected patients can 
develop resistance to these drugs within a few days of initiating treatment.  
Combination antiretroviral therapy (cART) including efavirenz (non-nucleoside reverse 
transcriptase inhibitor) with tenofovir or emtricitabine (nucleotide analogue reverse 
transcriptase inhibitor (NRTIs)) is the gold standard for HIV treatment and was established 
in 2006 (98).  
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Further combination with integrase and protease inhibitors can also be used in order to 
reduce viral loads within the patient.  
Upon initiation of ARV treatment, the viral load will drop below the limit of detection (<39 
copies per mL) and the CD4+T-cell count will rise in most patients. This is due to the 
inhibition of re-infection of CD4+T-cells and trafficking of these cells from the lymphoid 
tissues within the peripheral blood (98).  
Once a patient has initiated ARV therapy, it is important to routinely monitor total CD4+T-
cells, VL, and serum β2 microglobulin levels (important for the loading and transportation of 
class I to the host cell surface) (49,98). Furthermore, it is also important to monitor 
antiretroviral resistance as the high rate of HIV replication generates multiple variants. This 
contributes considerably to HIV-related mortality.  
As of 2013, 107,800 HIV-infected individuals were living in the UK (127). Of this population, 
6,000 new individuals were newly diagnosed and 320 individuals were diagnosed with 
AIDS (127). As of 2013, 530 individuals in the UK died as a result of HIV-associated 
infections (127). As of 2014, 36.9 million individuals were living with HIV with 2 million 
newly diagnosed individuals worldwide (128). In 2014, 1.2 million individuals died as a 
result of HIV-associated infections worldwide (128).  
1.12 Pneumococcal Treatment in HIV 
In the UHB HIV Service, first line treatment for pneumococcal pneumonia in HIV is Co-
trimoxazole. When the use of Co-trimoxazole is contraindicated, Clindamycin can be used in 
conjunction with Primaquine. Pentamidine may also be used. Maintenance of treatment may 
include treatment with Co-trimoxazole with Dapsone and Pentamidine used as alternative 
therapies. Treatment may vary depending on hospital protocols.  
Antibiotic prophylaxis is not recommended for preventative treatment of bacterial 
pneumonia (129).  
1.13 Existing Knowledge of Pneumococcal Vaccination in HIV-patients 
Previously, it has been suggested that two doses of a conjugate pneumococcal vaccine are 
more immunogenic than one dose (130). Furthermore, a three dose primary course plus 
booster dose of PCV-13 is recommended in HIV-infected children (131). Also, a dose-
ranging study has been performed that investigated the use of a pneumococcal conjugate 
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vaccine. A dose-dependent response was observed. Local reactions were seen with the 4x 
dose as opposed to the 2x dose (132).  
The lack of evidence is not confined to HIV and a control population will provide important 
information on the longevity and quality of the response to booster vaccines, in healthy 
individuals, as well as investigating the effect of HIV on the immune response. Ultimately, a 
randomised control trial (RCT) such as AIR II will help to inform researchers, clinicians, and 
policy makers whether or not a second or even third dose of PCV-13 is needed to sustain a 
long-term Pn-specific antibody response. 
Historically, HIV-infected individuals have suboptimal responses to pneumococcal 
vaccination. There is a lack of evidence in HIV- infected individuals with regards to 
protective and functional antibody responses, as well as the longevity of the immune 
response to pneumococcal vaccination.  
Pneumococcal vaccination studies using PPV-23 have been trialled in HIV-infected 
individuals; however, protective antibody levels were significantly lower in HIV-positive 
individuals for all of the serotypes covered in the vaccine (133). In another study, PPV-23 
was found to be ineffective in HIV-infected Ugandan adults. Increased rates of 
pneumococcal disease were reported in vaccine recipients (134)  .  Anti-polysaccharide IgG 
levels, poor opsonophagocytosis, and IPD was associated with PPV-23 vaccination in HIV-
infected Africans (135).  
Trials investigating pneumococcal conjugate vaccine were to be assessed in the HIV-infected 
population. In one study, HIV-infected adults were randomised to receive different 
combinations of vaccines including placebo-placebo, placebo-polysaccharide, conjugate-
conjugate and conjugate-polysaccharide. The second dose was given 8 weeks post the initial 
vaccination. The conjugate-conjugate and conjugate-polysaccharide vaccine combinations 
had higher antibody concentrations and opsonophagocytic killing (OPKA) titres after the 
second dose (136). Another combined vaccination schedule was trialled in France in HIV-
infected adults. PCV-7 was administered as an initial vaccination at week 0 followed by a 
booster dose of PPV-23 at week 4. The frequency and magnitude of anti-PS IgG responses 
were greater when compared with the PPV-23 alone (137).  
Another study suggested that past receipt of PPV-23 did not affect the response to conjugate 
vaccination (138). The studies carried out in the current AIR study suggest that it will and 
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has affected the response to conjugate vaccination, particularly if the individual has been 
vaccinated within 2-5 years of receiving PPV-23 ie hyporesponsiveness.  
A study performed by the Health Protection Agency (HPA) in 2011 found that 61% of HIV-
positive adults suffered from IPD episodes and therefore, called for the usage of PCV-13 in 
HIV-infected adults, as the benefits from herd protection from the immunisation of children 
did not reach this population (139).  
Two separate studies have been conducted by Pfizer in 2012. In Study 6115A1-3017, HIV-
infected adults previously immunised with PPV-23 were given 3 doses of PCV-13 at 6-
month intervals. Patient responses remained above initial baseline levels (140). In Study 
6115A1-3002, HIV-infected children, adolescents, and adults who had not received any 
pneumococcal previously were vaccinated with 3 doses of PCV-13 and a single dose of PPV-
23 given at one month intervals (140). Robust immune responses were seen after the initial 
dose with PCV-13, although there were only modest increases after doses 1,2, and 3.  
Although these studies have investigated the immune response to single vaccine doses at 
various time points, they have not investigated the immune response to double doses nor 
the longevity of the immune response. There has been much debate with regards to 
achieving the optimal vaccination schedule in HIV-infected adults in the UK.  
PPV-23 has limited efficacy in HIV-infected adults and Pn-specific antibody levels may 
decline over time. This may also occur with regards to HIV-infected patients that receive a 
single dose (SD) of PCV-13. However, boosting with PCV-13 appears to elicit a better 
immunological response than when boosting with PPV-23 (80,141).  
In a placebo-controlled RCT using PCV-7 in Malawi in HIV-infected adults, patients were 
given two doses with a one month gap. Although it reduced vaccine serotype IPD by 74%, it 
did not show any advantage over a single dose schedule (142). Limitations to this study 
include the fact that the investigators did not test Pn-specific concentrations and investigate 
the longevity of the immune response, nor did they look at timing of the booster vaccination.  
It has been suggested that patients receive an initial dose of PCV-13 and then a booster dose 
of PPV-23 to include vaccine coverage against additional serotypes. However, the caveat to 
this vaccination schedule is that patients will not be able to be re-vaccinated for 2 to 5 years 
even if they are unprotected. One study evidenced that Pn-specific antibody concentrations 
were enhanced once given a conjugate Pn-polysaccharide vaccine and then a booster of 
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PPV-23 nine months later. However, limitations to this study include the fact that they only 
tested 4 serotypes and post-vaccination concentrations were only higher for 3 of the 
serotypes that were tested (143).  
Another study investigating this prime-boost approach suggested that HIV-infected adults 
who received an initial dose of PCV-7 and then a booster dose of PPV-23 after 4-weeks. The 
study found that after 8-weeks, patients had a 2-fold increase of Pn-specific IgG 
concentrations and sustained these levels at week 24 (144). A limitation to this study was 
that the investigators neglected to look at the longevity of the response at one and two years 
post-vaccination with regards to hyporesponsiveness and a decline in Pn-specific IgG 
concentrations. 
One RCT found that when boosting with PCV-7 after receiving an initial dose of PPV-23 (3-8 
years prior), HIV-infected patients had a greater Pn-specific IgG response at 2 months post-
vaccination than those that were boosted with PPV-23. Furthermore, at 6 months, patients 
who had received a booster dose of PCV-7 had similar Pn-specific IgG concentrations to 
those that received a booster dose of PPV-23 (145). However, this decline in Pn-specific 
antibody concentrations may be due to hyporesponsiveness.  
In contrast, an RCT carried out in Brazil with HIV-infected adults suggested that the 
administration of a booster dose of PPV-23 after PCV-7 was not advantageous over a booster 
dose of PCV-7. Patients that received a booster dose of PCV-7 sustained Pn-specific IgG 
concentrations greater than a four-fold increase compared to patients that received a booster 
dose of PPV-23 (146).  
Current BHIVA guidelines suggest that HIV-infected adults receive a SD of PCV-13 
regardless of their ARV/HAART usage, VL, and/or CD4 count consistent with our group’s 
findings, in addition to those of Iyer et al. (147). BHIVA suggests that HIV-infected adults 
(below the age of 65) should be given PCV-13 at least 3 months post-vaccination with PPV-
23 and those that are 65 and older should be given a SD of PPV-23. They also recommend 
against repeat vaccination with PPV-23 and/or PCV-13, but fail to give evidence which 
suggests why it is not advantageous (80).  
By comparing a single pneumococcal booster dose with a double pneumococcal booster 
dose (DD) in an RCT such as AIR II, we will be able to see whether or not boosting is safe in 
HIV-infected and HIV-uninfected adults. Pneumococcal boosting studies with PCV-13 have 
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not been trialled extensively to date in adults (aged 18-65) or HIV-infected adults, thus, the 
study findings would influence and impact local, national, and global healthcare policies. 
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1.14 Aims and Objectives: 
The aim of this project is to investigate the immune response to pneumococcal vaccination in 
the context of HIV infection. This will be achieved by employing a variety of immunological 
and microbiological techniques to assess the quantity and quality of pneumococcal-specific 
antibody produced in response to vaccination. Also, we will assess how HIV and its 
associated co-morbidities impact the cellular response to immunisation. To do this, the 
following questions will be addressed: 
 What is the quantity of pneumococcal-specific antibody produced in response to  
pneumococcal vaccination? 
o What is the duration of the immune response at 12, 24, 36, 48, and 60 months 
post-vaccination? 
 There may be pneumococcal-specific opsonic antibody present, but is it functional? Is 
it able to enhance or mediate phagocytosis and cell-mediated killing? 
 How does HIV impact the cellular response to pneumococcal vaccination? What is 
the phenotype of B and T-cells in the context of HIV infection when compared to 
normal controls? 
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Chapter 2: Impact of HIV-infection on 
the vaccine response to pneumococcal 
polysaccharide vaccination  
Publication: MacLennan CA, Richter A, Hodson J, Faustini S, Birtwistle J, Whitelegg A, et al. 
Immunization of HIV-infected adults in the UK with Haemophilus influenzae b/meningococcal C 
glycoconjugate and pneumococcal polysaccharide vaccines. J Acquir Immune Defic Syndr Nov  2016 
Oral presentation: 12th European Meeting on the Molecular Biology of the 
Pneumococcus EuroPneumo 2015, St. Catherine’s College, University of Oxford, July 2015.  
2.1 Aims  
The aim of this chapter was to investigate how HIV-infection affects the response to 
pneumococcal vaccination. The study was set up by Professor(s) Calman MacLennan and 
Mark Drayson and I was brought into this study as part of my PhD project in order to test 
the archived serum samples (pre- and post-vaccination), as well as the annual serum 
samples collected in order to investigate the longevity of the immune response to 
pneumococcal vaccination. Furthermore, I established a multiplexed opsonophagocytic-
killing assay (OPKA) (discussed later in Chapter 5) and multiplexed Pn-specific IgG1 and 
IgG2 Luminex multiplex immunoassays (MIAs) (discussed later in Chapter 6).   
2.2 Objectives 
The objective of this study was to: 
1) Investigate Pn-specific IgG pre-and post- vaccination (4-weeks) serum antibody 
concentrations following a single dose of Pneumovax-23® (PPV-23) in HIV-infected and 
HIV-negative individuals.  
2.3 Ethical Approval 
Ethical approval for the collection of blood from HIV-infected and non-HIV- infected 
individuals in the UK was granted by the University Hospital Birmingham (UHB) Research 
and Development Trust, NHS Research and Ethics Committee (REC) under the AIR 
(Assessment of Immune Responses to Routine Immunisations in HIV-infected patients) 
study. Ethical approval for the use of blood and serum samples was also granted by the 
University of Birmingham (UoB) Clinical Research Office who also sponsored the trial.  
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UHB R&D Trust: RRK3743  
Main REC Ref: REC-09/H12041/53 
Sponsor’s Protocol Number: RG_09_034, ERN_14-1166 
2.4 AIR Study (2009-2010) Background 
The current AIR (Assessment of Immune Responses to Routine Immunisations in HIV-
infected adults) I study, was undertaken at the University Hospital Birmingham (UHB) and 
the Whittall Street Clinic ( a genitourinary medicine clinic in the Birmingham city centre) in 
conjunction with investigations carried out via the Clinical Immunology Service (CIS) at the 
University of Birmingham (UoB), set out to investigate the immune responses to routine 
vaccinations recommended nationally for HIV-infected patients by the British HIV 
Association (BHIVA).  
There was a clinical need for the study due to the increased risk of vaccine-preventable 
infections and mortality associated with HIV-infected individuals. HIV-infected individuals 
are also more susceptible to encapsulated bacteria, most notably Haemophilus influenza and    
Streptococcus pneumoniae even though they may be on a highly activated antiretroviral 
therapy (HAART) regime. There are available vaccines against these extracellular pathogens 
but the impact of HIV infection on the response to vaccination is poorly understood. The 
AIR study was established in order to understand the implications of HIV-infection on the 
immune response to vaccinations within the patient cohort.   
Patients attending clinic were routinely offered Hepatitis B and annual influenza 
vaccinations. However, patients enrolled on the study additionally received vaccines against 
pneumococcus (Pneumovax-23®, PPV-23), a combined vaccine called Menitorix which 
protects against bacterial infections caused by Haemophilus influenza b and meningococcal C, 
and the low dose Diphtheria, Tetanus, and Polio vaccine. For the purposes of this chapter 
and thesis, only the Pn-specific IgG antibody concentrations will be reported.  
2.5 Materials and Methods 
This study was conducted between September 2009 and December 2010 at the UHB HIV 
Department as part of the AIR study. HIV-infected and HIV-negative individuals were 
enrolled from the UHB HIV service, as well as the Whittle Street genitourinary medicine 
clinic (Birmingham, UK). Participants received a single dose of PPV-23 (0.5 mL). Inclusion 
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criteria were proven HIV-positive test or HIV-negative test (control group) and older than 
18 years of age. Individuals who were previously administered a pneumococcal vaccine 
were excluded from this study.  
2.5.1 HIV testing 
HIV antibody testing (Abbott Laboratories; Abbott Park, IL, USA) and HIV-1 viral load (VL) 
measurements were carried out on study patients. Study patients were bled pre-vaccination 
and 4 to 6 weeks post-vaccination.  
2.5.2 19-plex multiplex Luminex assay IgG Antibody Quantification 
Pn-specific IgG antibody levels to 12 Pn serotypes (1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 
and 23F) were measured in serum using the Luminex multiplex immunoassay (MIA).  
The 19-plex assay is a multiplexed antibody assay that measures vaccine specific IgG 
antibodies using a Luminex 100/200 analyser (Merck Millipore, Texas, USA) in conjunction 
with Bioplex Manager 6.1 software (Bio-Rad Laboratories, Inc.). This assay is instrumental in 
measuring a patient’s antibody response to vaccination and it gives researchers and 
clinicians alike an insight into the status of his/her respective immune systems. It can and 
has been used as a tool to measure protective antibody levels and indicate when booster 
vaccinations should be administered to particular patients. This assay is routinely used in 
the Clinical Immunology Service (CIS) at the University of Birmingham (UoB) and measures 
twelve S. pneumoniae serotypes simultaneously including(Pn1,3,4,5,6B,7F,9V,14,18C,19A,19F 
,23F) all found in PCV-13 (148).  It also measures tetanus, diphtheria, meningococcal and 
Haemophilus influenzae b (Hib) –specific IgG.  
S. pneumoniae antigens (Pn1,3,4,5,6B,7F,9V,14,18C,19A,19F, 22F, and 23F) were acquired from 
the American Type Culture Collection (ATCC; Virginia, USA). 22F was not analysed in the 
assay. Instead, it was used to adsorb cross-reactive antibodies. Tetanus toxoid was obtained 
from Quadratech (Epsom, UK).  
There is much controversy with regards to correlates of protection against pneumococcus. 
Two levels have been proposed for the Pn serotypes: 1.3 µg/mL (AAAAI) (149) and 0.35 
µg/mL (WHO)(150) . However, a recent study of PCV-13 in infants raises concerns about 
whether or not these levels are appropriate for assessing pneumococcal vaccine responses in  
HIV-infected patients (151). 
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2.5.2.1 PLL (Poly-L-Lysine) conjugations 
Hib and pneumococcal (5 mg/mL) polysaccharides, meningococcal (2 mg/mL), and tetanus 
and diphtheria toxoid (50 mg/mL) were added to 0.01% NaOH. Cyanuric chloride (Sigma, 
UK) was used  to conjugate the polysaccharide to 0.1% PLL (Sigma, UK). The conjugated 
polysaccharide was then purified using G25 PD-10 Sephadex desalting columns (GE 
Healthcare, Chalfont St. Giles, UK).  
2.5.2.2 Bead Conjugations 
Hib and pneumococcal (5 mg/mL) polysaccharides, meningococcal (2 mg/mL), and tetanus 
and diphtheria toxoid (50 mg/mL) were added to 0.01% NaOH. Cyanuric chloride (Sigma, 
UK) was used  to conjugate the polysaccharide to 0.1% PLL (Sigma, UK). The conjugated 
polysaccharide was then purified using G25 PD-10 Sephadex desalting columns (GE 
Healthcare, Chalfont St. Giles, UK).  
2.5.2.3 19-plex assay method 
Samples were prepared, diluted, and loaded onto a 96 well dilution plate (Millipore, UK) 
using the Dynex machine (Dynex Technologies Ltd., Worthing, UK) one day prior to 
running the assay. Serum samples were diluted 1 1:100 of 1% BSA, 0.05% Tween 20, cell wall 
polysaccharide (CWPS) (Statens Serum Institute, Copenhagen, Denmark) (5 µg/mL), and Pn 
22F (5 µg/mL). Pn22F was added to absorb non-specific antibodies (152) . Seven four-fold 
serial dilutions at a 1:20 dilution were carried out manually using 007 serum, a human 
pneumococcal standard reference serum, as the control standard (153). A 96- well filter plate 
(Millipore) was pre-wet with PBS-Tween and 25 µl of the master bead mix was added to 
each well. The loaded plate was then washed with PBS 0.05 % Tween using a vacuum pump 
(Millipore). 25 µl standards, controls, and samples were then transferred from the dilution 
plate to the luminex plate and then incubated in the dark on the orbital shaker (500 rpm) for 
1 hour at RT. The luminex plate was then washed with PBS 0.05 % Tween and then 
incubated with 100 µl of the secondary antibody (mouse anti-human IgG or IgM 
phycoerythrin (PE)-conjugate (Southern Biotech) at a 1:200 dilution for 30 minutes in the 
dark on an orbital shaker (500 rpm). Following washes with PBS 0.05 % Tween, beads were 
then resuspended in 125 µl of PBS 0.05 % Tween in each well in order to analyse on the 
Luminex 100/200 instrument. A standard curve of median fluorescence intensities (MFIs) 
was generated for 007sp antibody concentrations in order to assign specific antibody 
concentrations for test samples.  
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2.5.3 Statistical Methods 
Non-parametrical analysis was used to compare Pn-specific IgG levels between HIV-
negative and HIV-infected patients due to skew in levels and truncation of results by the 
clinical limits of the Luminex MIA assays. Furthermore, Pn-specific IgG levels were treated 
as continuous variables and compared against HIV status, CD4 count, VL, and usage of 
ART. Mann-Whitney and Kruskal-Wallis tests were used. Pn-specific IgG was used as a 
binary variable according to whether patients were above WHO and/or AAAAI protective 
thresholds and comparisons were carried out across the groups using a Fisher exact test.   
Pre- and post-vaccine Pn-specific IgG levels, fold change post-vaccination, and the 
percentage of previously un-protected patients reaching protective threshold Pn-specific IgG 
levels were determined using IBM SPSS Statistics (IBM Corporation, Armonk, NY). P-values 
were Bonferroni corrected for 36 comparisons (12 antigens by 3 outcomes), with P<0.0009 
considered as statistically significant. HIV-infected patients were stratified according to CD4 
count (TruCount assay; Becton Dickinson, San Jose, CA) (<350, 350-490, 500-690, and >700 
cells per mL). 
2.6 Patient Population 
211 HIV-infected adults and 73 HIV-uninfected adults (controls) were recruited for 
vaccination with a single dose of PPV-23. The study patients and controls were recruited 
under the AIR study. HIV-uninfected patients were enrolled from the UHB genitourinary 
medicine clinic attendees that tested negative for HIV-infection. This was carried out in 
order to reduce study bias. Most of the AIR HIV-patients were on HAART in accordance 
with the BHIVA-recommended national guidelines (83%-176 total). Most patients received a 
non-nucleoside reverse transcriptase inhibitor (NNRTI) 73% (128 total) had viral loads (VL) 
of less than 50 copies per mL. 62 HIV-infected patients had detectable viral loads greater 
than 50 copies/mL. The median VL was 5060 copies/mL (interquartile range (IQR) 482-
51,933 copies/mL). Patients had a median CD4 count of 500 cells/µl (IQR 350-630 cells/µl). 
Patients were then stratified according to CD4 counts, which resulted in four subgroups of 
approximately 50 patients per group (<350 (47 patients), 350-490 (56 patients), 500-690 (68 
patients), and >700 ( 40 patients)). In the HIV-infected cohort, 42% of patients were 
Caucasian, 43% African, 10% Caribbean, 6% Asian, and 6% other/unknown. In the HIV-
uninfected cohort, 52% of patients were Caucasian, 18% African, 8% Asian, and 8% 
other/unknown.  
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2.7 Vaccine Safety 
No serious adverse events occurred following vaccination with PPV-23 or PCV-13.  
2.8 Results:  HIV-negative patients respond better to one dose of PPV-
23 than HIV-positive patients 
2.8.1 Vaccine responses to AAAAI protective thresholds 
Pre-vaccination Pn-specific IgG concentrations were significantly lower in the HIV-infected 
group for Pn serotypes  7F (p<0.001) according to the AAAAI protective threshold of 1.3 
µg/mL (Table 2.1; Figure 2.2). HIV-negative patients responded significantly better to Pn1 
(p<0.0001), 7F (p<0.001), 18C (p<0.001), and 23F (p<0.001) (Table 2.1, Figure 2.3). It should be 
noted that although not significant post-Bonferroni correction, HIV-negative patients 
responded better to Pn serotypes 4 (p=0.044), 5 (p=0.003), 6B (p=0.031), 9V (p=0.002), 19A 
(p=0.035), and 19F (p=0.008) (Absolute values; Table 2.1, Figure 2.3).  Furthermore, there was 
a greater fold change for HIV-negative patients post-vaccination for Pn1 (8.01; p<0.001). 
However, it is worth noting that there was a >4-fold change in Pn-specific IgG 
concentrations for HIV-infected patients for Pn5 (4.15; ns), 7F (5.56, ns), and 18C (5.47, ns) 
(Table 2.1).  
2.8.2 Vaccine responses to WHO protective thresholds 
Pre-vaccination Pn-specific IgG concentration were significantly lower in the HIV-infected 
group for Pn serotypes 5 (p=0.020), 7F (p<0.001), 9V (p=0.003), and 23F (p=0.010) according 
to the WHO protective threshold (Table 2.3, Figure 2.4).  HIV-negative patients responded 
significantly better to Pn1 (p=0.019), 7F (p=0.032), 9V (p=0.007), 18C (p=0.002), and 19A 
(p=0.028) (Table 2.4/Table 2.5, Figure 2.5). 
2.8.3 Lack of association between CD4 Count and VL on Pneumococcal 
Vaccine Responses 
There was a distinct lack of association between pre-vaccination, post-vaccination, and fold-
change in Pn-specific IgG levels, CD4 count stratification, full VL suppression, or ARV 
therapy (Table 2.4/Table 2.5). In order to assess the effect of ARV therapy on Pn-specific IgG 
levels, study participants with a CD4 count of > 500 cells/mL and fully suppressed VL were 
compared with all of the other HIV-infected subgroups. There was very little difference 
between the two groups. A normal CD4 count is approximately 1200 cells/µl (normal range 
500-1500 cells/ µl) (148). 
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Table 2.1. Pn-specific IgG Levels to Pneumococcal Vaccination in Study Participants According to HIV Status 
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Figure 2.1 Pn-specific IgG antibody levels pre-and post-pneumococcal vaccination with PPV-23 (µg/mL). The WHO protective threshold is denoted at 0.35 µg/mL. The AAAI 
protective threshold is denoted at 1.3 µg/mL. Each point represents one study participant. Solid horizontal lines (in red) indicate medians. Dotted horizontal lines (blue) indicate 
protective thresholds for post-vaccination Pn-specific IgG titres. 
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Figure 2.2. Pn-specific IgG concentrations pre-vaccination with one dose of PPV-23. HIV+(HIV-infected)  n=211, HIV- 
(HIV-negative) n=73.  Percent protected according to the AAAAI 1.3 µg/mL protective threshold.  
Figure 2.3. HIV-negative patients respond better to one dose of PPV-23 than HIV-positive patients- AAAAI threshold. 
Percentage of patients protected 4-weeks post-vaccination with PPV-23. There was a greater percentage of HIV-negative 
patients that showed statistical significance for Pn 1, 7F, 9V, 18C, 19F, and 23F. HIV+(HIV-infected)  n=211, HIV- (HIV-
negative) n=73.  Percent protected according to the AAAAI 1.3 µg/mL protective threshold. 
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Table 2.2  Percent Protected Pn-specific IgG concentrations (AAAAI threshold) according to HIV status 
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Table 2.3  Percent Protected Pn-specific IgG concentrations (WHO threshold) according to HIV status 
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Figure 2.4. Pn-specific IgG concentrations pre-vaccination with one dose of PPV-23 (WHO threshold) 
HIV+(HIV-infected)  n=211, HIV- (HIV-negative) n=73.  Percent protected according to the WHO 0.35 µg/mL 
protective threshold. 
Figure 2.5. HIV-negative patients respond better to one dose of Pneumovax-23 (PPV-23) than HIV-positive 
patients- WHO threshold. The percentage of patients protected 4-weeks post-vaccination with PPV-23. There 
was a greater percentage of HIV-negative patients that showed statistical significance to Pn 1, 7F, 9V, 18C, 19A, 
and 23F. HIV+(HIV-infected)  n=211, HIV- (HIV-negative) n=73.  Percent protected according to the WHO 0.35 
µg/mL protective threshold. 
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Table 2.4. Median Pn-specific IgG levels (µg/mL) in HIV-infected patients according to CD4 count, VL, and ART 
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Table 2.5 Median Fold Changes- Pn-specific IgG levels in HIV-infected patients according to CD4 count, VL, ART 
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2.9 Discussion 
2.9.1 HIV-infected patients mount a poor immune response to PPV-23 
HIV-uninfected subjects produced a protective response to the plain polysaccharide vaccine   
PPV-23, but HIV-infected subjects had only a poor response to PPV-23 with a lack of 
association between vaccine responses and CD4 count, ARV therapy, and/or VL.  
The AIR study cohort is a unique HIV-infected cohort in the UK as patients were able to 
receive booster vaccines if they failed to mount a response to an initial dose of PPV-23 or 
PCV-13. Previous studies tend to focus on single vaccinations. One study found similar 
responses to PPV-23 in HIV-infected (recently seroconverted) and HIV-negative patients 
(154). However, it’s important to note that other studies investigating PPV-23 vaccination in 
HIV-infected patients have established opposing responses. Two studies have indicated a 
strong immunogenic response to PPV-23 (155,156). However, another two studies have 
indicated a poor immunogenic response similar to our study results (157,158). 
Consistent with our study findings, there have been studies examining pneumococcal 
vaccination in HIV infection that found no correlation between the CD4 count and the 
pneumococcal antibody response (156,158). However, there were two studies that found 
poor responses to PPV-23, which was associated with low CD4 counts (159,160).  
ARV therapy did not have an effect on the response to PPV-23 vaccination in the AIR study 
cohort and this has been established in other studies, one of which found that there is no 
benefit from delaying pneumococcal vaccination until the patient has received 6 to 12 
months of ARV therapy (160,161). 
The lack of association between vaccine responses to PPV-23 and CD4 counts, VL, and ARV 
therapy supports the policy of early vaccination following a positive HIV diagnosis. The 
results from this AIR study suggest that there is a need to investigate the functionality of 
CD4+T-cells and B-cells that are also characterised as being dysfunctional in HIV-infection 
(117,162).  
Inability to achieve cohort protection to PPV-23 led to a change in the study protocol to give 
patients the pneumococcal conjugate vaccine, Prevenar-13 – PCV-13, used in infants in the 
UK. Infants’ immune systems cannot respond to PPV-23,  but do respond to PCV-13 which 
is designed to stimulate adolescent immune systems; and has been found to work better 
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than PPV-23 in patients who have an impaired immune system through age or diseases that 
reduce immune competence (163–165). Furthermore, there have been studies that suggest 
that antibody responses to pneumococcal conjugate vaccines are significantly higher than 
responses to PPV-23 in clinical settings where ARV therapy is available (146,166). 
Further evidence to support the use of pneumococcal conjugate vaccines in HIV-infected 
adults has been established in a South African cohort of HIV-infected children which has 
shown protection against pneumonia and IPD (167).  
The only randomised placebo-controlled trial of pneumococcal conjugate vaccination in 
HIV-infected adults demonstrated enhanced protection against recurrent pneumococcal 
infections in Malawi, which further supports the idea of pneumococcal conjugate 
vaccination (142).  
From the AIR study findings, a single vaccine doses of PPV-23 against pneumococcus does 
not provide an immediate immunogenic response in an HIV-infected adult population. A 5 
year longitudinal study following HIV-infected patients who received a SD of PPV-23 do not 
maintain their responses to vaccination even with ARV therapy and with low CD4 counts 
(168). 
Mixed vaccination schedules have been performed with varying results dependent on the 
patient population and geographical location of the studies (136,138,144,145,169). 
Vaccination with two doses of PCV-7, followed by PPV-23 established immunological 
memory in HIV-infected children (170). Furthermore, another study found that in HIV-
infected adults, revaccination with PPV-23 after 5 years on ARV therapy can establish 
immunological memory (147). However, it must be stressed that boosting patients with 
multiple doses of polysaccharide vaccines can induce hyporesponsiveness, which was first 
described by Felton and Bailey in 1926 (171,172). Another study in which three doses of 
PCV-13 were administered following a dose of PPV-23 gave an immediate rise in antibody 
concentration following vaccination; however, overall levels did not change following each 
dose (173).  
It is important to highlight that there is a lack of controlled studies investigating vaccination 
against S. pneumoniae in HIV-infection. Due to the poor immune response to a single dose of 
PPV-23, it was decided to change the study protocol and initially give HIV-infected study 
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participants a single dose of PCV-13 and further boosters as required, which will be 
discussed later in Chapter 4.  
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Chapter 3. Validation of the 19-plex 
assay and AIR patient samples 
3.1 Introduction 
Previous validation work was performed during the course of this PhD project that 
indicated that concentrations produced by the 19-plex assay (Chapter 2; section 2.5.2.3) were 
not stable over time. Initially, AIR study post-vaccination concentrations were lower than 
pre-vaccination concentrations, which indicated that the samples needed to be re-run on the 
19-plex assay. The analysis was performed using the originally recorded results from the 
AIR study and the results were found to be unreliable when examining longitudinal sample 
results. 
 
Examining the 3 controls (in-house (HUS and CAL) and external control samples from 
NEQAS) gave consistent results, indicating that there was variability in the assay which 
varied in magnitude over time.  
 
 Internal controls – HUS (normal human serum (Sigma Aldrich, UK ) and CAL (normal 
human serum source from one healthy control donor vaccinated with PPV-23). 
 External controls – NEQAS (human quality control serum samples from The United 
Kingdom National External Quality Assessment Source) 
 HIV-infected patient samples –Pre-vaccine/baseline serum samples of the AIR cohort 
 
To further qualify this, a sample of AIR samples were selected and retested, to determine 
where a larger retesting programme was required.  
 
To further quantify the variability in the assay, a representative subset of samples were re-
run, and compared to the originally reported concentrations to inform the retesting strategy. 
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3.2 Aims and Sample Selection 
 
There were two main aims of the analysis: 
1) To assess the consistency of unvaccinated baseline bloods over time  
The assumption was that the baseline AIR patient antibody concentrations would not vary 
significantly over time. None of the patients had been vaccinated at this time point, so any 
trends in antibody concentrations over time would have implied that the level of protection 
in the population had changed over time. For each year 2009-2015, ten patients with pre-
vaccine blood samples available were randomly selected for retesting. The resulting 
concentrations were tested for trends over time, as well as being compared back to the 
original measurements, to check for consistency of the assay. 
 
2) To assess the variability of antibody concentrations over time on a patient basis 
The ten samples from 2010/2011 from the previous aim had been stratified such that those 
from 2010 had PPV-23 as their initial vaccine, and those from 2011 had PCV-13, and that all 
patients had subsequent blood tests on at least an annual basis. All available samples for 
these patients were retested. This allowed the response to the initial vaccine (and any 
boosters) to be assessed, as well as the longevity of this response. The longitudinal values 
from the original and retested values could be plotted together, to see whether the changes 
in concentrations were reasonable (i.e. increased after a vaccine, and declined over time), 
and to see how much of a difference was present between the original and retested samples. 
 
Patient selection of the validation analysis is summarised in Table 3.1.  
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Table 3.1. Inclusion criteria for re-testing of AIR samples for longitudinal analysis 
 
 
The final list of samples contained 50 solely for Aim 1 (10 per year in 2009, 2012-2015), and 
181 for Aim 2 (all follow up for 20 patients), of which 20 samples were also used in Aim 1. 
This left a total of 231 samples for retesting. 
3.3 Materials and Methods 
3.3.1 Validation of the 19-plex assay 
As with any functional assay, there is a certain amount of intra- and inter-assay variability. 
Standard QC control (S1, S8, CAL, and HUS) data were collected from each 19-plex assay 
(described in Chapter 2, section 2.5.2.3) since 2009. Observed concentrations were converted 
from mg/mL to µg/mL, logged, and plotted in order to compile scatter plots. Standards 
were checked to see if there were any differences. The scatter plots revealed that from the 
period of 2009-2011, the standard ranges varied considerably. This could have been due to 
the fact that serum samples were manually diluted into sample buffer during this time 
period. In 2012, the Dynex machine was introduced and the serum samples were 
automatically diluted, thus further standardising the dilution assay to eliminate manual 
control error, as this can vary considerably amongst different users. Also, in 2011, there was 
Year Inclusion Criteria 
Samples 
Used for 
Aim 
2009  First blood sample is pre vaccine (or up to 1 week after to allow for 
delays) 
1 
2010  Pre-vaccine sample available (Up to 4 weeks before vaccine) 
 Post-vaccine sample available (4-16 weeks after vaccine) 
 Vaccinated with PPV-23 
 At least one sample available in 5 distinct years  
1,2 
2011  Pre-vaccine sample available (Up to 4 weeks before vaccine) 
 Post-vaccine sample available (4-16 weeks after vaccine) 
 Vaccinated with PCV-13 
 At least one sample available in 5 distinct years 
1,2 
2012  First blood sample is pre vaccine (or up to 1 week after to allow for 
delays) 
1 
2013  First blood sample is pre vaccine (or up to 1 week after to allow for 
delays) 
1 
2014  First blood sample is pre vaccine (or up to 1 week after to allow for 
delays) 
1 
2015  First blood sample is pre vaccine (or up to 1 week after to allow for 
delays) 
1 
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another step-change in the control serum, which is most likely due to the change from the 
usage of the pooled standard control serum, 89-SF to 007SP. Furthermore, there is another 
step-change from 2013-2014; however, no cause was determined and this was further 
investigated by myself and the CIS team. Since the beginning of 2014, the assay standards 
displayed a similar range. Thus, it was decided to re-test a small subset of samples that were 
tested from 2009-2015 on the 19-plex assay and re-analyse the data based on those results. 
Baseline and post-vaccine samples were run on the same plate to reduce interassay 
variability.   
3.4 Results 
3.4.1. First-bloods over time 
Previous validation analyses showed that pre-vaccine concentrations within the cohort varied 
over time. In order to ascertain whether this was due to a true variation in baseline immunity, 
or to variability in the assay, comparisons were made between the pairs of originally reported 
and retested concentrations for the samples included in the validation analysis. Separate 
analyses were produced for the each year being considered, using Kruskal-Wallis tests. The 
resulting p-values are in Table 3.2 below, with significant (p<0.05) differences reported with 
single asterisks (*) and highly significant (p<0.01) p-values with double asterisk (**): 
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As can be seen, there were many cases where the retested concentrations came out to be 
significantly different to those that were originally reported. The results were generally 
consistent with previous validation, with those serotypes where validation samples varied 
considerably with time (e.g. Pn1, 3, 23F) having the greatest number of significant differences, 
whilst those that had more stable validation samples (e.g. Pn9V, 14) having the least. One 
serotype that showed a lot of variability over time (Pn3) and one with low variability over 
time (Pn9V) are visualised in more detail in the plots in section 3.4.2 and 3.4.3. 
 
3.4.2 Pn3 
Figures 3.1 for Pn3 shows the previous validation performed on this titre. Both the internal 
(HUS) external (NEQAS) and HIV-infected patient samples (First Bloods – the original 
concentrations for pre-vaccine blood tests of the AIR cohort) samples showed a similar trend, 
with the titre reducing over time, before flatting out from around 2013 onwards. 
 
Figure 3.2 shows the retested concentrations, which are much more stable over time, and do 
not show the previously mentioned trends. The second graph in Figure 3.2B compared the 
Table 3.2. Variation between originally reported and retested concentrations  for first blood samples 
included in the validation analysis. 
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original (blue) to the retested (green) samples in every year, which established that the original 
runs of the samples gave significantly higher concentrations than the re-runs in the early 
period, becoming closer over time. 
 
This is further broken down in Figure 3.3; the first graph shows the fold differences between 
the original and retested concentrations for each sample. Again, this is consistent with other 
analyses, showing that the original samples gave higher concentrations until around 2012, 
after which there was greater consistency.  
 
The other two graphs in Figure 3.3 compared the original (Figure 3.3B) and retested (Figure 
3.3C) concentrations in 2010 and 2015. In the former, the original run gave higher 
concentrations for every sample being compared, whilst in 2015, the original runs and retests 
were more similar. 
 
3.4.3 Pn9V 
The same graphs are reported for Pn9V (Figure 3.4-3.6) , which show that this serotype was 
much more consistent over time, as a result of the original and retested concentrations being 
more consistent than in Pn3. 
 
In conclusion, this analysis suggests that the observed variability over time in the antibody 
concentrations is likely a reflection of assay, rather than patient variability. As a result, 
comparing samples that were tested at different times, either to compare the responses to the 
PPV-23 and PCV-13 vaccines, or to look at the longevity of response in a single patient, is 
likely to give unreliable and unrepresentative results. 
3.4.4 Longitudinal analysis 
In order to show how the variability in the assay would impact analysis of longitudinal data, 
the serial antibody concentrations, both from the original run on the assay and the re-test, 
were plotted over time and compared. Figures 3.7-3.10 were considered for two of the AIR 
patients, considering Pn3 and Pn9V for the reasons discussed earlier. These are representative 
plots and not all of the data for every patient will be presented in this thesis.  
 
Again, this shows large differences between the original and retested Pn3 concentrations over 
time (Figure 3.7 and 3.9). The retested samples (blue) show a modest increase in 
concentrations after both the initial and the booster vaccine, which decline with time, as would 
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be expected. However, the original runs of the samples (red) showed a larger increase in 
concentrations after the first vaccine, which continued to increase over the course of a year. 
Concentrations then dropped when the booster was given, and continued to fall at a rapid 
rate.  
 
Comparing the shape of the original runs of the samples (red) on this graph to the plot of the 
HUS samples over time shows a strong correlation, implying that the drop observed after the 
booster vaccine is a reflection of assay variability, rather than a true reflection of the antibody 
concentrations of the patient. 
 
For the longitudinal plot of Pn9V for this patient (Figures 3.8 and 3.10), both the original and 
retested samples gave more consistent results, as would be expected, based on the lower 
variability in the assay over time for this serotype. 
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Pn Serotype 3 
Figure 3.1 Validation of Pn Serotype 3. A) First Bloods- Old Data-Pre-vaccine titres from originally tested serum samples B) HUS-Internal control sample showing 
variability over time C) NEQAS- External control sample showing fold differences over time. D) NEQAS- External control samples showing truncated error over time. 
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Pn Serotype 3  
A. First Bloods- Pn3 Absolute Pn-specific IgG Titres B. First Bloods- Pn3 Yearly Pn-specific IgG Averages 
Figure 3.2 Validation of Pn Serotype 3 including first bloods analysis of absolute Pn-specific IgG concentrations and yearly averages. A) First Bloods-Pn 3 Pn-specific IgG titres. 
Kruskal-Wallis Test of Pn3 ANOVA- Multiple Comparisons show non-significance between years of assay. B) First Bloods- Pn3 Yearly Specific IgG Averages. Blue=Old results; Green= 
New Results.Wilcoxon Matched-Pairs Signed Rank Test show significance in the years of 2009, 2010, and 2014 between the old data and new re-tested sample data. 
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A. 
B. C. 
Figure 3.3 Validation of Pn Serotype 3 including fold differences between old and new analyses on first blood samples for longitudinal analysis A) Fold 
differences between old versus new Pn3-IgG specific titres from 2009-2015 B) Plot of old versus new results of Pn3-IgG specific titres in 2010 C) Plot of old versus new 
results of Pn3-IgG specific titres in 2015. 
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Pn Serotype 9V  
A. First Bloods –Old Data B. HUS  
C. NEQAS fold-differences D. NEQAS-Error  
(Truncated) 
Figure 3.4. Validation of Pn Serotype 9V. A) First Bloods-Old Data-Pre-vaccine titres from originally tested serum samples  B)HUS- Internal control 
sample showing variability over time C) NEQAS-External control sample showing fold differences over time D) NEQAS- External control samples showing 
truncated error over time. 
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  Pn Serotype 9V  
A. First Bloods- Pn9V Absolute Pn-specific IgG Titres B. First Bloods- Pn9V Yearly Pn-specific IgG Averages 
Figure 3.5 Validation of Pn Serotype 9V including first bloods analysis of absolute Pn-specific IgG concentrations and yearly averages. A) First Bloods-Pn 9V Pn-specific IgG titres. 
Kruskal-Wallis Test of Pn9V ANOVA- Multiple Comparisons show non-significance between years of assay. B) First Bloods- Pn9V Yearly Specific IgG Averages.Blue=Old results; 
Green=New Results Wilcoxon Matched-Pairs Signed Rank Test show non-significance between the old data and new re-tested sample data. 
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A. 
Figure 3.6 Validation of Pn Serotype 9V including fold differences between old and new analyses on first blood samples for longitudinal analysis A) 
Fold differences between old versus new Pn9V-IgG specific titres from 2009-2015 B) Plot of old versus new results of Pn9V-IgG specific titres in 2010 C) Plot of old versus 
new results of Pn9V-IgG specific titres in 2015. 
B. C. 
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Figure 3.7. Longitudinal analysis of Pn3 IgG concentrations post-vaccination comparing old and new analyses on retested AIR samples from an AIR study patient. Points on the 
graph indicate multiple time post-vaccination following an initial dose of PPV-23 (Vacc 1) and a second dose of PCV-13 (Vacc 2).  
Example from an AIR 
study patient 
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Figure 3.8 Longitudinal analysis of Pn9V IgG concentrations post-vaccination comparing old and new analyses on retested AIR samples from an AIR study patient. Points on the 
graph indicate multiple time post-vaccination following an initial dose of PPV-23 (Vacc 1) and a second dose of PCV-13 (Vacc 2). 
Pn9V Example 
from an AIR study 
patient 
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Figure 3.9 Longitudinal analysis of Pn3 IgG concentrations post-vaccination comparing old and new analyses on retested AIR samples from an AIR study patient. Points on the 
graph indicate multiple time post-vaccination following an initial dose of PPV-23 (Vacc 1) , a second dose of PCV-13 (Vacc 2), and a third dose of PCV-13 (Vacc 3).  
Pn3 Example from 
an AIR study 
patient 
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Figure 3.10 Longitudinal analysis of Pn9V IgG concentrations post-vaccination comparing old and new analyses on retested AIR samples from an AIR study patient. Points 
on the graph indicate multiple time post-vaccination following an initial dose of PPV-23 (Vacc 1) , a second dose of PCV-13 (Vacc 2), and a third dose of PCV-13 (Vacc 3). 
Pn9V Example 
from an AIR study 
patient 
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3.5 Discussion 
The original validation analyses indicated that there was variability over time in the assay, 
and this additional analysis has returned similar results. The early years of the study are a 
period where the trends over time are at the greatest magnitude, which is also the time of 
the change from PPV-23 to PCV-13. As such, by using the results of the original assay runs 
of the samples, a reliable comparison of the effectiveness of these vaccines cannot be 
performed. 
 
The trend over time in the variability in the assay also has a considerable effect on the 
longitudinal antibody concentrations for patients. Hence, analysis of longevity of protection, 
or the relative effectiveness of boosters to the original vaccine could not be reliably 
performed. 
 
The majority of the discussion in these analyses relates to relative measures (i.e. original vs. 
retested titre or longitudinal changes in patient concentrations). One of the key aspects of 
this study was to report protection rates, using the WHO/AAAAI thresholds. The 
validation analysis found that the original concentrations produced by the assay were 
generally highest in the early period of the study, and declined over time. Hence, if these 
data sets were used, the protection rates measured in the early period of the study were 
likely to be vast overestimates, which would decline with time, causing a considerable 
underestimate in longevity of protection and effectiveness of the boosters. 
 
With so much variability over time from 2009-2015, there were many points to consider with 
regards to the analysis of the original and re-tested AIR study data, including whether or not 
a statistical adjustment factor to the pre-existing AIR data and/or running a larger subset of 
AIR study samples in order to obtain a more reliable data set. This would include the 
assignment of IgG concentrations to the re-tested samples based on the 007sp standard.  
 
Therefore, it was decided not to use the application of a statistical adjustment factor and to 
re-run a larger subset of samples in order to obtain a more reliable dataset, which is 
discussed in Chapter 4. The percentage of HIV-infected adults who achieve threshold 
vaccination antibody levels with a single dose of PPV-23 and PCV-13 is investigated in 
Chapter 4. For patients who do not achieve threshold vaccination antibody levels with one 
dose of vaccination, it is important to investigate whether or not this can be achieved with 
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further booster vaccination. Subsequently, for those patients who do achieve threshold 
antibody levels with vaccination, the longevity of the threshold levels is investigated and 
discussed in Chapter 4.  
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Chapter 4.  The Longevity of the 
Immune Response to a Single Dose of 
PPV-23 versus PCV-13 and booster PCV-
13 Vaccinations in an HIV-infected 
Population in the UK 
Oral presentation:  5th Network Meeting of the MIA Network in Den Bosch, The Netherlands, Luminex 
Corporation, May 2017.  
Oral presentation: Public Health England, Vaccine Evaluation Unit, National Infection Service, 
Manchester Royal Infirmary, Manchester, UK, September 2017. 
Manuscript in preparation. 
4.1. Introduction 
Immunocompromised individuals, including patients with HIV, are at increased risk of 
pneumococcal infection. The annual incidence of invasive pneumococcal disease is 2.5 per 
1000 in the HIV population, which is fifty times higher than the general population (2)  and 
has increased  50-fold in England and Wales from 2000-2009 (1). Bacterial pneumonia is the 
most common infection in HIV positive individuals and 70% of these pneumonias are 
caused by Streptococcus (S.) pneumonia (2). Despite modern antibiotics the case fatality rate 
for pneumococcus remains high and so vaccination has a key role to play in prevention. 
Perversely, those most at risk of infection are often the least able to respond to vaccination. 
Vaccination strategies for adults at risk of infection are often pragmatic rather than evidence 
based. Assessment of these strategies requires a careful chain from patient testing to national 
microbiological surveillance programmes and these data are difficult to systematically and 
successfully collate.  
Pneumococcal vaccination is offered by two strategies; firstly, a pure polysaccharide vaccine, 
which contains 23 (out of 95) pneumococcal serotypes and secondly, a protein 
polysaccharide conjugate vaccine which can contain either 10 or 13 (out of 95) serotypes. The 
vaccines differ in their ability to recruit T-cell help, which is required for the generation of 
high affinity antibody and memory.  Conjugate vaccines are used in the infant vaccination 
schedule as naïve immune systems generate an inadequate T-independent response 
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required by the polysaccharide vaccine.  In contrast, the polysaccharide vaccine has been 
used for patients at risk of pneumococcus including in the UK all adults over the age of 60.  
There is variation in guidelines for pneumococcal vaccination in HIV. In the UK, the British 
HIV Association (BHIVA) recommend a single-dose of the 13 valent conjugate vaccination 
Prevenar-13 (Pfizer)(PCV-13) followed by a single dose of Pneumovax-23 (PPV-23) 
polysaccharide vaccine, although this was not recommended at the time of the change in 
study protocol in 2010 (174) . The US Centre for Disease Control provides the same advice as 
BHIVA (175). Factors which influence these decisions include; the higher cost of PCV-13, the 
ability to boost PCV-13 whilst repeat vaccination in PPV-23 results in hyporesponsiveness 
(176), the wider coverage of serotypes in PPV-23 and the limited and short response of PPV-
23, herd protection resulting in much reduced rates of PCV-13 serotype disease since 
introduction into the infant schedule in 2010 (177). 
The Assessment of Immune Responses to Routine Immunisation in HIV-infected Adults 
(AIR) observational study is a collaboration under between the Clinical Immunology Service 
at the University of Birmingham, UK and the HIV service at University Hospitals 
Birmingham NHS Trust.  This was the largest UK vaccination study in HIV infected adults 
which aimed to improve vaccine uptake in HIV and to monitor the immune response to 
vaccination. Between 2009-2015 the study recruited 839 HIV patients and 73 controls who 
attend the sexual health clinic and were confirmed to be HIV negative. At the initiation of 
this study, BHIVA and the JCVI recommended a single dose of PPV-23(75,82). As of 
November 2015, the JCVI  have not changed their position with regards to the advice of 
adult pneumococcal vaccination and still support PPV-23 vaccination in adults (85). Patients 
were also offered vaccination against Influenza, Menitorix (the Haemophilus influenzae type b 
and meningococcal C glycoconjugate vaccine), hepatitis A and B and DTaP (Diphtheria, 
Tetanus and Pertussis) following diagnosis. Need for and response to vaccination was 
assessed by achieving a threshold antibody concentration as measured by multiplex 
immunoassay (MIA). The first results from the AIR study found that HIV infected adults 
had similar antibody response to Menitorix as HIV-negative controls (178) . In contrast, HIV 
patients had significantly lower responses to Pneumovax-23 compared with controls whose 
response was also limited (33% v 53%). Interim analysis at one year highlighted this lower 
response and a major study amendment changed the pneumococcal vaccine to Prevenar-13.  
This provided retrospective comparison between responses to PPV-23 and PCV-13 in HIV-
infected adults and prospective monitoring of longevity of response and need for booster 
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vaccination which antibody levels fell below threshold (World Health Organization (WHO) 
protective threshold 0.35 µg/mL in  ≥ 8/12 serotypes) (179). 
4.2 Aims  
The aim of this chapter is to investigate how HIV-1 infection affects the short-term and long-
term immune response to pneumococcal plain polysaccharide (PPV-23) and conjugate (PCV-
13) vaccination.  
4.3 Objectives 
The objective of this study was to: 
1) Investigate Pn-specific IgG pre-and post- vaccination (4-weeks) serum antibody 
concentrations following a single dose of Pneumovax-23® (PPV-23) and Prevenar-
13® (PCV-13) in HIV-infected and HIV-negative individuals.  
2) Investigate the longevity of the Pn-specific IgG post-vaccine responses annually 
following initial pneumococcal vaccination and subsequent boosters for 6 years.  
 Assess threshold protection by pneumococcal serotype. 
3) Assess the number of pneumococcal vaccine doses required to achieve threshold 
protective levels.  
4.4 Materials and Methods 
4.4.1 Ethical Approval 
Ethical approval for this study is described in section 2.3.  
4.4.2 19-plex multiplex Luminex assay IgG Antibody Quantification 
This method is described in detail in section 2.5.2. 
4.4.2.1. Preparation of Luminex Beads 
4.4.2.1.1 PLL (Poly-L-lysine) conjugations 
This method is described in section 2.5.2.1.  
4.4.2.1.2 Bead conjugations 
This method is described in section 2.5.2.2.  
4.4.2.1.3 19-plex multiplex assay 
This method is described in section 2.5.2.3.  
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4.4.3 Opsonophagocytic Killing assay (OPKA) 
A 4-plexed multiplexed OPKA (for Pn serotypes 4, 6B, 14, and 23F) was developed by 
myself and Dr. Jenny Herbert (Post-Doctoral Fellow, Pneumococcal Research Group, 
Professor Tim Mitchell’s laboratory, University of Birmingham, Edgbaston, UK)  and used to 
determine the functionality of specific antibodies against pneumococcus, which is known to 
be impaired in some immunosuppressed groups including older patients. This assay 
assessed bacterial opsonophagocytosis via killing of pneumococcal serotypes using 
differentiated HL-60 cells both using a flow cytometric and a plate method  (180,181).  
4.4.3.1 HL-60 cell culture 
HL-60s were used as the phagocytes in the assay. HL-60 cells were obtained from Dr. Farhat 
Kharim’s group (University of Birmingham, U.K.). Cells were propagated in a culture 
medium containing RPMI 1640, 20% fetal bovine serum, FBS, and 1% L-glutamine (Gibco 
Invitrogen, UK). Cells were differentiated for 5 days in the above culture medium 
supplemented with 0.8% dimethyl formamide (DMF) (Sigma, UK). Cell morphology was 
assessed via cytocentrifugation and the Romanowsky method and the images were taken 
and displayed in Figure 4.1.  Differentiated cells (Panel B, Figure 4.1) should be 
hypersegmented and granular in appearance. 
The HL-60 cell phenotype should be determined every 4 weeks via FACS analysis. To 
determine if the cells are appropriately differentiated and working properly, cells should be 
stained for CD35 (> 55% expression, differentiated-upregulated) and CD71(<20% 
expression, differentiated-downregulated).   (Please see Figures 4.2 and 4.3, which are 
Figure 4.1. Cytocentrifugation of undifferentiated (20x dry magnification) (A) versus differentiated (40x 
magnification, oil immersion) (B) HL-60s using the Romanowsky staining method (Image taken by Sian E. 
Faustini using the Leica DM6000 (Leica Microsystems, UK). 
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representative flow cytometry plots that was acquired from a mOPA experiment). Also, cell 
viability must be above 90% (trypan-blue). 
Master cell banks were prepared from the original flask of cells and were grown to a density 
of 5 x 105 cells/mL for approximately 3 weeks. Cells were prepared in freezing medium 
containing: 50% FBS (heat-inactivated for 30 minutes at 56°C, 0.1% DMSO, and 40% RPMI-
1640. Cells were transferred to 50 mL falcons and centrifuged at ~350g (1200 rpm) for 5 
minutes. The supernatant was removed and 2.5 mL of freezing medium was added to each 
50 mL tube to gently re-suspend the cell pellets. Cell pellets were combined and 1 mL was 
aliquoted into to distribute into cryovials for freezing. Each vial contained 1 x 107 cells/mL. 
Cryovials were placed into a controlled-rate freezer to begin a freezing program and once 
frozen, cryovials were transferred into a liquid nitrogen storage facility. One vial was kept to 
test for mycoplasma contamination (MycoAlert, Lonza) and other microbial contamination.  
Working cells stocks are passaged every Monday, Wednesday, and Friday if differentiating 
cells for up to two times per week. For example, cells that are differentiated on Wednesday 
will be used 5-6 days later on the following Monday or Tuesday.  
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Figure 4.2 An example of a flow cytometric plot of the undifferentiated HL-60 cell population (Acquired by 
Sian E. Faustini on a FACSFortessa (BD Biosciences, USA )using FACSDiva software (BD Biosciences, USA) for 
analysis). 
Figure 4.3 An example of a flow cytometric plot of the differentiated HL-60 cell population (Acquired by Sian 
E. Faustini on a FACSFortessa (BD Biosciences, USA) using FACSDiva software (BD Biosciences, USA) for 
analysis). 
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4.4.3.1.1 Cytocentrifugation of HL-60 cells 
Prepare cell suspensions as needed in the relevant assay.  Microscope slides (Fisher, UK) 
were labelled. The rough side of a filter card was placed onto (ThermoFisher,UK) onto a 
cytocentrifuge funnel (ThermoFisher, UK).  The filter card and funnel was locked together 
into a stainless steel clip (ThermoFisher, UK)using the relevant key. The entire assembly was 
placed in the cytocentifuge rotor (ThermoFisher, UK) and 100 µl of RPMI 1640 (Sigma, UK) 
and  2% newborn calf serum (NCS) (Gibco, UK) was added to the funnel. 7-11 µl of the 
relevant sample was added to the funnel. The cover was fixed onto the rotor and placed 
onto the impellor. The slides were centrifuged for 3 minutes at 500 RPM. The clip was then 
carefully disassembled and the slide was removed and allowed to air-dry for 5 minutes 
before staining the slides via the Romanowsky method. 
4.4.3.1.1.1 Staining of slides and cytospins by the Romanowsky method 
Fresh air-dried cytospin slides were arranged in a rack. The rack was placed on the hook in 
the StainMate processor (R.A. Lamb (now Fisher)). The stain process was automatic and the 
timings were as follows: 
1) Methanol (VWR, UK)  fixation (5 minutes) 
2) May-Grunwald (VWR, UK)  stain (10 minutes) 
3) Water rinse ( 30 seconds) 
4) Giemsa stain (VWR, UK)  ( 10 minutes) 
5) Water rinse (30 seconds) 
Once the slides were dry, the slides were mounted with an aliquot of DPX mounting 
medium (VWR, UK) and a cover glass (Fisher, UK) and allowed to dry before 
viewing/taking photographs on an appropriate microscope. 
The staining solutions were prepared as follows: 
1) Staining Buffer (Sorenson’s pH 6.8) (TCS Biosciences, Ltd., UK) : 25 mL of stain 
buffer to 5 L of de-ionised water.  
2) May-Grunwald (for staining carbohydrate-rich structures): 150 mL of staining buffer 
to 50 mL of May-Grunwald stain. 
3) Giemsa (for staining of nucleic acids): 180 mL of staining buffer to 20 mL of Giemsa 
stain. 
4.4.3.2 Bacterial culture 
Bacterial master stocks  (Pn 4, 6B, 14, and 23F) were obtained from BEI Resources (Manassas, 
VA, USA). Thirteen different antibiotic resistant S. pneumoniae strains were used for the 
assay and were grown from frozen glycerol stocks or blood agar base (BAB) by taking a 
sweep of bacteria using a sterile loop. Bacterial strains were then inoculated in Brain Heart 
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Infusion (BHI) broth and incubated at 37°C statically. Bacterial strains were allowed to grow 
to an optical density of 600 (OD600) and then processed accordingly. 15% glycerol was added 
if making frozen bacterial stocks. The bacterial strains were natural variants resistant to 
specific concentrations of antibiotics derived from wild-type strains and are described in 
Table 4.1 (182).  
Table 4.1. Bacterial Strains and their Antibiotic Resistance 
Antibiotic C1 C2 C3 C4 
Optochin (Orep) 4 18C 7F 3 
Spectinomycin (Spec) 6B 19F 1 6C 
Streptomycin (Strep) 14 9V 5 33F 
Trimethroprim 
(Trim) 
23F 6A 19A 22F 
4.4.3.2.1 Viable Counting of Bacteria 
Bacteria were counted before the assay in order to account for bacterial death, which will 
naturally occur once a freeze-thaw occurs. A volume of 180 µl of PBS was added to 6 wells in 
a 96-well round-bottomed plate (Greiner, UK). 20 µl of bacterial sample was pipetted into 
the first well, whilst pipetting up and down (20x).  A new sterile tip was used and then 20 µl 
of well 1 was transferred to well 2 and mixed as in the previous step. This process was 
repeated until the 6th well.  A serial dilution results (10-1 to 10-6) and bacteria could be plated 
(3 x 20 µl) onto a BAB plate (Figure 4.4) .  Plates are then placed into an incubator overnight 
for 16 hours at 37°C.  Counts are then performed the next day. Colonies should be countable 
(30-100 CFU per spot).  
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4.4.3.3 Human serum samples 
Human serum samples were used in this assay. Serum samples were stored at -80°C until 
needed for testing. Samples were removed from the freezer and kept at RT until thawed 
completely. Once samples were thawed, test samples were heat inactivated in order to 
inhibit endogenous complement activity at 56°C in a water bath for 30 minutes. 
4.4.3.4 Baby rabbit complement 
Baby rabbit complement (Pel-freez Biologicals, Rogers, AR, USA) was used in the OPKA 
assay in the presence of human serum and differentiated HL-60 cells in order to opsonise the 
bacterial cell surface, which results in the uptake and killing via the HL-60 cells.  
Figure 4.4. Example of a viable count plate 
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4.4.3.5 Multiplexed Opsonophagocytic Killing Assay (University of Alabama- mOPA 
procedure) 
A detailed protocol of this assay can be found at www.vaccine.uab.edu (183).  Prior to 
testing, human test serum samples and complement  (control A) were heat-inactivated at 
56°C for 30 minutes. Control B was normal serum. Round bottomed 96-well plates (Corning 
Inc., Corning, NY, USA) were prepared. Serum samples (30 µl) were added to the plate in 
duplicate in addition to 10 µl of OPA buffer (80 mL sterile water, 10 mL of 10XHBSS (with 
Ca++/Mg++), 10 mL of 1% gelatin and 5.3 mL of FBS (heat inactivated at 56°C for 30 
minutes)) in each well. Test samples were diluted initially at a 4-fold dilution and then a 3-
fold serial dilution by reverse pipetting.  
A frozen working stock tube of each of the four bacterial strains were washed twice in OPA 
buffer via centrifugation at 12000g for 2 minutes and then diluted to the appropriate 
bacterial density (~105 CFU/mL for single-serotype assays and ~ 2 x 105 for multiplexed 
serotype assays). Equal volumes of the four bacterial suspensions in each cassette ie (C1, C2, 
C3, and C4) were combined and 10µl of the suspensions were added to each well including 
control wells A and B (Figure 4.5). 
Figure 4.5 . Plate plan for mOPA (Figure taken from (183). 
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Test serum and bacteria were then incubated at RT on an orbital shaker at 700 rpm for 30 
minutes.  
10 µl of complement and 40 µl of prepared and differentiated HL-60 cells (prepared at 1 x 107 
cells/mL) were added to each well. Prior to addition of HL-60 cells to the plate, cells were 
washed twice with 1X HBSS (without Ca++/Mg++) at ~350 g for 5 minutes at RT and then 
with 1X HBSS (with Ca++/Mg++) at ~350 g for 5 minutes.  
Plates were then incubated on an orbital shaker for 45 minutes at 37°C and 5% CO2 at 700 
rpm. After the incubation period, plates were put on ice for 20 minutes to stop the 
phagocytic reaction. 10 µl of the reaction mixture was spotted onto four Todd-Hewitt Yeast 
Agar(THYA) (Becton-Dickinson) plates and tilted immediately in order to prevent the 
mixing of spots. Plates were left to dry at RT for 20 minutes and then a 2,3,5- 
triphenyltetrazolium chloride (TTC) (Sigma, UK) overlay containing one of the four 
antibiotics was added to each replicate plate.  
Once the overlay was solidified, the plates were incubated upside down for 16-18 hours at 
37°C. Colonies that grew on the THYA plates with the Orep overlay were the bacterial 
strains resistant to optochin and likewise for the Spec, Strep, and Trim overlays.  
After the overnight incubation period, colonies were counted manually or using an 
automated counter. Colonies could also be enumerated using a software developed by the 
University of Alabama (UAB) lab in conjunction with the US National Institute of Standards 
and Technology (NIST) that counts colonies from a digital image. It is available via the 
website: ftp://ftp.nist.gov/pub/physics/mLclarke/NICE/. Opsonisation titres (OT) were 
then calculated using a free program available from the UAB lab called Opsotitre 3. The 
serum dilution that kills 50% of bacteria was classed as the OT. 
4.4.3.5.1. Key Conclusions from the University of Alabama (UAB) OPKA method 
After repeated unsuccessful attempts at replicating the UAB OPKA method, a new OPKA 
method was developed by Siân E. Faustini and Dr. Jenny Herbert (Post-Doctoral Fellow, 
Pneumococcal Research Group, Professor Tim Mitchell’s laboratory, University of 
Birmingham, Edgbaston, UK)  in order to obtain a working single-plex assay.  
Pneumococcus does not grow under traditional UAB OPKA conditions using the shaking 
technique. Pneumococcal strains are not cultured whilst shaking. Instead, they grow under 
static, anaerobic conditions. Therefore, it is illogical to shake them vigorously for any length 
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of time. Additionally, the amount of bacteria is not counted using this method. Therefore, 
the amount of the bacteria that is put into the test well is unknown. Bacterial counts and 
serial dilutions are performed in order to ensure that the amount of bacteria that is put into 
the test well is correct. 
4.4.3.6 New Optimised Method for OPKA 
The key problem with the UAB-mOPA assay is as follows: 
1) Pneumococcus does not grow well under traditional OPA conditions using the 
shaking technique. When pneumococcus is grown, they are grown under static, 
anaerobic conditions. They do not grow well under shaking, aerobic conditions such 
as the methods employed using the UAB OPKA method. 
Due to inconsistent results with the UAB-mOPA method, Dr. Jenny Herbert and I developed 
our own opsonophagocytic killing assay as follows: 
4 x 107 HL-60 cells were differentiated with 0.8% DMF for 5 days. Serum was heat-
inactivated at 56°C for 30 minutes and then added to the plate. Serum was diluted (1:2 ) up 
to 8 wells. 2.5 x 105 S. pneumoniae were added to each well and incubated for 30 minutes at 
4°C. The plate was then centrifuged for 5 minutes at 3060 g and then supernatants were 
removed. After this incubation period, 5 x 105 HL-60 cells (ATCC) and baby rabbit 
complement (7.5 µl) were added to the 96-well plate and then placed in the incubator at 37°C 
and 5% CO2 for 40 minutes. After the second incubation period, the sample wells are serially 
diluted 10-fold and plated (1:10) onto a BAB plate using a tilt method. The plates are then 
incubated overnight (16-18 hours) at 37°C and 5% CO2   and the colonies could be manually 
counted on the next day. Colonies should be countable (20-100 CFU).  
Once the plates were counted and 
recorded, opsonophagocytic killing 
assay (OPKA) titres could be assigned 
at 50% killing in comparison to 
bacteria, complement, and cells only 
control (no serum added) (see Figure 
4.6). Pn serotype 4, 6B, 14, and 23F 
antiserums (SSI- Statens Serum 
Institut) were used as internal 
controls.  
Figure 4.6. Assignment of OPKA titre (Taken from (339)). 
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4.4.3.6.1 Anti-serum controls show a high percentage of pneumococcal killing 
Specific human anti-serums against Pn 4, 6B, 14, and 23F were used as controls in order to 
calculate opsonophagocytic (OPKA) titre. Titres are defined as the reciprocal of the two-fold 
dilution that exhibited ≥50% killing compared to the complement control wells (BCC) where 
no antibody source is added to the test well). An OPKA titre > 1:8 is considered positive. 
Serotypes 4, 14, and 23F exhibited a high percentage of killing (93-97%) in the initial test 
well. However, serotype 6B exhibited a lower percentage of killing in the initial test 
well(66%) (Table 4.2). OPKA titres were high for each anti-serum control  and were as 
follows Pn 4 (320), 6B (80), 14 (160), and 23F (160) (Figure 4.7 A-D). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.2. Anti-serum control values (CFUs and percentage killing) in the OPKA assay. 
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Figure 4.7. Anti-serum controls show a high percentage of killing in the opsonophagocytic killing assay (OPKA). A. Pn4 anti-serum (1:100 dilution)(1:10 plating) B. Pn6B anti-serum (Neat 
dilution) (1:10 plating) C. Pn14 anti-serum (1:100 dilution) (1:10 plating). D. Pn23F anti-serum (1:100 dilution) (1:10 plating).  
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4.4.4 Data collection 
This study was based on a subset of the cohort of patients from the AIR study. The majority 
of patient samples were available; however, all samples needed to be re-run (as discussed 
extensively in Chapter 3), hence the available study cohort was much smaller than 
anticipated. Additionally, although contemporaneous measurements of Pn serotypes were 
available, since the samples had been tested over an extended period of time, all samples 
were chosen to be re-tested for the study, in order to minimise the impact of inter-plate 
variability. Pneumococcal vaccination was with PPV-23 until November 2010, at which 
point it was substituted for PCV-13. As such, in order to minimise the impact of any 
confounding factors that varied with time, patients were selected from those recruited prior 
to 2012 (N=527).  From these, we included only those with available pre-vaccine (up to 4 
weeks prior) and post-vaccine (4-17 weeks subsequently) blood samples taken for their 
initial vaccine (N=507).  Since longevity was being considered, any patients that did not 
have at least one annual sample in the subsequent years were excluded, leaving N=152. 
4.4.5 Statistical methods 
Initially, patients were divided into two groups depending on the first vaccine they were 
administered (PCV-13 or PPV-23). Patient demographics were compared using independent 
samples t-tests or Fisher’s exact tests, as applicable. The concentrations for each of the 
serotypes being considered were then compared between these groups for both the pre- and 
post-vaccine blood samples, as well as the fold change increase, using Mann-Whitney tests. 
The proportion of patients that had protective concentrations for each serotype were then 
identified, and compared between groups using Fisher’s exact tests. To test for any 
associations between the concentrations considered and either VL or CD4 count, a set of 
correlation analyses were then performed, using Spearman’s rho correlation coefficients. 
The number of doses required to achieve protective levels were then compared between the 
groups. This used all available blood samples for a patient to identify the time at which 
protection was achieved, and compared the number of doses administered before this point 
was recorded. Patients that were lost to follow up before achieving protection were treated 
as censored after receiving their final vaccine. The cumulative protection rates after different 
numbers of vaccines were then estimated using Kaplan-Meier curves, and comparisons 
between the PCV-13 and PPV-23 groups were performed using a log-rank test.  
Longevity of protection was also assessed using a Kaplan-Meier approach. Follow up 
started at the point that a patient achieved protection on at least 8 of 12 Pn serotypes, and 
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ended either when protection was found to be lost, or a booster vaccine was administered, 
with patients censored at the end of follow up. Comparisons were made by the first vaccine 
type (PCV-13 vs. PPV-23), as well as between those patients that required single vs. multiple 
doses for protection within the PCV-13 and PPV-23 subgroups. 
Longevity was then further assessed on an individual serotype basis. Since the decision to 
vaccinate had been made on the basis of protection on at least 8 of 12 Pn serotypes, it was 
not possible to produce a valid Kaplan-Meier approach for separate serotypes, due to issues 
with informative censoring. Instead, for the subgroup of patients that were not protected at 
the point of their initial vaccination, and were followed up until the point that they lost 
overall protection, the concentrations of the individual serotypes were assessed at the point 
that protection was lost. 
All analyses were performed using IBM SPSS 22 (IBM Corp. Armonk, NY), with p<0.05 
deemed to be indicative of statistical significance throughout. 
4.4.5.1 Sensitivity analyses 
Due to the long study duration, over six years from the first to the last included blood 
sample, retrospective validation was performed the assay used to measure the antibody 
concentrations (discussed in Chapter 3). This found inconsistency over time in the 
measurements produced by the assay, particularly in the early years of the study. As a 
result, all samples used in the analysis were re-tested contemporaneously, in order to 
minimise the impact of inter-plate variability on the results.  
Whilst this retesting should increase the reliability of the concentrations included in the 
analysis, the clinical decisions to vaccinate patients were still made based on the 
concentrations reported when the sample was originally tested. As such, there were cases 
where patients were vaccinated, despite their retested samples reporting that they were 
already protected against at least 8 of 12 Pn serotypes, and vice versa. As a result, when 
considering the number of doses required for protection, a proportion of patients were 
already found to be protected at baseline. In addition, when considering longevity, some 
patients were re-vaccinated, despite the fact that the retested samples identified them as still 
being protected at the time.  
In order to assess the impact of this on the results, sensitivity analyses were performed. For 
the analysis of protection rates, those patients that were identified as already being protected 
prior to their initial vaccination were excluded. For the remainder of the cohort, the 
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protection rates remained significantly higher after a single dose of PCV-13 than for PPV-23, 
with 47% vs. 23% of patients protected on at least 8 of 12 Pn serotypes (p=0.007). The 
protection rates were still higher in the patient group that received PCV-13 after boosting, 
with 86% vs. 60% and 100% vs. 82% of patients protected after a total of two and three doses, 
respectively. 
To investigate longevity of the immune response to pneumococcal vaccination, the analysis 
was repeated, with patients who were revaccinated before losing protection being censored 
at this point, rather than being treated as having lost protection. This increased the median 
longevity of protection for the cohort as a whole to 24.4 months (95% CI: 19.3 – 29.6), with 
the difference in longevity between those initially vaccinated with PCV-13 and PPV-23 
remaining significant (median: 32.6 vs. 12.5 months, p=0.021). 
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4.5 Results 
4.5.1 Demographics 
Data were available for N=152 patients, with an average age of 41.1 ± 10.2 years at the point 
of vaccination, and of whom 66% were male. Of these, 89 (59%) received PPV-23 and 63 
(41%) PCV-13 as their first vaccine. Comparisons between the groups (Table 5.1) found a 
similar gender distribution (p=0.490), with the PPV-23 group being marginally younger at 
the point of vaccination (mean: 39.5 vs. 43.2 years, p=0.028). Whilst the pre-vaccine CD4 
count was not found to differ significantly between the groups (p=0.056), the VL was 
significantly higher in the patients receiving PPV-23, with 39% vs. 21% having VL≥50. 
Table 4.3 – Patient Demographics 
 Whole Cohort 
(N=152) 
PCV-13 
(N=63) 
PPV-23 
(N=89) p-Value 
Age at Vaccination (Years) 41.1 ± 10.2 43.2 ± 10.8 39.5 ± 9.5 0.028 
Gender (N,% Male) 101 (66%) 44 (70%) 57 (64%) 0.490 
Pre-Vaccine CD4 506 ± 215 547± 229 477 ± 200 0.056 
Pre-Vaccine VL≥50 48 (32%) 13 (21%) 35 (39%) 0.021 
Data reported as mean±SD, with p-values from independent t-tests, or N (%), with p-values from Fisher’s exact 
tests, unless stated otherwise. 
Pre-vaccine VL and CD4 counts were unavailable for one patient, who was excluded from these analyses. 
Bold p-values are significant at p<0.05 
 
4.5.2 Single dose of PPV-23 vs. PCV-13  
The Pn concentrations for the included patients are reported in Table 4.4. Prior to 
vaccination, no significant differences were detected between the PCV-13 and PPV-23 
groups in the concentrations of any of the 12 Pn serotypes considered. After vaccination, the 
patients receiving PCV-13 had significantly greater fold change increases compared to PPV-
23 to 8 out of 12 Pn serotypes (Pn1, 3, 4, 5, 6B, 7F, 9V and 18C).  
The data were also analysed based on the proportion of patients with protective levels on 
each serotype (Table 4.5). Prior to the initial vaccination, the numbers of patients protected 
(>0.35 µg/mL) to at least 8 of the 12 Pn serotypes was similar in the two groups (PCV-
13=16%, PPV-23=17%, p=1.000). After vaccination, 54% of patients treated with PCV-13 
achieved protection, which was significantly greater than the 33% of patients receiving PPV-
23 (p=0.012) giving a relative risk for protection of 1.66 (95% CI: 1.10 – 2.46). 
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Table 4.4 – Comparisons of concentrations between vaccines 
Data are reported as medians and interquartile ranges, with p-values from Mann-Whitney tests 
Bold p-values are significant at p<0.05 
 
 
 
Serotype 
Pre-Vaccine Post-Vaccine Fold Change 
PCV-13 (N=63) PPV-23 (N=89) p-Value PCV-13 (N=63) PPV-23 (N=89) p-Value PCV-13 (N=63) PPV-23 (N=89) p-Value 
Pn1 0.07 (0.04 - 0.15) 0.07 (0.02 - 0.16) 0.599 0.59 (0.23 - 3.65) 0.35 (0.12 - 0.81) 0.003 8.53 (2.76 - 30.29) 4.97 (1.84 - 11.68) 0.006 
Pn3 0.07 (0.05 - 0.14) 0.10 (0.06 - 0.15) 0.147 0.19 (0.09 - 0.51) 0.13 (0.08 - 0.26) 0.042 2.14 (1.37 - 4.19) 1.38 (0.82 - 2.80) <0.001 
Pn4 0.08 (0.05 - 0.18) 0.08 (0.05 - 0.18) 0.827 0.36 (0.17 - 1.41) 0.15 (0.09 - 0.36) <0.001 3.28 (1.47 - 15.64) 1.75 (1.07 - 2.64) <0.001 
Pn5 0.21 (0.07 - 0.44) 0.13 (0.08 - 0.29) 0.281 0.67 (0.29 - 2.31) 0.27 (0.11 - 0.54) <0.001 2.82 (1.47 - 10.26) 1.80 (1.03 - 3.23) <0.001 
Pn6B 0.12 (0.05 - 0.62) 0.19 (0.08 - 0.52) 0.282 0.57 (0.21 - 4.33) 0.29 (0.11 - 1.56) 0.046 3.45 (1.26 - 11.46) 1.64 (0.88 - 3.91) 0.002 
Pn7f 0.50 (0.28 - 1.05) 0.76 (0.41 - 1.19) 0.103 0.85 (0.43 - 2.34) 0.80 (0.42 - 1.51) 0.483 1.41 (1.00 - 2.02) 1.22 (0.73 - 1.71) 0.045 
Pn9V 0.32 (0.20 - 0.76) 0.48 (0.25 - 0.82) 0.155 0.94 (0.37 - 2.51) 0.52 (0.28 - 1.06) 0.014 1.58 (1.09 - 4.94) 1.12 (0.70 - 1.85) <0.001 
Pn14 2.03 (0.56 - 8.14) 1.82 (0.71 - 4.61) 0.891 8.22 (1.65 - 10.00) 3.53 (1.03 - 10.00) 0.100 1.57 (1.00 - 3.89) 1.45 (1.00 - 2.87) 0.221 
Pn18C 0.17 (0.07 - 0.95) 0.17 (0.05 - 0.66) 0.692 1.45 (0.39 - 6.75) 0.61 (0.15 - 3.23) 0.012 5.71 (2.26 - 17.24) 3.53 (1.33 - 9.24) 0.011 
Pn19A 0.32 (0.10 - 1.13) 0.30 (0.13 - 0.95) 0.963 1.24 (0.27 - 4.96) 0.48 (0.18 - 3.74) 0.178 1.99 (1.13 - 5.84) 1.77 (1.01 - 4.37) 0.353 
Pn19F 0.29 (0.08 - 1.46) 0.28 (0.11 - 1.07) 0.918 1.53 (0.24 - 5.37) 0.82 (0.23 - 3.98) 0.333 1.92 (1.16 - 6.78) 2.58 (1.04 - 6.31) 0.821 
Pn23F 0.22 (0.05 - 0.52) 0.12 (0.06 - 0.41) 0.380 0.84 (0.14 - 3.99) 0.37 (0.10 - 1.26) 0.026 3.11 (1.21 - 10.46) 2.28 (1.23 - 5.67) 0.101 
Men C 0.14 (0.06 - 0.55) 0.38 (0.18 - 0.75) 0.002 1.84 (0.82 - 4.83) 1.89 (0.48 - 3.54) 0.354 10.39 (3.42 - 32.56) 4.11 (1.44 - 9.41) <0.001 
Tetanus 0.34 (0.06 - 0.62) 0.28 (0.06 - 0.66) 0.847 1.55 (0.28 - 3.03) 0.96 (0.23 - 2.46) 0.062 5.38 (3.16 - 9.09) 2.91 (1.28 - 7.97) 0.013 
Diphtheria 0.02 (0.01 - 0.04) 0.03 (0.02 - 0.05) 0.008 0.08 (0.03 - 0.20) 0.02 (0.01 - 0.04) <0.001 3.43 (1.84 - 7.26) 0.80 (0.59 - 1.14) <0.001 
Hib 1.25 (0.48 - 2.90) 1.54 (0.87 - 2.84) 0.124 7.32 (2.27 - 20.00) 2.90 (1.59 - 10.22) 0.005 4.18 (1.90 - 9.64) 1.84 (1.10 - 4.29) <0.001 
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Table 4.5. Concentrations for individual serotypes at the point that overall protection was achieved and lost 
   At Overall Protection (N=100)* At Loss of Overall Protection (N=63)** 
  
 Median Titre 
(IQR) % > 0.35µg/mL 
Median Titre 
(IQR) % > 0.35µg/mL 
Pn1  0.56 (0.27 - 1.85) 69 (69%) 0.22 (0.13 - 0.46) 20 (32%) 
Pn3  0.24 (0.15 - 0.57) 39 (39%) 0.12 (0.08 - 0.16) 7 (11%) 
Pn4  0.54 (0.20 - 1.21) 64 (64%) 0.19 (0.08 - 0.37) 16 (25%) 
Pn5  0.56 (0.32 - 2.15) 71 (71%) 0.27 (0.15 - 0.48) 20 (32%) 
Pn6B  1.14 (0.40 - 4.22) 80 (80%) 0.37 (0.18 - 1.39) 33 (52%) 
Pn7F  1.25 (0.70 - 2.29) 96 (96%) 0.49 (0.31 - 1.15) 40 (63%) 
Pn9V  1.24 (0.61 - 2.49) 95 (95%) 0.43 (0.28 - 0.79) 38 (60%) 
Pn14  6.39 (2.29 - 10.00) 99 (99%) 2.39 (0.82 - 6.53) 56 (89%) 
Pn18C  1.41 (0.53 - 4.93) 87 (87%) 0.46 (0.23 - 1.72) 36 (57%) 
Pn19A  1.35 (0.50 - 4.97) 87 (87%) 0.43 (0.19 - 2.88) 36 (57%) 
Pn19F  1.79 (0.75 - 5.22) 90 (90%) 0.64 (0.20 - 2.64) 40 (63%) 
Pn23F  1.13 (0.46 - 3.89) 84 (84%) 0.37 (0.17 - 0.78) 33 (52%) 
 *Values reported are from the first post-vaccine blood test which showed protective levels (>0.35 µg/mL) on at least 
8/12 serotypes. Patients already protected at the point of their first vaccine were excluded. 
**Values reported are from the first blood test after achieving protection where patients had lost overall protection, i.e. 
less than 8/12 serotypes having levels >0.35 µg/mL. Patients who were already protected at the point of their first 
vaccine were excluded, or who were revaccinated before losing protection were exclud
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4.5.2.1 Comparative data on a selection of study participant serum investigating the 
quantitative and qualitative responses to a single dose of PPV-23 or PCV-13. 
From Pn-specific IgG serum studies (section 4.5.2), it was evidenced that a single dose of 
PCV-13 appears to be more immunogenic than a single dose of PPV-23; however, the 
functionality of the Pn-specific IgG was not assessed in multiplexed Luminex studies.  
Furthermore, there is no protective correlate for OPA GMTs in the OPKA, so it hasn’t been 
assessed whether or not patients are protected post-vaccination (151). 
Evidence in the elderly suggests that an individual can have antigen-specific antibodies 
present; however, they may not necessarily be functional with regards to opsonising 
pneumococcal strains (56,184,185). Thus, Pn-specific IgG concentrations and 
opsonophagocytic killing assay titres were assigned in post-vaccination serum samples so 
that a relationship could be established between the amount and functionality of Pn-specific 
IgG.  
There was no clear correlation found between Pn-specific IgG and OPKA titres (Pn 4,6B, 14, 
and 23F) as evidenced by regression analyses in Figure 4.8/Table 4.6. 
 
 
Vaccine Type OPKA Pn4 Pn-specific IgG Pn4 OPKA Pn6B Pn-specific IgG Pn6B OPKA Pn14 Pn-specific IgG Pn14 OPKA Pn23F Pn-specific IgG Pn23F
SD PCV 11 0.07 893 0.05 437 1.23 19 0.02
SD PCV 10 0.12 16 0.3 1564 9.5 838 0.1
SD PCV 10 0.14 19 0.11 11 1.83 718 4.19
SD PCV 792 0.19 1321 1.15 8 5.29 2819 8.46
SD PCV 1548 4.53 700 0.35 2961 8.62 3921 2.85
SD PCV 10 0.01 19 0.02 13 0.45 19 0.01
SD PPV 10 0.06 28 0.02 8 0.57 1288 0.05
SD PPV 10 0.02 21 0.02 702 3.08 1231 0.84
SD PPV 10 0.3 16 4.12 267 9.4 U-shaped curve 1.7
SD PPV 1245 0.13 N-shaped curve 0.07 470 1.7 847 0.2
Table 4.6. Comparison of quantitative and qualitative Pn-specific IgG against Pn-serotypes (Pn 4, 6B, 14, and 23F) 
OPKA titres are reported as OPA GMTs (opsonic phagocytic assay geometric mean titre)  and Pn-specific IgG is reported as µg/mL. An OPKA titre 
above 8 is considered protective although there have been no correlates of protection established for PCV-13 vaccination, particularly in an HIV-
infected cohort.  A Pn-specific IgG titre of 0.35 µg/mL (WHO threshold) is considered the protective threshold,  
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4.5.3 Correlations between concentrations and CD4/VL 
On account of the significant difference in VL between the two groups at point of 
vaccination, a set of correlation analyses were performed to assess whether either VL or CD4 
impacted on vaccine response (Table 4.7). Neither CD4 nor VL were found to be 
significantly correlated with the concentrations of any of the Pn serotypes in either the pre- 
and post-vaccine periods. Additionally, neither PPV-23 or PCV-13 vaccine responses were 
affected by VL or CD4 counts. 
Figure 4.8. Comparison of Pn serotypes 4, 6B, 14, and 23F OPA GMT titres and Luminex (ELISA) Pn-specific 
IgG antibody titres from post-vaccination (4-weeks) serum. Regression analyses were performed. Data are 
reported as logged values of OPA GMTs (opsonic phagocytic assay geometric mean titre) and Pn-specific IgG is 
reported as µg/mL. R2 values are reported as the coefficients of determination. P values < 0.05 are considered 
significant.  
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          Table 4.7 - Correlations between CD4/VL and concentrations 
  CD4 VL 
  Pre-Vaccine Post-Vaccine Fold Change  Pre-Vaccine Post-Vaccine Fold Change 
Pn1 0.037 (p=0.651) 0.074 (p=0.366) 0.027 (p=0.738) 0.021 (p=0.800) -0.052 (p=0.528) 0.001 (p=0.989) 
Pn3 -0.090 (p=0.273) -0.069 (p=0.397) -0.001 (p=0.986) 0.113 (p=0.167) 0.031 (p=0.703) -0.056 (p=0.497) 
Pn4 0.044 (p=0.594) 0.052 (p=0.524) -0.009 (p=0.916) -0.001 (p=0.991) -0.012 (p=0.882) 0.011 (p=0.891) 
Pn5 -0.012 (p=0.885) 0.072 (p=0.377) 0.048 (p=0.555) 0.134 (p=0.102) 0.042 (p=0.610) -0.005 (p=0.956) 
Pn6B -0.043 (p=0.601) -0.003 (p=0.968) 0.066 (p=0.421) 0.028 (p=0.730) 0.002 (p=0.983) 0.009 (p=0.911) 
Pn7f -0.048 (p=0.560) -0.018 (p=0.830) 0.086 (p=0.294) 0.155 (p=0.057) 0.086 (p=0.295) -0.082 (p=0.318) 
Pn9V -0.096 (p=0.243) 0.002 (p=0.985) 0.091 (p=0.267) 0.126 (p=0.123) 0.078 (p=0.340) -0.015 (p=0.853) 
Pn14 0.037 (p=0.648) 0.051 (p=0.535) 0.000 (p=0.999) 0.011 (p=0.895) 0.019 (p=0.816) 0.023 (p=0.775) 
Pn18C -0.085 (p=0.302) -0.025 (p=0.760) 0.027 (p=0.745) 0.102 (p=0.213) 0.039 (p=0.638) -0.097 (p=0.234) 
Pn19A 0.057 (p=0.485) 0.069 (p=0.400) 0.029 (p=0.722) 0.033 (p=0.686) 0.041 (p=0.617) 0.012 (p=0.883) 
Pn19F 0.018 (p=0.825) 0.074 (p=0.363) 0.057 (p=0.485) -0.012 (p=0.887) 0.018 (p=0.827) 0.022 (p=0.787) 
Pn23F -0.094 (p=0.250) -0.012 (p=0.885) 0.074 (p=0.366) 0.029 (p=0.725) 0.076 (p=0.351) 0.061 (p=0.454) 
MenC -0.144 (p=0.077) 0.012 (p=0.883) 0.147 (p=0.071) 0.133 (p=0.104) -0.074 (p=0.365) -0.182 (p=0.025) 
Tetanus -0.016 (p=0.846) 0.104 (p=0.205) 0.171 (p=0.036) 0.134 (p=0.101) -0.028 (p=0.733) -0.145 (p=0.076) 
Diphtheria -0.155 (p=0.057) -0.028 (p=0.736) 0.067 (p=0.414) 0.151 (p=0.065) 0.066 (p=0.423) -0.024 (p=0.770) 
Hib -0.194 (p=0.017) 0.015 (p=0.859) 0.167 (p=0.040) 0.190 (p=0.020) 0.053 (p=0.520) -0.086 (p=0.296) 
Data are reported as Spearman’s rho correlation coefficients and p-values. Correlations that were significant at p<0.05 are in bold. One patient had no recorded CD4 or VL prior to        
the vaccine, and so was excluded from the analysis.
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4.5.4 Number of vaccine doses required for protection 
An analysis was then performed to consider the number of vaccines received by patients in 
order to achieve protection on 8 of 12 Pn serotypes (Figure 4.9). This found that patients 
receiving PCV-13 as their initial vaccine required significantly less doses to achieve Pn 
protection (p<0.001). After their initial vaccine, 39% of patients receiving PPV-23 and 70% 
receiving PCV-13 were protected. It must be noted that the percent protected reported after 
a single vaccine in the previous analysis (Table 4.8) differs from that found in this analysis 
(Figure 4.9). This is since the former only considers the immediate post-vaccine sample (4-17 
weeks after the vaccine) for each patient, whilst the latter includes all available blood 
samples taken after the first vaccine, and before any subsequent vaccines. Hence, patients 
that developed protection after an extended period will be classified as protected in the 
latter, but not the former. 
Patients receiving PPV-23 followed by a boost with PCV-13 had a similar rate of protection 
to those receiving a single dose of PCV-13 (67% vs. 70%), and those receiving PPV-23 
followed two doses of PCV-13 had similar rates of protection to those receiving two doses of 
PCV-13 (85% vs. 88%). After receiving three doses of PCV-13, the cumulative protection rate 
in the cohort was 100%. 
 
 
 
 
 
 
 
 
 
 
 
109 | P a g e  
 
 
 
 
 
 
 
 
 
 
Figure 4.9.  Protection rates by number of vaccines. Rates are Kaplan-Meier estimates, and the p-
value is from a log-rank test. The “number unprotected” is the number at risk after the stated vaccine, 
hence represents the number of patients that remain unprotected after the specified number of vaccines. 
*The number of patients who were censored between the stated vaccine numbers, due to being lost to 
follow up without achieving protective levels. 
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                                                            Table 4.8– Comparison of protection rates between vaccines 
  
Pre-Vaccine Post-Vaccine 
PCV PPV p-Value PCV PPV p-Value 
Pn1 9 (14%) 10 (11%) 0.624 39 (62%) 45 (51%) 0.188 
Pn3 7 (11%) 3 (3%) 0.094 20 (32%) 15 (17%) 0.050 
Pn4 6 (10%) 7 (8%) 0.773 32 (51%) 23 (26%) 0.002 
Pn5 20 (32%) 19 (21%) 0.187 42 (67%) 36 (40%) 0.002 
Pn6B 19 (30%) 30 (34%) 0.726 41 (65%) 42 (47%) 0.033 
Pn7F 39 (62%) 72 (81%) 0.015 50 (79%) 74 (83%) 0.672 
Pn9V 29 (46%) 59 (66%) 0.019 48 (76%) 58 (65%) 0.156 
Pn14 52 (83%) 79 (89%) 0.341 59 (94%) 82 (92%) 1.000 
Pn18C 23 (37%) 31 (35%) 0.865 48 (76%) 53 (60%) 0.037 
Pn19A 31 (49%) 38 (43%) 0.509 42 (67%) 48 (54%) 0.133 
Pn19F 29 (46%) 42 (47%) 1.000 44 (70%) 58 (65%) 0.601 
Pn23F 21 (33%) 25 (28%) 0.591 40 (63%) 45 (51%) 0.136 
8 of 12 Pns* 10 (16%) 15 (17%) 1.000 34 (54%) 29 (33%) 0.012 
Men C 5 (8%) 12 (13% 0.312 30 (48%) 43 (48%) 1.000 
Tetanus 44 (70%) 63 (71%) 1.000 58 (92%) 75 (84%) 0.214 
Diphtheria 6 (10%) 11 (12%) 0.795 28 (44%) 11 (12%) <0.001 
Hib 35 (56%) 63 (71%) 0.060 57 (90%) 76 (85%) 0.458 
         Data are reported as the N (%) of patients that had protective levels for individual serotypes 
     Protective levels were: 0.35 for Pns, 2 ug/mL for Men C, 1 ug/mL for Hib and 0.1 IU/mL for Dip. and Tet. 
     *Protective levels on 8 or more serotypes. 
     p-Values are from Fisher’s exact tests, and bold values are significant at p<0.05 
 
 
111 | P a g e  
 
4.5.5 Longevity of protection 
After excluding those 25 patients that were already protected at the time of their first 
vaccination, a total of 100 patients achieved protective levels on at least 8 of 12 Pn serotypes 
at some point during the follow up. This protection was found to last for a median of 17.4 
months (95% CI: 9.4 – 25.4), with 56%, 37% and 23% retaining protective levels for at least 1,2 
and 3 years, respectively. 
Patients whose initial vaccination was with PCV-13 were found to retain their protection for 
significantly longer than those whose first vaccine was PPV-23 (p=0.010, Figure 4.10), with 
median longevities of 23.5 (95% CI: 19.2 – 27.8) vs. 11.1 (9.1 – 13.2) months, and a hazard 
ratio of 1.80 (95% CI: 1.14 – 2.84). Subgroup analyses were then performed within these two 
groups to assess whether the longevity of protection differed between those patients who 
only needed a single vaccine to achieve protection, and those that required a booster (Figure 
4.11A/4.11B). No significant difference was detected between these groups in either those 
patients that received PCV-13 (p=0.830) or PPV-23 (p=0.472) as their initial vaccine. 
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Figure 4.10. Longevity of Pn protection by first vaccine type. Follow up starts at the point that protection (8/12 Pns>0.35) 
was achieved, and ends at the first blood test showing a loss of protection, or at the time that a booster vaccine was given, 
with patients being censored at the end of follow up. Those patients who did not achieve protective levels during the study 
period (N=27), or were already protected at the point of their first vaccine (N=25) were excluded from the analysis. 
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                    A. 
 
                         B. 
 
Figure 4.11. Longevity of Pn protection by vaccine regimen for patients A) Vaccine regimen for patients that 
receive PCV-13 as their first Pn vaccine B) Vaccine regimen for patients that receive PPV-23 as their first Pn vaccine. 
Follow up starts at the point that protection (8/12 Pns>0.35) was achieved, and ends at the first blood test showing a loss of 
protection, or at the time that a booster vaccine was given, with patients being censored at the end of follow up. Those 
patients who did not achieve protective levels during the study period (N=7 PCV, 20 PPV), or were already protected at the 
point of their first vaccine (N=10, 15) were excluded from the analysis. 
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4.5.6 Protection by serotype 
The concentrations of the individual serotypes were then further assessed for the 100 
patients that achieved protective levels on at least 8 of 12 Pn serotypes at some point during 
the follow up (Table 4.5). At the point that overall protection was achieved, concentrations 
were highest for Pn14, with a median of 6.39µg/mL, and 99% of patients having 
concentrations >0.35 µg/mL for this serotype. In contrast, Pn3 had the lowest median 
concentrations at the point of overall protection, at 0.24µg/mL, with only 39% of patients 
having concentrations >0.35 µg/mL.  
For the subgroup of 63 patients who subsequently lost protection on at least 8 of 12 Pn 
serotypes, the concentrations were similarly assessed at this point. Despite losing overall 
protection, levels of Pn14 remained high, with median concentrations of 2.39µg/mL, and 
89% of patients retaining levels >0.35µg/mL. 
4.6. Discussion 
PCV-13 covers approximately 61% of the serotype distribution amongst people co-infected 
with  invasive pneumococcal disease (IPD)  and HIV (1). In fact, three out of every 5 IPD 
episodes among HIV-positive adults could be prevented by successful vaccination with 
PCV-13 (1). 
The AIR study provided an opportunity to directly compare polysaccharide and conjugate 
vaccinations in HIV infected adults due to a deliberate change in the study schedule 
pneumococcal vaccination that occurred after 1 year of AIR study. 
This study provides further evidence that pneumococcal conjugate vaccination appears a 
more successful strategy than pure polysaccharide vaccination and has the added advantage 
that patients who receive PCV-13 as an initial dose can be boosted. A randomised placebo-
controlled trial of PCV-7 in HIV-infected adults was carried out in Malawi and 
demonstrated enhanced immunogenic protection against recurrent pneumococcal disease 
(142). Protein conjugate vaccination works by eliciting T-cell help rather than a T-
independent response traditionally associated with pure polysaccharide vaccine. HIV has 
multiple effects on the immune system but the hallmark association is a low CD4-T cell 
count. It seems counter intuitive that a vaccine that requires T-cell help for immunogenicity 
would be more successful in a disease where CD4-T cells are deficient or dysregulated, 
however, we found no association between response to conjugate vaccination and CD4 
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count, viral load or anti-retroviral (ARV) therapy. This is consistent with our group’s 
previous findings (178), as well as other studies which found no correlation between the 
pneumococcal-specific antibody response and CD4-T cell count (156,158). This suggests that 
the B-cell compartment may be responsible for successful responses to pneumococcal 
conjugate vaccination. However, some studies have reported inadequate vaccine responses 
with a low CD4-T cell count (159,160). Furthermore, the lack of effect of ARV therapy on 
pneumococcal –specific antibody response has been shown in other studies (160). 
Conversely, it has been shown that antibody responses to PCV-13 are greater than with 
PPV-23 in patients that have received ARV therapy (146,166). 
Vaccination regimes including both conjugate and polysaccharide vaccines have shown 
conflicting results, which suggests that there is potential variability in study design and 
patient settings (136,138,144,145,186). It was clear that neither a single dose of 
polysaccharide or conjugate vaccination was sufficient to provide adequate coverage for the 
HIV- population and that booster regimens may be more effective.  
Additionally, no clear correlations were found between Pn-specific IgG quantities and 
OPKA titres from a preliminary analysis on a subset of single dose vaccine samples. This 
finding has also been evidenced in one additional study in patients with multiple myeloma 
and other B-cell disorders (187). Thus, these results highlight the need for the assignment of 
OPKA titres because it reflects the functionality of the Pn-specific antibody response to 
pneumococcal vaccination. Used in conjunction with the Pn-specific IgG data, which 
establishes the breadth and granularity of the Pn-specific IgG response to pneumococcal 
vaccination, OPKA assays can be utilised to assess opsonic capacity. Thus, a larger sample 
size should be considered in future studies in order to further assess the opsonic capacity of 
Pn-specific IgG in single dose and booster dose samples.  
Given that there were no surrogate markers that could predict response to vaccination, this 
suggests that either schedules have to include vaccine response testing or the whole cohort 
could be routinely vaccinated with at least 2 conjugate vaccines. Our study only vaccinated 
when threshold levels drops so an appropriate booster schedule would have to be 
elucidated in adults. 
This study describes for the first time longevity of the antibody response to different 
pneumococcal vaccines.  Following successful vaccination, the conjugate vaccine had a 
significantly longer effect than the polysaccharide vaccine. However, the median response 
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even for the conjugate vaccine was short lived providing evidence that a booster schedule is 
necessary. We know from childhood pneumococcal vaccine studies that a 3 dose schedule is 
most effective in preventing invasive pneumococcal disease and it is likely that at least a 2 
dose schedule is required for HIV infected adults (77,164,165).  A study that gave three doses 
of PCV-13 in HIV-infected adults who were previously vaccinated with  PPV-23 found an 
initial increase in pneumococcal-specific antibodies, but had an overall similar level after 
each vaccine (173). It is interesting that both the UK and US, HIV associations recommend 
conjugate followed by polysaccharide vaccination to enable broader serotype coverage. 
However, we have evidence from this study that the polysaccharide response is very short 
lived at only 11 months and jeopardises response to further booster conjugate vaccination.  It 
is also currently recommended (The Green Book, Chapter 25) not to use polysaccharide 
pneumococcal vaccination within 5 years because of hyporesponsiveness (188). In patients 
that remain at risk of pneumococcal disease long term, there is a real need for newer 
conjugate vaccinations with wider serotype coverage that can be used in boosting regimens. 
It is important to highlight that there is a lack of controlled studies investigating vaccination 
against S. pneumoniae in HIV-infection. Although the AIR study aimed to improve patient 
care in the context of HIV-infection through the implementation of BHIVA vaccination 
guidelines, it had its potential weaknesses including the use of fixed vaccine doses without 
specified booster vaccine dates. Patients were only given a booster vaccination if they failed 
to mount an immune response to 8 out of 12 pneumococcal (Pn) serotypes.   
Limitations of our study include lack of understanding appropriate correlates of protection 
for pneumococcal plain polysaccharide and conjugate vaccines in HIV-infected adults, 
suggesting that the WHO threshold of 0.35 µg/mL may not be representative of this cohort 
and a higher correlate for protection  (0.81 µg/mL) may be more appropriate (151) . 
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Chapter 5. Pn-specific Subclass 
Assignment and Investigation of HIV-
infected Serum Samples 
Oral presentation: xMAP Connect 2017, Amsterdam, The Netherlands, November 2017 
Abstract submitted: ISPPD-11, The 11th International Symposium on Pneumococci and 
Pneumococcal Diseases (ISPPD), Melbourne, Australia, April 2018. 
5.1 Introduction 
IgG comprises about 10-20% of plasma protein in human serum and it is the most abundant 
class of the five immunoglobulins in humans. Each of these immunoglobulin classes are 
closely related; however, they differ in their effector functions and heavy chain structure 
(189). The IgG protein can be divided into four subclasses (discovered in the 1960s): IgG1, 
IgG2, IgG3, and IgG4, which are named in numerical order for their decreasing abundance 
in human serum (190). The generation of human monoclonal antibodies by Köhler and 
Millstein in 1975 has allowed for the investigation of antibody-antigen specificity (191).  
Furthermore, each IgG subclass has a unique function with regards to the binding of 
antigens, activation of complement proteins, formation of immune complexes, and 
activation of effector cells (189). Therefore, IgG responses to different antigens will activate 
the production of specific IgG subclasses (Figure 5.1).  
Although the structures of the IgG subclasses are very similar, there is still a great deal of 
variation within their hinge regions and CH2/CH3 domains (of the Fc portion of the 
antibody), particularly, an N-linked glycosylation site at position 297 of IgG, which can 
affect the quaternary structure of the Fc portion, thus exposing a larger area for FcγR (IgG-Fc 
receptors) to bind to (Figure 5.1) (189).  
The hinge region is the area of the IgG antibody that forms a bridge between the Fab and Fc 
portion. It has varying degrees of length and flexibility amongst the IgG subclasses and 
therefore, it affects active binding to FcγR and complement (C1q), binding of antigens, and 
formation of immune complexes. The hinge region is also an important structural difference 
that can impact the effector function of antibodies, most notably, the C1q binding site and 
FcγR on innate immune cells (189). Most notably, variation in flexibility of the hinge region 
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will contribute to the orientation and movement of the Fab and Fc portion of the antibody. 
Thus, Fab flexibility with respect to the length of the hinge region differs vastly across the 
IgG subclasses in this decreasing order: IgG3 > IgG1 > IgG4 > IgG2 (192).  
Protein antigens typically result in activation of B-cells by T-helper cells through MHC-class 
II binding, which results in an IgG1, IgG3, or IgG4 response (189). Non-protein or 
polysaccharide antigens results in a T-cell independent response, which involves class-
switching to IgG2. 
IgG1 is the most abundant subclass. IgG1 responses are produced as a result of antibody 
responses to soluble protein antigens and membrane proteins. Furthermore, a lack of IgG1 
can result in low total IgG concentrations (hypogammaglobulinemia) and recurrent 
infections (193,194). 
IgG2 is the second most abundant subclass, which is almost entirely due to IgG responses to 
encapsulated bacteria surrounded by polysaccharide (193,195–197). Furthermore, a lack of 
IgG2 can result in the complete loss of IgG anti-carbohydrate antibodies, although, it has 
been established that IgG1 and IgG3 will compensate for the loss of IgG2 (198,199).In IgG2 
deficiencies, patients have an increased susceptibility to bacterial infections, which suggests 
that IgG2 is integral in the bacterial immune response (200).  
Furthermore, it has been evidenced that total IgG1 and IgG3 responses are common immune 
responses to second-generation pneumococcal vaccines (including protein-conjugated 
polysaccharides such as those in PCV-13) in normal healthy individuals, which is contrary to 
wide spread belief that total IgG2 is the most common immune response (201).  
IgG3 is a pro-inflammatory antibody with a short half-life (limits excessive inflammatory 
responses) (189). Interestingly, IgG3  and IgG1 subclass antibodies tend to appear in the 
primary course of viral infections (193). IgG4 antibodies are produced following chronic 
exposure to an antigen in a non-infectious environment, which have the possibility of 
becoming a dominant subclass i.e. long-term bee keepers (189).  Additionally, IgG4, IgG1, 
and IgE responses are produced in response to allergens, such as bee-stings and allergic 
individuals (202–204). Furthermore, helminth and filarial parasite infections induce a robust 
IgG4 response (205,206). 
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Traditionally, Pn-specific IgG has been used to quantify patient immune responses to 
pneumococcal vaccination. However, it is known that in older children and adults, serotype-
specific antibodies following plain polysaccharide vaccination and/or natural exposure to 
pneumococcus in the environment tend to be IgG2-subclass specific as a result of a T-cell 
independent response  (195,196,207–210). However, serotype-specific antibodies following 
protein glycoconjugate vaccination against the non-toxic mutant of diphtheria toxin 
(CRM197)  and the tetanus toxoid tend to be IgG1-subclass specific as a result of a T-cell 
dependent response (211–213).  
As the patients within the AIR study were vaccinated with both plain polysaccharide 
pneumococcal vaccination (PPV-23) and pneumococcal polysaccharide conjugate 
vaccination (PCV-13), it seemed very appropriate to assign Pn-specific IgG1 and IgG2 
antibody concentrations to the standard lot 007sp for the multiplex Luminex assays in 
addition to the Pn-specific IgG that was also assessed. Assessing and quantifying these Pn-
specific subclasses is essential for understanding the immune response to different vaccines 
in this patient cohort.  
Other reasons for quantifying Pn-specific IgG subclasses include a study in adults that 
found Pn-specific IgG2 naturally acquired as a result of previous exposure to pneumococcus 
(207). Furthermore, other studies have shown that both IgG1 and IgG2 Pn-specific 
antibodies are produced in response to pneumococcal vaccination (207,214).  IgG subclasses 
should also be quantified and measured in response to pneumococcal vaccination as there 
are known functional differences including avidity, neutralisation, opsonic activity between 
subclasses found from previous studies investigating immune responses to other 
encapsulated bacteria (215–217).  
Furthermore, not much is understood with regards to which IgG subclass is responsible for 
immune recognition and defence against pneumococcus and other encapsulated bacteria 
Figure 5.1. Diagram of the IgG subclasses: IgG1, IgG2, IgG3, and 
IgG4  (Adapted from (189)). This diagram depicts the structure of 
each IgG subclass in addition to their CH2, CH3, and hinge regions. 
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(218–220). Also, with so much chronic immune inflammation and humoral dysregulation in 
HIV-infected adults, there could be an inhibitory effect of a particular IgG subclass, which 
inhibits opsonisation, successful phagocytosis, and clearance of pneumococcus and 
particular encapsulated bacteria as seen in three studies investigating immune responses to 
Salmonella typhimurium and Pseudomonas aeruginosa  (221–223).  
Two separate weight-based antibody assignments were performed in order to assign values 
from the pneumococcal reference serum standard lot 89-SF for IgG1 and IgG2 (224,225). 
However, in recent years, the pneumococcal reference serum was switched to 007sp and 
there have not been any bridging experiments performed to assign IgG1 and IgG2 antibody 
concentrations to 007sp. Therefore, we have performed a bridging experiment using a 
multiplex Luminex method in order to assign IgG1 and IgG2 antibody values from 89-SF to 
007sp. We have also tested a subset of HIV-infected serum samples in order to assess if there 
is a predominant IgG subclass produced in response to pneumococcal vaccination and 
whether there is a difference in subclass produced depending on the type of pneumococcal 
vaccination administered.  
Furthermore, whole PCP-IgG and PCP-IgG2 ELISA Binding Site assays were compared to 
Pn-specific IgG and IgG2 multiplex assays in order to assess whether or not the Binding Site 
assays predicted protection against 8 out 12 Pn serotypes. The pitfalls of the whole PCP-
Binding Site Assays include misdiagnosing protection against pneumococcus or 8 out of 12 
Pn serotypes because Pn serotype-specific IgG levels are not determined in these assays. 
Thus, high Pn-specific IgG concentrations against a specific serotype such as Pn14, may 
mask protection against other Pn serotypes in the Binding Site Assays investigated in this 
chapter. 
5.2 Materials and Methods 
5.2.1. Ethical Approval 
Ethical approval for the serum samples used in this investigation is outlined in section 2.3.  
5.2.2. 18-plex Luminex assay IgG subclass Antibody Quantification and 
Assignment from human reference standard serum 89-SF to 007sp 
The same methods (described in section 2.5.2) to assess Pn-specific IgG subclasses (IgG1-4) 
were performed in order to assign and quantify Pn-specific IgG subclass antibody 
concentrations in HIV-infected human serum. S. pneumoniae antigens (Pn 
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1,3,4,5,6B,7F,9V,14,18C,19A,19F, and 23F) in addition to PPV-23 and PCV-13 vaccine beads 
were assessed. However, Pn19A, PPV-23, and PCV-13 IgG1 and IgG2 antibody 
concentrations were not assigned from standard lot 89-SF to 007sp as there were no available 
antibody concentrations assigned to lot 89-SF from the original experiments performed by 
Soininen et al (224) and Sikkema et al (225). Furthermore, Pn-specific IgG3 and IgG4 
antibody concentrations are expressed as MFIs as opposed to concentrations as these 
assignments have not been performed because previous studies have found these 
concentrations to be below the limit of detection in 89-SF (225). 
5.2.2.1. Conjugation of whole PPV-23 and PCV-13 vaccines to Luminex beads for use in the 
Luminex IgG assay 
5.2.2.1.1 Conjugation of whole PPV-23 vaccines to Luminex beads 
Whole PPV-23 (Total concentration of each polysaccharide is 50 µg/mL) was conjugated to 
PLL (described previously in section 2.5.2.1.) except two 0.5 mL vials (575 µg polysaccharide 
per vaccine vial) were combined on G25 PD-10 Sephadex desalting columns to double the 
concentration of each pneumococcal polysaccharide in the PPV-23-PLL eluate (Estimated 
concentration was 328.6 µg/mL).  
Furthermore, we found that 65 µg of PPV-23-PLL conjugated to 1 x 106  Luminex beads (as 
described previously in section 2.5.2.2) achieved optimal MFIs in the Luminex Pn-IgG assay.  
6.2.2.1.2 Conjugation of whole PCV-13 vaccines to Luminex beads 
The whole PCV-13 vaccine was conjugated directly to Luminex beads (as described 
previously in section 2.1.2) via the CRM197 protein. The total concentration of the Pn-
polysaccharides in the vaccine (0.5 mL) was 30.8 µg (2.2 µg of Pn 1,3, 4, 5, 6A, 7F, 9V, 13, 18C, 
19A, 19F, and 23F; 4.4 µg of Pn 6B). The total amount of the CRM197 protein was 32µg per 0.5 
mL of vaccine. 
Furthermore, we found that 12 µg of CRM197  (0.8 µg of each Pn polysaccharide except 1.6 µg 
Pn 6B in the PCV-13 vaccine) conjugated to 1 x 106  Luminex beads (as described previously 
in section 2.5.2.2) achieved optimal MFIs in the Luminex Pn-IgG assay. Previous 
experiments found that pre-absorption with the CRM197 protein had a minimal effect on 
007sp standard reference serum curves; therefore, it was decided not to pre-absorb the 
patient serum samples with the CRM197 in subsequent experiments.  
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5.2.3 Anti-PCP IgG Antibody Quantification using the Binding Site Assay Kit 
Anti-PCP IgG antibody concentrations were measured using commercially available 
VaccZyme™ PCP IgG ELISAs (The Binding Site Group Limited, Birmingham, UK).  
Methods were described as per manufacturer’s guidelines (226). The cut-off for protection 
required for an adequate immune response to pneumococcal vaccination was >50 mg/L, as 
identified by Chua and colleagues (227). 88 HIV-infected patient serum samples were 
randomly selected from four quartiles (low, low medium, high medium, high) based on MFI 
titres to the whole PPV-23 Luminex bead investigation. Of the 88 patient serum samples, 11 
patients received a single dose of PPV-23 and 11 patients received a single dose of PCV-13 as 
part of the AIR study.  
5.2.4. Anti-PCP IgG2 subclass Antibody Quantification using the Binding Site 
Assay Kit  
PCP IgG2 subclass antibody concentrations were measured using commercially available 
VaccZyme™ PCP IgG2 ELISAs (The Binding Site Group Limited, Birmingham, UK).  
Methods were described as per manufacturer’s guidelines (210). The cut-off for protection 
required for an adequate immune response to pneumococcal vaccination was 12 mg/L, as 
identified by Parker and colleagues (210). 88 HIV-infected patient serum samples (pre- and 
post-vaccination) were used. 22 patients received a single dose of PPV-23 and 22 patients 
received a single dose of PCV-13 as part of the AIR study.  
5.2.5. Serum 
Human anti-pneumococcal standard reference serum lot 89-SF (1:20 dilution) and 007sp 
(1:10 dilution) were used in order to quantitate Pn-specific IgG1 and IgG2 antibody 
concentrations. 
HIV-infected serum (1:100 dilution) from 50 patients (pre- and post-pneumococcal 
vaccination) was used in order to quantify Pn-specific IgG1 and IgG2 antibody 
concentrations. IgG1 and IgG2 antibody MFIs were reported for antigen Pn19A. 
Furthermore, HIV-infected serum from a subset of 17 patients was used in order to quantify 
Pn-specific IgG3 and IgG4 antibody MFIs for all of the antigens mentioned in section 5.2.2.  
5.2.6. Monoclonal Antibodies against Human IgG Subclasses 
Murine monoclonal anti-human IgG1 (MG6.41 #200113/2), anti-human IgG2 (HP-6200 
#050513/1), anti-human IgG3 (MG5.161 #260914/3), and anti-human IgG4 (RJ4 #210816/P) 
were used to detect the binding of Pn-specific subclass antibodies in the 18-plex Luminex 
assay (Available from Sera Science, Abingdon Health, Dr. Margaret Goodall). The 
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specificities of these anti-human IgG subclass antibodies have been established in a 
collaboration with the WHO and the International Union of Immunological Societies (228–
230). 
5.2.6.1. Conjugation of anti-human monoclonal antibodies against human IgG subclasses 
using Lightning-Link RPE technology 
Anti-human monoclonal antibodies as mentioned in section 5.2.5 were conjugated to R-
Phycoerythrin (RPE) (Lightning Link R-PE Conjugation Kit; Innova Biosciences, Cambridge, 
UK) in order to be used as secondary antibodies in the 18-plex Luminex assay. Antibodies 
were conjugated at 1 mg/mL. A volume of 1 µl of LL-modifier reagent (Lightning Link R-PE 
Conjugation Kit; Innova Biosciences, Cambridge, UK) was added for every 10 µl of antibody 
conjugated to RPE. The antibody and LL-modifier reagent mixture was then added to the 
Lightning-Link lyophilised mixture in a glass vial (Lightning Link R-PE Conjugation Kit; 
Innova Biosciences, Cambridge, UK). Once added, the vial was left to incubate in the dark at 
RT overnight. Then, 1 µl of LL-quencher (Lightning Link R-PE Conjugation Kit; Innova 
Biosciences, Cambridge, UK) was added for every 10 µl of antibody conjugated to RPE. The 
conjugates can be stored safely in the dark at 4°C for up to 18 months.  
5.2.6.2. Titration of anti-human RPE-conjugated monoclonal antibodies 
Anti-human monoclonal antibodies as mentioned in section 5.2.5 were titrated at various 
concentrations (5 µg/mL, 2 µg/mL , 0.5 µg/mL, and 0.25 µg/mL) using standard lot 007sp 
(1:10 dilution in standard buffer as mentioned in section 5.2.2.) against the antigens 
mentioned in section 5.2.2. in the 18-plex Luminex assay. Samples were tested in duplicate 
and average MFIs were generated. Optimal MFIs were generated for IgG1-RPE at 0.5 
µg/mL, IgG2-RPE at 5 µg/mL, and IgG3-RPE and IgG4-RPE at 2 µg/mL. A volume of 100 µl 
of the secondary-antibody conjugates was added to the Luminex sample wells as described 
in section 5.2.2.  
5.2.6.3. Equivalence-of-absorbance method for assigning serotype-specific IgG1 and IgG2 
quantities 
The Pn-specific quantities assigned to IgG1 and IgG2 assigned previously for human 
reference standard serum 89-SF (224,225) to serotypes 1,3,4,5,6B,7F,9V,14, 18C, 19F, and 23F 
were used to extrapolate serotype-specific IgG1 and IgG2 values in the human reference 
standard serum 007sp using an equivalence of absorption method (153). Not all MFIs 
reached 1000, as used monoclonal antibodies which will only bind one epitope, not multiple 
epitopes with regards to polyclonal antibodies. Independent standard curves were 
generated for each serotype-specific subclass reference by plotting the log of optical density 
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versus the log of serum dilution using a validated curve fitting data analysis software 
(MasterPlex ReaderFit; Hitachi Solutions, Irvine,CA,USA) (224,225).  The concentration of lot 
007sp (µg/mL) for a given MFI was calculated using either a four or five-parameter logistic 
curve fitting algorithm (Figure 6.3 and 6.5) that were suitable for all 11 Pn serotypes. Lots 89-
SF and 007sp were tested in duplicate and run three times for 16 (IgG1) and  (IgG2) standard 
points (in order to establish the dynamic range of the assay) and an average of the MFIs 
(Figure 5.2 and 5.4) were calculated for each serotype-specific IgG1 and IgG2 subclass and 
used to assign a new subclass value for each serotype in lot 007sp (Table 5.1).  
The dynamic range of the Pn-IgG1 assay for each of the 11 Pn serotypes tested was 
established as 0.01-3 µg/mL. Pn-IgG2 assay for each of the 11 Pn serotypes tested was 
established as 0.01-6 µg/mL. For any patient sample results that were below or above these 
limits, the cut-off values were applied.  
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Figure 5.2. Pn serotype-specific IgG1 MFIs in standard reference lot 007sp and 89-SF.  These graphs show 16-point 
standard curves that were used in order to establish the dynamic ranges of the Pn-specific IgG1 assays using 89-SF and 
007sp. Furthermore, the MFIs from 007so were used to assign a new subclass value for each 11 serotypes in 007sp.  
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Standard 1 in 20 Pn14 89-SF MFI 1 in10 Pn14 007sp MFI
Type Dilution MFI Dilution MFI
S1 0.05 623.3 0.1 467
S2 0.025 445.2 0.05 342
S3 0.0125 341 0.025 253
S4 0.00625 235.7 0.0125 168
S5 0.003125 149.2 0.00625 120
S6 0.0015625 83.2 0.003125 76
S7 0.00078125 50.2 0.001563 44
S8 0.000390625 30.7 0.000781 25
S9 0.000195313 17 0.000391 15
S10 9.76563E-05 11 0.000195 9
S11 4.88281E-05 6.7 9.77E-05 5
S12 2.44141E-05 4.7 4.88E-05 4
Figure 5.3. Representative schematic of the equivalence-of-absorbance method for assigning serotype-specific IgG1 
using ReaderFit Curve fitting software for assignment of Pn14 IgG1-specific antibody titres from 89-SF to 007sp. A) 
This graph shows averaged MFIs (Log10) for Standards 1- 12 dilutions of both Pn-14 IgG1 in 89-SF and 007sp. B) This 
table shows each averaged MFI recorded for both the 89-SF and 007sp curves shown in Panel A. C) This graph depicts 
a 5-parameter logistics calculation in the ReaderFit program that has been applied to both the 89-SF and 007sp 
standard curves in order to assign a Pn14-IgG1 antibody titre to 007sp.  
A. 
B. 
C.  
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Figure 5.4. Pn serotype-specific IgG2 MFIs in standard reference lot 007sp and 89-SF.  These graphs show 16-point 
standard curves that were used in order to establish the dynamic ranges of the Pn-specific IgG1 assays using 89-SF 
and 007sp. Furthermore, the MFIs from 007so were used to assign a new subclass value for each 11 serotypes in 
007sp. 
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Standard 1 in 20 Pn14 89-SF MFI 1 in10 Pn14 007sp MFI
Type Dilution MFI Dilution MFI
S1 0.05 --- 0.1 887.3
S2 0.025 718.7 0.05 851.0
S3 0.0125 624 0.025 803.2
S4 0.00625 469 0.0125 683.3
S5 0.003125 298.7 0.00625 536.5
S6 0.0015625 208 0.003125 376.2
S7 0.00078125 125.3 0.0015625 240.0
S8 0.000390625 74.5 0.00078125 160.2
S9 0.000195313 40 0.000390625 88.0
S10 9.76563E-05 19.8 0.000195313 54.7
S11 4.88281E-05 10.7 9.76563E-05 27.7
S12 2.44141E-05 5.7 4.88281E-05 13.8
S13 1.2207E-05 3 2.44141E-05 6.7
S14 6.10352E-06 --- 1.2207E-05 4.3
S15 3.05176E-06 --- 6.10352E-06 2.3
S16 1.52588E-06 --- 3.05176E-06 2.3
A. 
B. 
C. 
Figure 5.5. Representative schematic of the equivalence-of-absorbance method for assigning serotype-specific IgG2 
using ReaderFit Curve fitting software for assignment of Pn14 IgG2-specific antibody titres from 89-SF to 007sp. A) 
This graph shows averaged MFIs (Log10) for Standards 1- 16 dilutions of both Pn-14 IgG2 in 89-SF and 007sp. B) This 
table shows each averaged MFI recorded for both the 89-SF and 007sp curves shown in Panel A. C) This graph depicts a 
5-parameter logistics calculation in the ReaderFit program that has been applied to both the 89-SF and 007sp standard 
curves in order to assign a Pn14-IgG2 antibody titre to 007sp.  
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Pn Serotype IgG1 IgG2 IgG1 + IgG2 Assigned Total IgG in 007sp
Pn1 0.21 1.85 2.06 8.50
Pn3 0.16 0.20 0.36 1.45
Pn4 1.14 0.28 1.42 3.33
Pn5 0.09 6.03 6.12 7.51
Pn6B 0.41 0.85 1.25 9.05
Pn7F 0.29 2.40 2.68 8.30
Pn9V 0.39 5.99 6.37 6.44
Pn14 0.15 2.13 2.28 37.99
Pn18C 0.41 6.40 6.81 7.30
Pn19F 0.26 20.48 20.74 14.61
Pn23F 0.14 0.11 0.25 5.95
Concentration (ug/ml)
Table 5.1. Novel assigned Pn-specific subclass antibody values from reference standard lot 007sp.  
Pn-specific IgG1 and IgG2 are represented in µg/mL. Pn-specific IgG1 and IgG2 antibody titres were assigned 
from standard reference lot 89-SF to 007sp.  
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5.3 Results: Examination of the IgG Subclass Response to 
Pneumococcal Vaccination 
5.3.1 Whole IgG versus IgG subclass response to vaccination  
The initial analysis was to examine MFIs pre- and post-vaccination for IgG and IgG1, IgG2, 
IgG3, and IgG4 (Figure 5.6/Table 5.2)). We found that the PPV-23 vaccine serotype response 
for IgG2 was much greater than the response to IgG1, IgG3, and IgG4; however, there was 
still a strong IgG1 response for all 11 Pn serotypes tested (Figure 5.6/Table 5.2). 
Furthermore, the PCV-13 vaccine serotype response for IgG1 and IgG2 was equivalent, 
which was more robust than the response to IgG3 and IgG4 (Figure 5.6/Table 5.2). 
However, the IgG3 response was higher in the PCV-13 vaccine cohort than the PPV-23 
vaccine cohort (Figure 5.6/Table 5.2). We also found that the IgG4 response was limited for 
both the PPV-23 and PCV-13 vaccine cohorts (Figure 5.6/Table 5.2).  
 
 
 
Table 5.2. Number of Pn vaccine antigens with a 
significant difference pre-to-post vaccination  
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Figure 5.6. Whole IgG versus IgG subclass response to pneumococcal vaccination in a cohort of HIV-infected 
patients in the UK. For pre-post vaccination: Wilcoxon Matched Pair t-tests, non-parametric. For pre and post-
vaccination between PPV and PCV groups: Mann-Whitney U t-tests, unpaired, non-parametric tests were performed.  
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5.3.2. Examination of Fold Changes 
We then went on to examine fold changes for Pn-specific IgG (Figure 5.7) and Pn-specific 
IgG subclasses (Figure 5.8). The IgG1-4 responses including the absolute antibody 
concentrations and fold changes differed across all of the 11 Pn serotypes. Furthermore, this 
was vastly different between the PPV-23 and PCV-13 cohorts. We then ranked fold changes 
to see which Pn serotypes had the greatest/lowest fold change for Pn-specific IgG and the 
IgG subclasses and then analysed these changes into vaccine cohorts (Figure 5.8/Table 5.3).  
We found that Pn 1 has the highest rank across the Pn-specific IgG and Pn-specific IgG1-4 
for both the PPV-23 and PCV-13 cohorts. This could be due to the fact that it is an invasive 
serotype, so therefore, patients mount a more robust immune response to this serotype as 
it’s not naturally acquired through the environment. Pn 1 is ranked as one of the most 
prevalent serotypes that causes IPD on a global scale even though it is not normally detected 
in nasopharyngeal carriage (231,232). It has been established that Pn 1 is carried for a 
relatively short period of approximately 9 days post-exposure in humans (233). Therefore, it 
has been hypothesized that Pn 1 may undergo a lower rate of genetic recombination due to 
lesser opportunities for genetic exchange during nasopharyngeal carriage (234,235).   
Furthermore, the Pn1 capsular polysaccharide is a zwitterionic structure that induces a T-cell 
dependent response, which could explain the robust Pn-1 specific IgG response seen in 
Figure 5.7 (235). However, Pn 14 can be naturally acquired through the environment, which 
is evidenced by the high antibody concentrations seen in  most patient samples . The fold 
change ranks across the subclasses for this serotype are relatively low, which reflects the 
idea that  this strain is naturally acquired through the environment.  
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Figure 5.7. Pn-specific IgG fold change and ranks for 11 Pn serotypes according to PPV-23 or PCV-13 vaccination. 
Fold changes are represented as medians.  
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Figure 5.8. Pn-specific IgG1-4 fold change and ranks for 11 Pn serotypes according to PPV-23 or PCV-13 vaccination. Fold changes are represented as medians. 
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Table 5.3. Pn-specific IgG and IgG subclasses- Examination of fold change ranks for 11 Pn serotypes according to PPV-23 or PCV-13.  
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5.3.3. Quality of the Pn-specific IgG response in an individual 
The proportional amount of Pn-specific IgG1-4 produced is different for each Pn serotype. 
Therefore, we examined absolute values, fold change, and IgG: IgG subclass ratios (Figures 
5.9- 5.19/Tables 5.4-5.9). The significant increase in whole IgG concentrations differ to 
examining IgG subclasses. Furthermore, IgG subclass analysis offers further understanding 
of the IgG response to different vaccines.  
5.3.3.1. Pn Serotype 1 
For Pn-serotype 1 (Figure 5.9), there was more IgG and IgG2 produced in the PCV-13 cohort. 
Significant differences were detected from baseline to post-vaccination for all of the IgG-
IgG4 assays in each cohort; however, there were no significant differences detected post-
vaccination between the PPV-23 and PCV-13 cohorts for the Pn-IgG1, IgG3, and IgG4 assays. 
Furthermore, there were no significant differences detected for fold changes between 
vaccine cohorts; however, it is important to note the vast differences in fold change for each 
Pn-IgG-IgG4 assay (Figure 5.8/Tables 5.4-5.9). A difference was seen in the amount of 
IgG:IgG1 produced for Pn1 between the PPV-23 and PCV-13 vaccine cohorts (p=0.0170). 
This suggests that the proportion of IgG to IgG1 produced in the PCV-13 cohort was greater 
in contrast to the amount of IgG produced in the PPV-23 cohort.  
5.3.3.2. Pn Serotype 3 
For Pn-serotype 3 (Figure 5.10), there were no significant differences found post-vaccination 
between PPV-23 and PCV-13 cohorts for absolute Pn3-IgG, Pn3-IgG3, and Pn3-IgG4 values. 
However, there was a significant difference (p=0.0445) seen pre-vaccination between the two 
cohorts. Furthermore, there was a significant difference seen from baseline to post-
vaccination in the PCV-13 cohort (p<0.0001). Significant differences were also seen from 
baseline to post-vaccination in both cohorts (PPV-23 (p=0.0098) and PCV-13 (p=0.0002) for 
Pn3-IgG1. However, only a significant difference was seen for the PCV-13 cohort for Pn3-
IgG2 (p<0.0001). Pn3-IgG3 and IgG4 MFIs were also quite low in both vaccine cohorts. A 
greater fold change was seen in the amount of Pn3-IgG produced for the PCV-13 cohort 
(p=0.0052, 2.22 median fold-change (1.32-3.89)) (Figure 5.10/Table 5.4). ). No other 
differences in fold change were seen in the Pn-IgG subclass assays for both vaccine cohorts; 
however, it is worthwhile to note that the fold changes varied widely. A difference was seen 
in the amount of IgG:IgG1 produced for Pn3 between the PPV-23 and PCV-13 vaccine 
cohorts (p=0.0028). This also suggests that the proportion of IgG to IgG1 produced in the 
PCV-13 cohort was greater in contrast to the amount of IgG produced in the PPV-23 cohort. 
There were no significant differences between the vaccine cohorts for the IgG:IgG2-4 ratios.  
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5.3.3.3 Pn Serotype 4 
For Pn-serotype 4 (Figure 5.11), there was a greater amount of Pn3-IgG (p=0.0009), Pn3-IgG2 
(p=0.0140), and Pn3-IgG3 (0.0230) produced post-vaccination for the PCV-13 cohort. 
Additionally, significant differences were seen from baseline to post-vaccination for both 
vaccine cohorts for Pn4-IgG (PPV-23 (p=0.0255) and PCV-13 (p<0.0001)), Pn4-IgG1 (PPV-23 
(p=0.0004) and PCV-13 (p<0.0001)), Pn4-IgG2 (PPV-23 (p=0.0003) and PCV-13 (p<0.0001)), 
and Pn4-IgG3 (PPV-23 (p=0.0204) and PCV-13 (p=0.0024)). Pn-IgG4 MFIs were low for both 
vaccine cohorts and no significant differences were detected. Furthermore, no significant 
differences were detected with regards to fold change for the Pn4-IgG-IgG4 assays; however, 
the PCV-13 cohort produced the greatest fold change in Pn4-IgG2 produced (median 3.68) 
compared to the PPV-23 cohort (median 2.06), although, this observation was non-
significant (p=0.2776). Differences were seen in the amount of IgG:IgG1 (p=0.0011) and 
IgG:IgG4 (p=0.0216)  produced for Pn4 between the PPV-23 and PCV-13 vaccine cohorts. 
This also suggests that the proportion of IgG to IgG1 and IgG4 produced in the PCV-13 
cohort was greater in contrast to the amount of IgG produced in the PPV-23 cohort. There 
were no significant differences between the vaccine cohorts for the IgG:IgG2-3 ratios. 
5.3.3.4 Pn Serotype 5 
For Pn-serotype 5 (Figure 5.12), there were no significant differences detected between the 
vaccine cohorts, however, there were differences seen from baseline to post-vaccination for 
Pn5-IgG (PPV-23 (p=0.0088) and PCV-13 (p<0.0001)), Pn5-IgG1 (PPV-23 (p=0.0229) and 
PCV-13 (p<0.0060)),and Pn5-IgG2 (PPV-23 (p<0.0001) and PCV-13 (p=0.0001)). There was a 
significant difference detected between baselines between the PPV-23 and PCV-13 cohort 
(p=0.0237). Pn5-IgG3 and Pn5-IgG4 MFI levels were quite low with no significant 
differences detected between the vaccine cohorts or from baseline to post-vaccination within 
the vaccine cohorts. Additionally, no significant differences were seen in fold-change for 
Pn5-IgG-IgG4. However, Pn5-IgG1-4 all produced median fold changes below 2. The 
greatest fold changes for Pn5 were detected for IgG (PPV-23 ( median 2.34) and PCV-13 
(median 2.45); ns)). Differences were seen in the amount of IgG:IgG1 (p=0.0014), IgG:IgG2 
(p=0.0059), IgG:IgG3 (p=0.0410)) produced for Pn5 between the PPV-23 and PCV-13 vaccine 
cohorts. This also suggests that the proportion of IgG to IgG1-IgG3 produced in the PCV-13 
cohort was greater in contrast to the amount of IgG produced in the PPV-23 cohort. There 
were no significant differences between the vaccine cohorts for the IgG:IgG4 ratio. 
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5.3.3.5 Pn Serotype 6B 
For Pn-serotype 6B (Figure 5.13), there were no significant differences detected between the 
vaccine cohorts, however, there were differences seen from baseline to post-vaccination for 
Pn6B-IgG (PPV-23 (p=0.0315) and PCV-13 (p<0.0001)), Pn6B-IgG1 (PPV-23 (p=0.0004) and 
PCV-13 (p<0.0007)),Pn6B-IgG2 (PPV-23 (p<0.0001) and PCV-13 (p<0.0001)), Pn6B-IgG3 
(PPV-23 (p=0.0317) and PCV-13 (p=0.0002)). There were no significant differences seen for 
Pn6B-IgG4 and MFIs were also low in both vaccine cohorts. The PCV-13 cohort had the 
greatest fold change (median 3.58) for Pn6B-IgG post-vaccination compared to the PPV-23 
cohort (median 2.03). However, this observation was non-significant (p=0.0642). Both PPV-
23 and PCV-13 cohorts had equivalent fold changes (medians 3.25) for Pn6B-IgG2 (ns; 
p=0.6472). There were no significant differences seen between the vaccine cohorts for the 
IgG:IgG1-4 ratios.  
5.3.3.6 Pn Serotype 7F 
For Pn-serotype 7F (Figure 5.14), there were no significant differences detected between the 
vaccine cohorts, however, there were differences seen from baseline to post-vaccination for 
Pn7F-IgG (PPV-23 (p=0.0450) and PCV-13 (p=0.0025)), Pn7F-IgG1 (PPV-23 (p=0.0067) and 
PCV-13 (p=0.0001)),Pn7F-IgG2 (PPV-23 (p<0.0001) and PCV-13 (p=0.0002)), Pn7F-IgG3 
(PCV-13 (p=0.0038). There were no significant differences detected for Pn7F-IgG4 and the 
MFIS were also low in both vaccine cohorts. The fold changes for both vaccine cohorts were 
below a median of 2 for Pn7F-IgG, Pn7F-IgG1, Pn7F-IgG3, and Pn7F-IgG4 and were also 
non-significant. However, both PPV-23 and PCV-13 vaccine cohorts produced median fold 
changes greater than 2 (PPV-23 (median 2.47) and PCV-13 (median 2.12)), although, these 
fold changes were non-significant (p=0.2629). There were no significant differences 
produced for Pn IgG:IgG1-4 for both vaccine cohorts (Table 5.9).  
5.3.3.7 Pn Serotype 9V 
For Pn-serotype 9V (Figure 5.15), there was a greater amount of Pn9V-IgG2 produced for the 
PCV-13 than the PPV-23 cohort (p=0.0217). Additionally, significant differences were only 
seen from baseline to post-vaccination in the PCV-13 cohort for Pn9V-IgG (p<0.0001), Pn9V-
IgG1 (p=0.0042), and Pn9V-IgG3 (p=0.0232). However, significant differences were detected 
for both vaccine cohorts for Pn9V-IgG2 (PPV-23 (p=0.0003) and PCV-13 (p~<0.0001)). Both 
vaccine cohorts did not produce greater than a 2-fold change for Pn9V-IgG1, Pn9V-IgG3, 
and Pn9V-IgG4. However, the PCV-13 cohort produced 2-fold changes for Pn9V-IgG  
(median 2.16) and Pn9V-IgG2 (median 2.32). The PCV-13 cohort produced a 2-fold change in 
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Pn9V-IgG, which was greater than the PPV-23 cohort (median 1.12) (p=0.0045). There were 
no significant differences produced for Pn IgG:IgG1-4 for both vaccine cohorts (Table 5.9). 
5.3.3.8. Pn Serotype 14 
For Pn-serotype 14 (Figure 5.16), there were significant differences seen from baseline to 
post-vaccination for Pn14-IgG (PPV-23 (p=0.0229) and PCV-13 (p=0.0010)), Pn14-IgG1 (PPV-
23 (0.0055) and PCV-13 (p=0.0192)), Pn14-IgG2 (PPV-23 (0.0007) and PCV-13 (p=0.0007)), 
and Pn14-IgG4 (PCV-13 (p=0.0352)). No significant differences were detected between 
vaccine cohorts. Furthermore, Pn14-IgG, Pn14-IgG1, Pn14-IgG3, and Pn14-IgG4 had fold 
changes below 2 for both vaccine cohorts. However, Pn14-IgG2 had a median fold change 
above 2 for the PPV-23 cohort (median 2.59) compared to the PCV-13 cohort (median 1.98), 
although there was no significant difference detected between the two vaccine cohorts 
(p=0.3316). There were no significant differences produced for Pn IgG:IgG1-4 for both 
vaccine cohorts (Table 5.9). 
5.3.3.9. Pn Serotype 18C 
For Pn-serotype 18C (Figure 5.17), the only significant different seen between vaccine 
cohorts was Pn18C-IgG (p=0.0350). Furthermore, the PCV-13 cohort only had a significant 
difference from baseline to post-vaccination (p<0.0001). Additionally, there were significant 
differences seen from baseline to post-vaccination for Pn18C-IgG1 ((PPV-23 (p=0.0167) and 
PCV-13 (p=0.0011)) , Pn18C-IgG2 (PPV-23 (p=0.0009) and PCV-13 (p<0.0001)), Pn18C-IgG3 
(PCV-13 (p=0.0459)), and Pn18C-IgG4 (PCV-13 (p=0.0193)). No significant differences were 
found between vaccine cohorts for fold changes for Pn18C-IgG1-4 and they were all well 
below a median of 2. However, the fold change for Pn18C-IgG for the PCV-13 vaccine cohort 
had a median of 4.48, which was significantly different than the PPV-23 vaccine cohort 
(median 1.63) (p=0.0028). There were no significant differences produced for Pn18C 
IgG:IgG1-4 for both vaccine cohorts (Table 5.9). 
5.3.3.10 Pn Serotype 19F 
For Pn-serotype 19F (Figure 5.18), there were no significant differences seen between vaccine 
cohorts; however, significant differences were found between baseline and post-vaccination 
for Pn19F-IgG (PPV-23 (p=0.0483) and PCV-13 (p<0.0001)), Pn19F-IgG1 (PCV-13 (p=0.0003)), 
Pn19F-IgG2  (PPV-23 (p=0.0004) and PCV-13 (p<0.0001)), and Pn19F-IgG3 (PCV-13 
(p=0.0007)). Pn19F-IgG4 MFIs were particularly low and no significant differences were 
found between vaccine cohorts. No significant differences were found between vaccine 
cohorts for fold changes for Pn19F-IgG1-4 and they were all well below a median of 2. 
140 | P a g e  
 
However, the fold change for Pn19F-IgG for the PCV-13 vaccine cohort  (median of 2.93) was 
greater than the PPV-23 vaccine cohort (median 2.04) (p=0.3938). There were no significant 
differences produced for Pn19F IgG:IgG1-4 for both vaccine cohorts (Table 5.9). 
5.3.3.11 Pn Serotype 23F 
For Pn-serotype 23F (Figure 5.19), there were no significant difference seen between vaccine 
cohorts; however, significant differences were found between baseline and post-vaccination 
for Pn23F-IgG (PPV-23 (p=0.0367) and PCV-13 (p<0.0001)), Pn23F-IgG1 (PPV-23 (p=0.0031) 
and PCV-13 (p=0.0001)), Pn23F-IgG2 (PPV-23 (p<0.0001) and PCV-13 (p<0.0001)), Pn23F-
IgG3 (PCV-13 (p=0.0035)), and Pn23F-IgG4 (PPV-23 (p=0.0166)). Furthermore, no additional 
significant differences were found for fold changes between vaccine cohorts; however, 
Pn23F-IgG1, Pn23F-IgG3, and Pn23F-IgG4 all had median fold changes below 2 (ns). 
Additionally, Pn23F-IgG had median fold changes above 2-fold (PPV-23 (2.39) and PCV-13 
(3.11) (ns; p=0.1623)) and Pn23F-IgG2 had median fold changes (PPV-23 (2.31) and PCV-13 
(3.23) (ns; p=0.2638)).   
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Figure 5.9. Pn-specific IgG, IgG1-4 responses to pneumococcal vaccination- Serotype 1. Each point represents one study participant. Solid horizontal lines indicate medians. Absolute 
values are represented as µg/mL. Fold changes are represented as medians. Ratios are represented as medians. P-values are significant at p<0.05.  
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Figure 5.10. Pn-specific IgG, IgG1-4 responses to pneumococcal vaccination- Serotype 3. Each point represents one study participant. Solid horizontal lines indicate medians. 
Absolute values are represented as µg/mL. Fold changes are represented as medians. Ratios are represented as medians. P-values are significant at p<0.05.  
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Figure 5.11. Pn-specific IgG, IgG1-4 responses to pneumococcal vaccination- Serotype 4. Each point represents one study participant. Solid horizontal lines indicate medians. Absolute 
values are represented as µg/mL. Fold changes are represented as medians. Ratios are represented as medians. P-values are significant at p<0.05.  
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Figure 5.12. Pn-specific IgG, IgG1-4 responses to pneumococcal vaccination- Serotype 5. Each point represents one study participant. Solid horizontal lines indicate medians. Absolute 
values are represented as µg/mL. Fold changes are represented as medians. Ratios are represented as medians. P-values are significant at p<0.05.  
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Figure 5.13. Pn-specific IgG, IgG1-4 responses to pneumococcal vaccination- Serotype 6B. Each point represents one study participant. Solid horizontal lines indicate medians. 
Absolute values are represented as µg/mL. Fold changes are represented as medians. Ratios are represented as medians. P-values are significant at p<0.05.  
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Figure 5.14. Pn-specific IgG, IgG1-4 responses to pneumococcal vaccination- Serotype 7F.  Each point represents one study participant. Solid horizontal lines indicate medians. 
Absolute values are represented as µg/mL. Fold changes are represented as medians. Ratios are represented as medians. P-values are significant at p<0.05.  
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Figure 5.15. Pn-specific IgG, IgG1-4 responses to pneumococcal vaccination- Serotype 9V. Each point represents one study participant. Solid horizontal lines indicate medians. 
Absolute values are represented as µg/mL. Fold changes are represented as medians. Ratios are represented as medians. P-values are significant at p<0.05.  
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Figure 5.16. Pn-specific IgG, IgG1-4 responses to pneumococcal vaccination- Serotype 14. Each point represents one study participant. Solid horizontal lines indicate medians. 
Absolute values are represented as µg/mL. Fold changes are represented as medians. Ratios are represented as medians. P-values are significant at p<0.05.  
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Figure 5.17. Pn-specific IgG, IgG1-4 responses to pneumococcal vaccination- Serotype 18C. Each point represents one study participant. Solid horizontal lines indicate medians. 
Absolute values are represented as µg/mL. Fold changes are represented as medians. Ratios are represented as medians. P-values are significant at p<0.05.  
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Figure 5.18. Pn-specific IgG, IgG1-4 responses to pneumococcal vaccination- Serotype 19F. Each point represents one study participant. Solid horizontal lines indicate medians. 
Absolute values are represented as µg/mL. Fold changes are represented as medians. Ratios are represented as medians. P-values are significant at p<0.05.  
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Figure 5.19. Pn-specific IgG, IgG1-4 responses to pneumococcal vaccination- Serotype 23F. Each point represents one study participant. Solid horizontal lines indicate medians. 
Absolute values are represented as µg/mL. Fold changes are represented as medians. Ratios are represented as medians. P-values are significant at p<0.05.  
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Table 5.4. Pn-specific IgG values pre-and post-pneumococcal vaccination – absolute IgG values (µg/mL) and fold changes.  
Data are reported as medians and interquartile ranges, with p-values from Mann-Whitney tests (unpaired) and Wilcoxon matched-pairs tests. Bold p-values are significant at p<0.05. 
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Table 5.5. Pn-specific IgG1 values pre-and post-pneumococcal vaccination – absolute IgG values (µg/mL)  and fold changes. 
Data are reported as medians and interquartile ranges, with p-values from Mann-Whitney tests (unpaired) and Wilcoxon matched-pairs tests. Bold p-values are significant at 
p<0.05. 
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Data are reported as medians and interquartile ranges, with p-values from Mann-Whitney tests (unpaired) and Wilcoxon matched-pairs tests. Bold p-values are significant at 
p<0.05. 
Table 5.6. Pn-specific IgG2 values pre-and post-pneumococcal vaccination – absolute IgG values (µg/mL)  and fold changes. 
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Table 5.7. Pn-specific IgG3 values pre-and post-pneumococcal vaccination – absolute IgG values (µg/mL) and fold changes. 
Data are reported as medians and interquartile ranges, with p-values from Mann-Whitney tests (unpaired) and Wilcoxon matched-pairs tests. Bold p-values are significant at 
p<0.05. 
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Table 5.8. Pn-specific IgG4 values pre-and post-pneumococcal vaccination – absolute IgG values (µg/mL)  and fold changes. 
Data are reported as medians and interquartile ranges, with p-values from Mann-Whitney tests (unpaired) and Wilcoxon matched-pairs tests. Bold p-values are significant at p<0.05. 
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Table 5.9. Pn-specific IgG:IgG subclass values post-pneumococcal vaccination  
Data are reported as medians and interquartile ranges, with values from Mann-Whitney tests (unpaired). Bold p-values are significant at p<0.05.  
158 | P a g e  
 
5.3.4. Pneumococcal serotypes versus novel less complex ‘whole’ 
pneumococcal assays 
Pneumococcal serotype assays offer information about the breadth of the vaccine response. 
The downside to pneumococcal assays is that they are expensive and take a considerable 
amount of laboratory staff time to complete in terms of routine clinical testing. There is also 
the additional complexity of reporting and interpreting multi-parameter results for 
clinicians.  
Whole PCP IgG assays are available for ELISAs, but not for MIAs. Therefore, we decided to 
conjugate both PPV-23 and PCV-13 to Luminex beads in order to compare patient antibody 
concentrations to the existing Pn serotype assays in two novel whole vaccine bead assays. 
5.3.4.1. Whole vaccine bead assays compared to 8/12 Pn serotypes as gold standard 
(WHO) 
When comparing the whole PPV-23 and PCV-13 beads with the Pn serotype data, ROC 
curve analysis for the prediction of patients who reach threshold for the Pn-serotype specific 
IgG assay (WHO) returned an area under the curve of 0.68 (p<0.0001) against the whole 
PPV-23 bead (Figure 5.20) and 0.87 (P<0.0001) against the whole PCV-13 bead (Figure 5.21).  
For the PPV-23 whole vaccine bead, if a measured patient sample achieved a response of 
309.5 MFI, this was considered indicative of a predictive response to 8/12 Pn serotypes with 
a sensitivity of 43% and specificity of 82%. For the PCV-13 whole vaccine bead, if a 
measured patient sample achieved a response of 1307.5 MFI, this was considered indicative 
Figure 5.20. ROC curve for PPV-23 whole vaccine beads 
as predictive of 8/12 Pn serotype (WHO) response. 
Figure 5.21. ROC curve for PCV-13 whole vaccine bead as 
predictive of 8/12 Pn serotype (WHO) response. 
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of a predictive response to 8/12 Pn serotypes with a sensitivity of 85.7% and specificity of 
80.6%. 
We then decided to investigate if there were any differences post-vaccination according to 
type of pneumococcal vaccine administered. We found that the PCV-13 whole vaccine bead 
is better at predicting protection to 8/12 Pn serotypes post-PPV-23 and PCV-13 vaccination. 
The area under the curve for the PPV- 23 whole vaccine bead was 0.619 and 0.825 for the 
PCV-13 whole vaccine bead post-PPV-23 vaccination (Figure 5.22). The area under the curve 
for the PPV-23 whole vaccine bead was 0.731 and 0.870 for the PCV-13 whole vaccine bead 
post-PCV-13 vaccination. (Figure 5.23).  
 
 
Figure 5.22. ROC curves for PPV-23 and PCV-13 whole vaccine beads predicting protection 
against 8/12 Pn serotypes post- PPV-23 vaccination. 
Figure 5.23. ROC curves for PPV-23 and PCV-13 whole vaccine beads predicting 
protection against 8/12 Pn serotypes post-PCV-13 vaccination. 
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 5.3.5. Comparison of novel whole vaccine bead assays with the Binding-Site 
PCP-IgG assay 
For Pn-specific IgG serotype assays, protection is deemed significant when two-thirds of 
measured serotypes reach the WHO threshold (179). The Binding Site anti-PCP IgG Assay is 
an ELISA using a polyclonal secondary IgG antibody against 23 different serotypes found in 
PPV-23. When the Pn serotype data was compared with the whole PCP-IgG (Binding Site) 
assay, 36.4% of patients that were deemed protected by the PCP-IgG assay, had a significant 
number of serotypes that failed to reach threshold (Figure 5.24). 
 
 
 
 
 
 
 
 
 
 
Figure 5.24. Number of Pn serotypes protected in MIA compared with protection in the whole PCP-IgG Binding 
Site Assay. 
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5.3.6. Comparison of the Pn-IgG2 MIA with the Binding-Site PCP-IgG2 assay 
For the PCP-IgG2 (Binding Site) assay (210), there were no post-vaccine differences between 
the PPV-23 and PCV-13 cohorts similar to the Pn-IgG2 MIA data (Figure 5.25). There were 
no differences between the total anti-PCP IgG2 produced post-vaccination; however, 
patients that received a first dose of PPV-23 initially produced a greater amount of IgG2 
than patients that received a first dose of PCV-13 (Figure 5.26).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.25. Anti-PCP IgG2 titres (Binding Site) for a single dose of 
PPV-23 or PCV-13 vaccination. For post-vaccine values, Mann-Whitney 
tests (non-parametric, two-tailed) P<0.05 is significant. For pre-post vaccine 
values, Wilcoxon matched-pairs test (non-parametric, two-tailed), P<0.05 is 
significant. 
Figure 5.26. Fold changes for anti-PCP IgG2 titres (Binding Site ) for 
a single dose of PPV-23 or PCV-13 vaccination. Mann-Whitney tests 
(non-parametric, two-tailed) P<0.05 is significant. 
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Furthermore, we investigated fold changes for our Pn-IgG2 assay and compared it with the 
Binding Site anti-PCP IgG2 assay (Figure 5.27). We found that the Pn-specific IgG2 response 
in the MIA varied widely (1.34-9.38 median fold change) (Table 5.6) between Pn serotypes 
and vaccine cohorts. These differences cannot be seen in the whole PCP-IgG2 assay (anti-
PCP IgG2 (PPV-23 (pre-vaccine (15.09 mg/L (5.27-18.83 IQR)) and post-Vaccine (42.02 mg/L 
(19.72-90.00 IQR)); median fold change 3.95 (1.96-5.75 IQR))) and PCV-13 (pre-vaccine (13.99 
mg/L (6.98-30.68 IQR) and post-vaccine (37.88 mg/L (17.81-74.20 IQR); median fold change 
1.82 (1.16-3.35 IQR))). Pn1-IgG2 produced the greatest fold change in both vaccine cohorts 
(PPV-23 (5.79 median) and PCV-13 (9.38 median)). A greater than 4-fold difference was 
produced for both in the MIA assay, which was potentially masked in the anti-PCP IgG2 
Binding Site assay.  
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Figure 5.27. Comparison of fold changes for anti-PCP IgG2 (Binding Site) and MIA Pn-IgG2 assays for a single dose of PPV-23 or PCV-13 vaccination. Mann-Whitney tests (non-
parametric, two-tailed) P<0.05 is significant. 
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5.4. Discussion 
This study has demonstrated differences in IgG subclass responses to PPV-23 and PCV-13 
vaccines. Furthermore, it challenges previous thinking that a plain polysaccharide response 
is predominantly IgG2 and that a conjugate vaccine response is predominantly IgG1. This is 
a really interesting notion as previously, studies have shown that the response to 
pneumococcal polysaccharides and other carbohydrate epitopes are notoriously, IgG2- 
directed (236,237). Our results from the PPV-23 vaccine cohort suggest that there is still a 
strong IgG1 response in addition to an IgG2 response. Von Gunten et. al. previously 
reported similar results suggesting that the IgG response is composed of a wide array of 
anti-carbohydrate antibodies that are not only restricted to the IgG2 subclass response (238). 
Furthermore, it has been suggested that CD4+ T-cells can provide help in generating 
carbohydrate-specific antibodies following glycoconjugate vaccination (239). Avci et al. 
established that the carbohydrate portion of glyconjugate vaccines can bind MHC-Class II to 
produce cytokines including IL-4 and IL-2, which are involved in the maturation of B-cells 
and the subsequent generation of carbohydrate-specific IgG antibodies (240).  
Investigating IgG subclass antibody responses is important to understanding the immune 
response to Pn vaccination because Pn-specific antibodies can bind pathogens with a high 
degree of specificity and form immune complexes, which activate mechanisms downstream 
of antigen binding that lead to subsequent removal from the immune system (241).  
Additionally, IgG1 and IgG3 antibodies are robust classical route complement activators, 
whereas IgG2 and IgG4 do not bind C1q as effectively (242–244). This could be investigated 
further by comparing Pn-specific IgG subclass serum antibody concentrations (post 
fractioning of the IgG subclasses from patient serum) to opsonophagocytic killing 
concentrations to their specific Pn serotypes in a future study.  Furthermore, it has been 
postulated that the long hinge region of the IgG3 subclass allows for a more exposed C1q 
binding site, thus allowing for more effective activation of complement in the immune 
response (245,246).  
It is important to highlight that the success of glyconjugate vaccines is dependent on the 
specific polysaccharide structure and the carrier protein that it is attached to i.e. 
pneumococcal polysaccharides conjugated to CRM197 in PCV-13. Previous studies have 
suggested that antigen processing of CRM197   is altered depending on the specific Pn 
serotype and its structure. Furthermore, the binding of the Pn polysaccharide to CRM197  can 
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alter the exposed epitopes produced if the proteolysis or MHC-binding of CRM197   is 
compromised (247,248).  
This study has also highlighted the variety of assays available for the investigation of Pn-IgG 
and IgG subclass responses.  
Additionally, the serotype-specific assays demonstrate that responses to individual 
serotypes are very different for both PPV-23 and PCV-13 vaccines and that this granularity 
cannot be visualised in combined serotype assays.   
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Chapter 6: Impact of HIV infection on B-
cell populations following conjugate 
pneumococcal vaccination 
6.1 Introduction 
6.1.1 Aims and Objectives 
The aim of this chapter is to examine the effect of pneumococcal conjugate (PCV-13) 
vaccination on B-cell populations in the context of HIV-infection.  
1) This will be investigated by examining B- and T-cell populations, total 
immunoglobulins (IgG, IgA, and IgM), and Pn-specific IgG antibodies pre-and post- 
vaccination (day 7 and 30).  
6.1.2. Dysregulated humoral immunity in HIV infection 
HIV infects CD4+T-cells, primarily (249). However, with induction of CD8+T-cells that 
neutralise HIV, CD4+T-cell counts can be preserved with the usage of ARVs. Conversely, 
without ARV treatment, HIV can lead to the infection and depletion of CD4+T-cells, which 
results in subsequent opportunistic infections, immunodeficiency, AIDS, and ultimately, 
death (250).  
HIV infection is also known to have an impact on other lymphocytes, particularly, B-cells 
(251,252). Hypergammaglobulinaemia caused by aberrant polyclonal B-cell activation, 
autoimmunity, and B-cell malignancy are very well characterised in HIV-infection 
(111,253,254). 
HIV has been known to interact with B –cells. The gp120 (glycoprotein) on the HIV virus can 
bind to variable region three (VH3) immunoglobulin genes that are expressed on specific B-
cell populations (approximately half of VH-expressing cells in peripheral B-cell populations) 
(255–259). VH3 antibodies are essential for immune defence against bacterial and viral 
pathogens, most notably, S. pneumoniae (260–264). The binding of gp120 to VH3-expressing 
B-cells leads to B-cell clonal expansion and resulting hypergammaglobulinaemia in HIV-
infected patients (265). Furthermore, these cell populations are proven to be depleted in later 
stages of HIV-infection (266). The subsequent depletion of these VH3-expressing cells may 
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contribute to dysregulated B-cell maturation, which may lead to decreased memory B-cell 
populations in HIV-infected individuals (267). 
Additionally, HIV can interact with B-cells through the complement receptor, CD21, which 
is expressed on the majority of B-cells, and complement proteins bound to opsonised HIV 
viruses. These events can lead to subsequent infection of CD4+T-cells and altered B-cell 
responses and ultimately, humoral dysregulation (268–270).  
Hyperactivation is also common in HIV infection and increased antibody secretion can be 
due to hyperactivated naïve B-cells, as well as clonally expanded CD21 low B-cell 
populations including activated, mature activated, and exhausted B-cells (see Table 7.1) 
(106,271,272). Furthermore, CD21 low B-cell populations have been known to produce 
autoreactive antibodies, which has been evidenced in HIV-infection (273,274). Autoreactive 
antibodies are defined as antibodies that are produced in response to self-antigens (275).  
Furthermore, circulating peripheral B-cells seen in HIV-infection are prone to abberant 
proliferation and hyperactivation (276). Furthermore, HIV infection predisposes B-cells to 
terminal differentiation, which in patients with high viral loads, can lead to increased cell 
death/apoptosis (277).  
Chronic inflammation and hyperactivation can lead to B-cell exhaustion (CD27 lowCD21 
low subpopulations) (117,273). CD27+CD21 low B-cells are prominent in HIV infection and 
are a result of chronic activation and differentiation into plasmablasts (113). CD10+CD21 low 
(immature transitional) B-cells are also a key feature of HIV infection, which results due to 
increased T-cell reduction in viraemic individuals (118). 
 Exhausted B-cells phenotypically express high levels of inhibitory receptors such as PD1 
(programmed cell death 1) and CTLA4 (cytotoxic T-lymphocyte antigen 4), which normally 
are associated with HIV-specific CD4+ and CD8+ T-cells (278–280). Furthermore, exhausted 
B-cell subpopulations show reduced levels of expressed homing receptors (CXC-chemokine 
receptor 4 and 5), CXCR4 and CXCR5, which are essential for the migration of B-cells to 
germinal centres where T-cell dependent B-cell interactions occur, which is important for the 
pneumococcal glycoconjugate vaccination response (55,281). Other features of B-cell 
exhaustion in HIV infection include reduced proliferation and effector functions of naïve 
and memory B-cells (273,282,283).  
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6.1.3. Peripheral B-cell populations and HIV infection 
Circulating peripheral B-cell populations vary widely amongst HIV-infected and HIV-
negative individuals (284). Table 6.1 describes the B-cell populations investigated in this 
thesis and a comparison of normal healthy control data versus HIV-infected individuals.  
Table 6.1. CD19+ B-cell subpopulations in normal healthy adults and HIV-infected individuals 
B-cell subpopulation 
name 
Significance of population 
(References) 
Normal Healthy 
Adult Control 
(Reference 
Ranges) 
HIV-related changes compared to 
normal healthy adult controls 
(References) 
Naïve B-cells (IgM+ 
IgD+CD27-) 
B- cells that have not encountered 
specific antigen and therefore, have 
not responded to it (285). 
42.6-82.3% 
(284,286) 
N/A; some studies suggest that 
these populations are 
increased/decreased 
(287,288,122,289)  
Marginal Zone (MZ) B-
cells (IgM+ IgD+CD27+) 
A population of B-cells found in the 
marginal zones of the spleen that 
respond rapidly to pathogenic 
encapsulated bacteria (283) 
7.2-32.5% 
(284,286,291) 
Decreased(292,293) 
Switched Memory B-
cells (IgM- IgD-CD27+) 
CD27+ B-cells that do not express 
IgD and have class-switched 
following somatic hypermutation in 
germinal centres post exposure to 
antigens. These cells express IgG, 
IgA, or IgE (287). 
6.5-31.4% 
(284,286,291) 
Decreased(105,108,124,122,292,295) 
Activated B-cells (CD38 
low CD21 low) 
Rare population of B-cells in the 
blood of healthy controls, but an 
expansion of >10% is associated with 
autoimmune disease (286,296) 
0.9-7.6% 
(284,286,291) 
Increased (273,113) 
Mature Activated B-cells 
(CD27+ CD21 low) 
Mature B-cells in HIV-infected 
individuals that show increased 
activation and terminal 
differentiation (277)   
N/A; not 
relevant in 
normal healthy 
control adults.  
Increased (277) 
Exhausted B-cells (CD27- 
CD21 low) 
Tissue-like memory B-cells found in 
HIV-infected patients. They express 
high levels of inhibitory receptors, 
have shorter replication histories, 
and lower immunoglobulin diversity 
(162,273) 
N/A; not 
relevant in 
normal healthy 
control adults. 
Increased (162,273) 
Plasmablasts B-cells 
(CD38+++IgM-) 
Short-lived, proliferating, antibody-
secreting B-cells that either die after 
a few days or undergo terminal 
differentiation into plasma cells, 
where they either migrate to the 
bone marrow (long-lived) or to the 
lymphoid organs (short-lived) to 
continue antibody secretion (297). 
0.4-3.6% 
(286,291) 
Increased (277,113,298,299) 
Transitional B-cells 
(CD38hiIgMhi) 
B-cells that are an intermediate 
between immature bone-marrow 
derived B cells and fully mature 
naïve B –cells in the peripheral blood 
(300,301) 
0.6-3.5% 
(286,291) 
Increased (118,293,302–304) 
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6.1.4 Impact of CD4+T-cells, Viral Load (VL), and Antiretroviral therapy 
(ARV) on B-cells in HIV infection 
HIV viral load can impact peripheral B-cell populations early on in HIV-infection, which 
may have detrimental effects on B-cell reconstitution in later stages of HIV infection (305).  
The introduction of ARVs has allowed for the reversal of aberrant antibody production and 
the restoration of antibody-producing VH3 B-cells (306,307). Furthermore, naïve B-cell 
populations may not be as severely affected by HIV-infection compared to memory B-cell 
populations (288,308). One study suggests that even after years of ARV treatment, 
dysregulation in  the CD27+ memory B-cell compartment persists even with undetectable 
viral loads (295).   
6.2. Materials and Methods 
6.2.1. Study Design 
This study investigated the effects of pneumococcal conjugate vaccination (PCV-13) on B-cell 
populations in HIV-infected adults by examining B- and T-cell populations, total IgG, IgA, 
and IgM immunoglobulins, and Pn-specific IgG antibodies (Pn serotypes 1, 3, 4, 5, 6B, 7F, 
9V, 14, 18C, 19A, 19F, and 23F).  
Pneumococcal vaccine naïve HIV-infected adults were administered one PCV-13 vaccine 
and monitored over the course of one month with 3 time-points (Day 0 (pre-vaccine), Day 7 
and 30 (post-vaccination)) at which lymphocyte (B and T-cell populations) and serum 
samples were analysed (Figure 6.1). HIV-infected adults (>18 years old) were recruited from 
the UHB HIV-department at the QE Hospital in Edgbaston, Birmingham. Patients were 
formally consented and a baseline (Day 0) blood sample was taken and one PCV-13 vaccine 
was administered intramuscularly.  
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6.2.2. Ethical Approval 
Ethical approval was obtained from the West Midlands-Edgbaston Research Ethics 
Committee (REC reference number 16/WM/0313; B-cell Immune Responses to 
Pneumococcal Vaccination in HIV-infected patients). Informed written consent was obtained 
from all eligible study participants.  
6.2.3. Vaccination Schedule 
All eligible study participants were administered a single dose of Prevenar-13™ (PCV-13) 
(Pfizer, UK) by intramuscular injection into a chosen deltoid muscle.  
6.2.4. Patient Recruitment 
20 HIV-infected adults were recruited from the UHB HIV- Department at the QE Hospital, 
Birmingham (Patients are still being recruited for this study at the time of writing this thesis 
so an interim analysis was performed on 10 HIV-infected adults who have completed the 
study). Patients were eligible for inclusion in the study if they were 18 years and older, had 
confirmed HIV-infection, were pneumococcal vaccine naïve (Pneumovax™ (Merck Inc, UK) 
or Prevenar-13™), and were able to give informed consent. Patients were excluded and 
deemed ineligible for the study if they were previously vaccinated with pneumococcal 
vaccines, had history of a pre-existing allergy to any component of PCV-13 or diphtheria 
toxoid vaccines, and/or were not able to give informed consent.   
Figure 6.1. Schematic of PCV-13 Study Design  
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6.2.5. Patient Demographics 
The demographics of the study participants are described in Table 6.2.  
Table 6.2. HIV-infected study participant demographical data 
 HIV-infected Study Participants 
N (total number of study participants) 10 
Age (Median + Range-years) 42.5 (20.0-64.0) 
Female 2 
Male 8 
Viral Load at Baseline (pre-vaccination)  
(Median + Range-copies/mL) 
1484 (<40-55,210) 
Viral Load at Day 30 (post-vaccination) 160 (<40-581) 
ARV status at baseline (Yes/No) Yes  
6.2.5. Data Collection 
ARV status was taken at baseline after collecting data from clinical records. HIV viral loads 
(VL) were also assessed at baseline and day 30 post-vaccination, as well as collected from 
clinical records. The HIV VL was calculated using an HIV-1 RNA assay (Abbott RealTime 
HIV-21; Abbott Molecular, Inc., USA). The lower limit of detection for the HIV VL assay is 
40 copies/mL.  
6.2.6. Preparation of samples 
6.2.6.1. Lymphocyte sample preparation for flow cytometry staining 
Blood for lymphocyte immunophenotyping (15 mL) was collected in lithium heparin 
vacutainer plastic tubes at each time point. Lymphocytes were isolated by Ficoll density 
centrifugation using Leucosep™ centrifuge tubes (Grenier Bio-One, Stonehouse, UK) and 
frozen in 10% DMSO and heat inactivated fetal bovine serum (Sigma, Dorset, UK) for batch 
processing.  
6.2.6.1.1. B-cell subpopulations 
Lymphocytes were gated based on forward (FSC) and side scatter (SSC). The P1 gate (as 
seen in Figure 6.2) is adjusted wide enough to include most of the lymphocytes. B-cells are 
selected by staining with CD19 and CD45. The remaining gated B-cell lymphocyte 
populations are further gated on IgD, CD27, CD21, CD38, and IgM (as described in Table 
6.1/Figure 6.2). Transitional B-cells and plasmablast gating is based on B-cell phenotypes 
from the EUROclass trial in CVID (Common Variable Immunodeficiency) patients and 
healthy adults (286). Exhausted and mature activated B-cells were gated initially with CD19 
and CD45 and then on CD21 and CD27 (Figure 6.3). The template was set up to acquire 
5,000 CD19+  population events in the P1 lymphocyte gate (Figure 6.2/6.3). All lymphocyte 
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samples were acquired on the FACSCanto II flow cytometer (BD Biosciences, Oxford, UK). 
Daily calibration and monitoring of the instrument was performed using CS and T beads 
(Cytometer Setup and Tracking beads) (BD Biosciences, Oxford, UK). Rainbow calibration 
particles (BD Biosciences, Oxford, UK) were used to standardise EuroFlow instrument 
settings (309). BD CompBeads (BD Biosciences, Oxford, UK) were used to apply 
compensation.  Compensation was performed using fluorescence minus one (FMO) 
techniques in order to identify and gate cells of interest due to the multiple fluorochrome 
staining in the investigated panels (310).  
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Figure 6.2. Example gating strategy for B-cell phenotyping in the HIV PCV-13 study to identify CD19+ 
subpopulations. Gating is shown on a study participant sample. A. Gate is set on the P1 lymphocyte population. B. 
Gate from P1 set on CD19+ and CD45+ B-cells C. Gated on the CD19+ population,  i. Naïve B-cells ( IgD+ CD27-)  ii. 
Marginal zone B-cells (IgD+ CD27+) iii. Switched memory B-cells (IgD_ CD27+) D. Gated on the CD19+ population, 
Activated B-cells (CD38 low CD21 low) E. Gated on the CD19+ population, i. Transitional B-cells (CD38 high, IgM high) 
ii. Plasmablasts (CD38 low IgM low). 
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Figure 6.3. Example gating for Exhausted and Mature Activated B-cell phenotyping in the HIV PCV-13 study.  Gating is 
shown on a study participant sample. A. Gate from P1 (Figure 7.2) set on CD19+ and CD45+ B-cells  B. Gated on the CD19+ 
population, i. Exhausted B-cells (CD27_ CD21 low) ii. Mature Activated B-cells ( CD27+ CD21 low). 
175 | P a g e  
 
 
6.2.6.1.2. T-cell subpopulations 
Lymphocytes were gated based on forward (FSC) and side scatter (SSC). The P1 gate (as 
seen in Figure 6.4) is adjusted wide enough to include most of the lymphocytes. T-cells are 
selected by staining with CD3 and CD45. The remaining gated T-cell lymphocyte 
populations are further gated on CD4 and CD8 in order to determine CD4:CD8 ratios. 
Gating is based on T-cell phenotypes from the ALPS (Autoimmune Lymphoproliferative 
Syndrome) classification panel in the Clinical Immunology Service (311). The template was 
set up to acquire 20,000 CD3+  population events in the P1 lymphocyte gate (Figure 6.4). All 
lymphocyte samples were acquired on the FACSCanto II flow cytometer (BD Biosciences, 
Oxford, UK). Compensations were applied as described in section 6.2.6.1.1.. 
 
 
Figure 6.4. Example gating strategy for T-cell phenotyping in the HIV PCV-13 study to identify CD3+ 
subpopulations. A. Gate is set on the P1 lymphocyte population. B. Gate from P1 set on CD3+ and CD45+ T-cells C. 
Gated on  CD4+   and CD8+ populations.    
A. 
B. C. 
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6.2.6.1.3. Flow cytometry staining 
Study participant cells were resuscitated from frozen by placing a frozen cryovial (5-10 x 106 
cells/mL) into a 37°C water bath and gently swirling until a few ice crystals remained. 
Cryovial contents were transferred into a pre-labelled Falcon with 10 mL warmed complete 
RPMI (10% HI FCS and 1% penicillin/streptomycin). The falcon was then topped up to 50 
mL with complete RPMI and spun at 300g for 10 minutes. The supernatant was then 
decanted and cells were resuspended in their residual volume. 2 mL of warmed complete 
RPMI was then added to each falcon in addition to 1 µl of Benzonase ® Nuclease (25 U/µl) 
(Merck Millipore, Hertfordshire, UK) for every 1 x 106 cells frozen down for 1 hour at 37°C, 
5% CO2 in order to reduce cell clumping and increase cell viability post-resuscitation (312). 
The falcon was then topped up to 50 mL with complete RPMI and spun at 300g for 10 
minutes. The supernatant was then decanted and cells were resuspended in 10 mL of 
warmed complete RPMI and cells were counted using an automated Horiba Cell Counter 
(ABX Micro ES60, Horiba Ltd., Northampton, UK). The falcon was then topped up to 50 mL 
with complete RPMI and spun at 300g for 10 minutes. The supernatant was then decanted 
and cells were resuspended at the desired concentration (approximately 3 x 105 cells per 
FACS tube) for use in the flow cytometry experiment.  
The resuspended cells were then incubated with a mastermix of extracellular staining 
antibodies (described in Table 6.3; all antibodies obtained from BD Biosciences, Oxford, UK). 
2 µl of each of the antibodies in Table 6.3 were added for each patient tube. The tubes were 
then incubated in the dark at 4°C for 15 minutes. Immediately after incubation, 500 µl of BD 
FACS lysis and fixative fluid (BD Biosciences, Oxford, UK) was added to each patient tube 
and incubated in the dark at 4°C for 15 minutes. Then, 2 mLs of BD FACS CellWASH buffer 
(BD Biosciences, Oxford, UK) was added to each patient tube and then spun at 1000 RCF for 
7 minutes. Post-centrifugation, the supernatant was poured off of each patient tube and then 
resuspended with 200 µl of BD FACS CellWASH buffer (BD Biosciences, Oxford, UK) in 
order to immediately acquire on the FACSCanto II. Patient tubes were kept in the dark at 
4°C until they were acquired.  
Table 6.3. Antibody mastermixes for B and T-cell lymphocyte staining 
Patient Sample 
Tube 
FITC PE PerCP PE Cy7 APC H7 V450 V500 
Tube 1 (B-cells) IgM CD21 CD27 CD38 CD19 IgD CD45 
Tube 2 (T-cells) - CD4 CD8 - CD3 - - 
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6.2.6.1.4. Flow cytometry analysis 
Analysis was performed using a FACSCanto II and FACSDiva™ (BD Biosciences, Oxford, 
UK) software. Lymphocytes were gated on FSC and SSC. B and T- lymphocytes were gated 
as described in 6.2.6.1.1 and 6.2.6.1.2, respectively. Compensation was performed 
automatically using FACSDiva™ software and compensation FMO controls previously in 
the Clinical Immunology Service. Additionally, analysis of the B and T-cell lymphocyte data 
was performed using FlowJo software, version 10.4.1. (Treestar, Inc., Oregon, USA). CD19+   
B-cells and CD3+ T-cell percentages were derived from the total lymphocyte count. Gating is 
described in section 6.2.6.1.1 and 6.2.6.1.2. Data was analysed by absolute counts and 
percentages. Additionally,  CD19+   B-cells and CD3+ T-cell subpopulations were expressed as 
percentages of the total  CD19+  and CD3+  counts.  
6.2.6.2. Serum sample preparation for Total IgG, IgA, and IgM, and Pn-specific IgG 
antibody quantification 
Blood for serum studies (5 mL) was taken into vacutainer plastic tubes with a clotting 
activator at each time point. Serum was then separated from whole blood by centrifugation 
at 3000 rpm for 5 min, aliquoted, and stored at -80°C for future studies. Blood was collected 
and serum was isolated/frozen down at -80°C within 24 hours of collection from 
venepuncture in the Clinical Immunology Service, University of Birmingham, Birmingham.  
6.2.6.2.1. Total IgG, IgA, and IgM serum antibody quantification 
Total IgG, IgA, and IgM antibody concentrations were quantified using nephelometry 
techniques, according to instructions described by the manufacturer (Roche Diagnostics 
GmbH, Mannheim, Germany).  Goat anti-human IgG antibodies react with antigen in the 
patient samples to form an antigen/antibody complex. Following antibody/antigen 
agglutination, the antigen/antibody complex is measured turbidimetrically using a COBAS 
c 311/501 analyser in the Clinical Immunology Service, University of Birmingham, 
Edgbaston, UK. Normal ranges for healthy adults are as follows: total IgG (6.0-16.0 g/L), 
IgA (0.8-4.0 g/L), and IgM (0.5-2.0 g/L) (313).  
6.2.6.2.2. Pn-specific IgG antibody quantification 
Pn-specific IgG concentrations were measured as described in section 2.5.2.3.  
6.2.7. Statistical Analysis 
Continuous data was presented as medians and interquartile ranges unless stated otherwise. 
Non-parametrical statistical tests were used throughout. Differences between time-points 
were analysed by Wilcoxon signed rank tests. Univariate correlations were performed using 
a Spearman’s Rank method. Mann-Whitney U tests were performed to detect differences 
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between CD19+ B-cell populations and serum antibody vaccine responses at pre- and post- 
vaccination.  Statistical analysis was performed using GraphPad Prism software (GraphPad 
Software, Inc., version 6). P-values of <0.05 were considered significant throughout. This 
was an observational pilot study; therefore, no formal power calculation was performed. 
The primary analysis for this study was to investigate the proportion of HIV-infected 
patients that produced a memory B-cell response to a single dose of Prevenar-13. The 
secondary outcomes were to investigate how HIV infection impacts the B-cell phenotype 
and correlates with quantifiable Pn-specific IgG and total serum antibody concentrations.  
6.3. Results  
6.3.1. Lymphocyte phenotyping 
6.3.1.1. Evaluation of B-cell populations at baseline and post-vaccination responses with 
PCV-13 
CD19+ B-cell populations were investigated in this section with descriptions and associated 
changes in the context of HIV-1 infection described in Table 6.1. 
6.3.1.1.1. Naïve B-cells 
The percentages of naïve B-cell populations in HIV-infected adults were similar compared to 
normal healthy controls across all post-vaccination time points (Figure 6.5/Table 6.5) 
(reference ranges described in Table 6.1).  
6.3.1.1.2. Marginal Zone B-cells 
A novel finding was that there were very low marginal zone (MZ) populations (<10%) 
compared to normal healthy controls across all post-vaccination time points (Figure 
6.5/Table 6.5) (reference ranges described in Table 6.1). 
6.3.1.1.3. Switched Memory B-cells 
Additionally, switched memory B-cells were relatively similar to normal healthy controls 
across all post-vaccination time points; however, there was a marked reduction from 
baseline to day 30 post-vaccination (p=0.0039) and day 7 to day 30 post-vaccination 
(p=0.0039)(Figure 6.5/Table 6.5) (reference ranges described in Table 6.1).  
6.3.1.1.4. Activated B-cells 
Activated B-cells were expanded compared to normal healthy controls (>10%) and there was 
a marked increase from day 7 to 30 post-vaccination (p=0.0195). However, mature activated 
B-cells were reduced from day 7 to 30 (p=0.0039) (Figure 6.5/Table 6.5). 
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6.3.1.1.5. Exhausted B-cells 
 Exhausted B-cell populations were expanded in this HIV-infected cohort; however, there 
were no significant differences between pre- and post-vaccination time points. It is 
important to note that mature activated and exhausted B-cell populations are unique to 
HIV-infection; therefore, it was not possible to make comparisons with normal healthy 
control reference ranges (Figure 6.5/Table 6.5). 
6.3.1.1.6. Plasmablasts  
Plasmablasts were expanded in the HIV-infected cohort compared to normal healthy control 
reference ranges (>5%); however, there was a reduction from day 7-30 post vaccination 
(p=0.0098) (Figure 6.5/Table 6.5) (reference ranges described in Table 6.1).  
6.3.1.1.7. Transitional B-cells 
The proportion of transitional B-cells were reduced compared to normal healthy control 
reference ranges (<0.5%) and there was a significant reduction from baseline to day 30 post-
vaccination (p=0.0488) (Figure 6.5/Table 6.5) (reference ranges described in Table 6.1).  
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6.3.1.2. Evaluation of T-cell populations post-vaccination with PCV-13 
The percentages of CD3+, CD4+, and CD8+ T-cells were evaluated in this HIV-infected cohort 
across all time points pre- and post-vaccination. There were no significant differences found 
between pre- and post-vaccination time points (Figure 6.6 and Table 6.6).  
CD4+ T-cell percentages were relatively normal across all pre-and post-vaccination time 
points. At baseline, the percentage of CD4+ T-cells (median 35.1% (IQR 24.0-43.1%) were 
normal and they did not change post-vaccination at day 7 (median 32.5%(IQR 24.4-42.4%)) 
and day 30 (median 35.1%(IQR 27.0-44.6%)).  
 CD8+ T-cell percentages were expanded above normal reference ranges (Table 6.4) across all 
pre and post-vaccination time points. At baseline, the percentage of CD8+ T-cells were higher 
than normal (median 53.4% (IQR 41.1-66.1%)) and this did not change at day 7 (median 
51.5% (IQR 42.5-63.6%)) and day 30 (median 51.0% (IQR 41.3-61.4%)) post-vaccination.  
 The CD4:CD8 ratios per study participant was below 1 at baseline (median 0.65 (IQR 0.37-
1.05)), day 7 (median 0.63 (IQR 0.38-1.12)), and day 30 (median 0.74 (IQR 0.45-1.12)) post-
vaccination (Figure 6.6 and Table 6.7). Inverse CD4:CD8 ratios are considered as markers of 
immunosenescence and predictors of mortality (314,315). Two studies investigating 
influenza and hepatitis B vaccination have associated inverse CD4:CD8 ratios and an 
impaired ability to respond to vaccination (316,317). 
                                     
 Table 6.4. Normal T-cell reference ranges for healthy adults (18-65 years old) 
T-cell lymphocyte population 
Normal Healthy Adult 
Reference Range 
CD3+ 49.1-83.6 (318) 
CD3+CD4+ 28.2-62.8 (318) 
CD3+CD8+ 10.2-40.1 (318) 
CD4:CD8 ratio >1 (314) 
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Figure 6.5. Changes in percentages of CD19+ B-cell subpopulations  in HIV-infected adults pre- and post-vaccination with PCV-13. Data are 
reported as percentages of total CD19+ populations, medians. and interquartile ranges with p-values from Wilcoxon-matched pairs signed rank 
tests. Bold p-values are significant at p<0.05. 
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Table 6.5. Percentages of  CD19+ B-cell subpopulations in HIV-infected adults pre- and post-vaccination with PCV-13. 
Data are reported as medians and interquartile ranges with p-values from Wilcoxon-matched pairs signed rank tests 
Bold p-values are significant at p<0.05 
CD19
+
B-cell population Baseline (N=10) Day 7 (N=10) Day 30 (N=10) Baseline vs Day 7 post-vaccination Day 7 vs Day 30 post-vaccination Baseline vs Day 30 post-vaccination
Naïve 59.4 (48.5-81.0) 58.8 (45.5-74.6) 60.5 (53.2-74.5) 0.4922 0.084 0.375
Marginal Zone 3.58 (2.32-7.38) 3.59 (1.71-5.20) 3.18 (1.65-5.78) 0.625 0.4922 0.4922
Switched Memory 20.6 (8.22-25.4) 20.4 (11.1-26.3) 18.3 (7.02-21.5) 0.625 0.0039 0.0039
Activated 15.4 (7.25-21.3) 15.6 (6.07-20.9) 17.5 (10.3-27.9) 0.5566 0.0195 0.1934
Plasmablasts 8.93 (3.61-12.3) 7.13 (4.94-14.7) 4.21 (2.34-8.53) 0.4316 0.0098 0.1934
Transitional 0.49 (0.28-1.29) 0.30 (0.08-0.88) 0.06 (0.0-0.23) 0.2324 0.25 0.0488
Mature Activated 6.69 (4.91-10.12) 7.79 (5.55-15.9) 5.77 (2.80-10.0) 0.375 0.0039 0.1934
Exhausted 20.0 (8.08-25.9) 16.0 (8.55-28.1) 18.3 (6.96-27.2) 0.5566 0.9219 0.9219
P-valuesTimepoint 
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Figure 6.6. Changes in percentages of CD3+ T-cell subpopulations in HIV-infected adults pre- and post-vaccination with PCV-13. Data are reported as 
percentages of total CD3+ populations, medians. and interquartile ranges with p-values from Wilcoxon-matched pairs signed rank tests. Bold p-values 
are significant at p<0.05. 
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Table 6.6. Percentages of CD3+ T-cell subpopulations in HIV-infected adults pre- and post-vaccination with PCV-13. 
Baseline (N=10) Day 7 (N=10) Day 30 (N=10) Baseline vs Day 7 post-vaccination Day 7 vs Day 30 post-vaccination Baseline vs Day 30 post-vaccination
CD4:CD8 ratio 0.65 (0.37-1.05) 0.63 (0.38-1.12) 0.74 (0.45-1.12) 0.8652 >0.9999 0.623
Timepoint P-values
Table 6.7 CD4:CD8 ratios in HIV-infected adults pre- and post-vaccination with PCV-13 
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6.3.2. Pn-specific IgG response to a single dose of PCV-13 
Patient serum samples obtained at baseline, day 7 and day 30 post-vaccination were 
analysed for Pn-specific IgG antibodies (Pn1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) 
(Figures 6.7-6.10/Table 6.8-6.9). 
At baseline, 10% of patients reached the >8 out of 12 Pn serotypes WHO (>0.35 µg/mL) 
threshold. By day 7 post-vaccination, 20% had an increase in protective antibody 
concentrations and by day 30, 70 % had an increased response to >8 out of 12 Pn serotypes 
(Figure 6.7).  
The median antibody concentrations for the HIV-infected study participants increased from 
baseline to day 7 for Pn 4, 6B, 9V, and 23F serotypes (Figures 6.7-6.10/Table 6.8-6.9). The 
median antibody concentrations for the HIV-infected study participants increased from day 
7-day 30 post-vaccination for  Pn 1, 3, 19A, 19F, and 23F serotypes (Figures 6.7-6.10/Table 
6.8-6.9).From baseline to day 30 post-vaccination, the median antibody concentrations 
increased for Pn 1, 3,4,6B, 18C, 19A, 19F, and 23F serotypes (Figures 6.7-6.10/Table 6.8-6.9). 
There were greater fold changes from baseline to day 30 post-vaccination compared with 
baseline-day 7 post-vaccination for Pn 1, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F serotypes 
(Figures 7.7-7.10/Table 7.8-7.9); No significant increases in fold change were produced for 
Pn 4 and 5. Additionally, there were greater fold changes produced for day 7-30 compared 
with baseline-day 7 post-vaccination for Pn3 and 19F (Figures 6.7-6.10/Table 6.8-6.9). Also, 
there were greater fold changes produced from baseline-day 30 post-vaccination compared 
with day 7-day 30 post-vaccination for Pn4 and 23F (Figures 6.7-6.10/Table 6.8-6.9). 
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Figure 6.7. Percentage of HIV-infected study participants that reach WHO threshold (0.35 
µg/mL) and > 8 out of 12 Pn serotypes protected pre and post-vaccination (Day 7 and 30) 
with PCV-13.  
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Figure 6.8  Pn-specific IgG (Pn 1, 3, 4 , and 5) vaccine responses (absolute values and fold changes) to a single dose of PCV-13. A. Pn-specific IgG values are reported as µg/mL. 
WHO Pn threshold antibody titres (0.35 µg/mL ) are denoted by dotted lines B. Fold Changes Pn-specific IgG .Data are reported as medians with p-values from Wilcoxon-matched 
pairs signed rank tests. Bold p-values are significant at p<0.05. 
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Figure 6.9. Pn-specific IgG (Pn 6B. 7F, 9V, and 14) vaccine responses (absolute values and fold changes) to a single dose of PCV-13. A. Pn-specific IgG values are reported as µg/mL. 
WHO Pn threshold antibody titres (0.35 µg/mL ) are denoted by dotted lines B. Fold Changes Pn-specific IgG .Data are reported as medians with p-values from Wilcoxon-matched pairs 
signed rank tests. Bold p-values are significant at p<0.05. 
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Figure 6.10. Pn-specific IgG (Pn 18C, 19A, 19F, and 23F) vaccine responses (absolute values and fold changes) to a single dose of PCV-13. A. Pn-specific IgG values are reported as 
µg/mL. WHO Pn threshold antibody titres (0.35 µg/mL ) are denoted by dotted lines B. Fold Changes Pn-specific IgG .Data are reported as medians with p-values from Wilcoxon-matched 
pairs signed rank tests. Bold p-values are significant at p<0.05. 
A 
 B  
190 | P a g e  
 
 
  
Table 6.8. Pn-specific IgG vaccine responses (absolute values) to a single dose of PCV-13.  
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Table 6.9. Pn-specific IgG vaccine responses (fold changes) to a single dose of PCV-13. 
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6.3.3. Total immunoglobulin (IgG, IgA, and IgM) responses to a single dose 
of PCV-13 
Patient serum samples obtained at baseline, day 7 and day 30 post-vaccination were 
analysed for total IgG, IgA, and IgM. Vaccine responsiveness was assessed to a single dose 
of PCV-13 in total IgG, IgA, and IgM (Figure 6.11/Table 6.10-6.11). HIV-infected study 
patients had relatively normal immunoglobulin concentrations compared with normal 
healthy adult reference ranges (described in section 6.2.6.2.1). 
There were no changes or significant differences detected between any vaccination time 
points for total IgG and IgM concentrations. However, there was a greater fold change from 
baseline to day 30 post-vaccination in contrast to baseline to day 7 post-vaccination for total 
IgA (Figure 6.11/Table 6.10-6.11).  
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Figure 6.11. Total IgG, IgA, and IgM vaccine responses (absolute values and fold changes) to a single dose of PCV-13. A. Total IgG, IgA, and IgM values are reported as g/L. Upper and 
lower normal reference values are depicted as dotted lines as described in section 7.2.6.2.1. B. Fold Changes for total IgG, A, and M. Data are reported as medians with p-values from 
Wilcoxon-matched pairs signed rank tests. Bold p-values are significant at p<0.05.  
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Table 6.10. Total IgG, IgA, and IgM  vaccine responses (absolute values) to a single dose of PCV-13 
Table 6.11. Total IgG, IgA, and IgM vaccine response (fold changes) to a single dose of PCV-13 
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6.3.4 Associations between CD19+ B-cell populations and serum antibody 
responses to pneumococcal conjugate vaccination (PCV-13) 
6.3.4.1 Do baseline B-cell populations predict WHO threshold responses to PCV-13? 
There were associations found between baseline CD19+ B-cell subpopulations and Pn-
specific IgG pre-and post- vaccine (day 7 and 30) antibody responses (Table 6.12). Marginal 
zone B-cell populations can predict Pn-specific IgG WHO threshold responses at day 7 
(r=0.68, p=0.0342, strong correlation) and 30 post-vaccination (r=0.48, p=0.1593, moderate 
correlation). Switched memory B-cells can also predict WHO threshold responses at day 7 
post-vaccination (r=0.48, p=0.1608, moderate correlation).  
Switched memory (day 30), activated (day 7&30), mature activated (day 7&30), transitional 
(day 7 &30), and exhausted (day 30) B-cells (at baseline) were all found to predict Pn-specific 
WHO threshold responses; however, these associations ranged from very weak to moderate 
correlations.  
However, naïve B-cells (day 7&30), plasmablasts (day 7&30), transitional (day 7&30), and 
exhausted (day 7) B-cells do not correlate with Pn-specific IgG antibody concentrations post-
vaccination (as described in Table 6.12).  
 
 
  
Table 6.12. Baseline CD19+ B-cell populations can predict WHO threshold responses to PCV-13 
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6.3.4.2 Do patients who are classed as good responders versus non-responders to PCV-13 
vaccination have different CD19+ B-cell profiles? 
Patients who reach WHO threshold to > 8 out of 12 Pn serotypes are classed as good 
responders in this analysis. Those who do not reach threshold values for < 8 out of 12 Pn 
serotypes are classed as non-responders with impaired/absent Pn-specific IgG antibody.  
There were no significant differences found between CD19+ B-cell subpopulation profiles 
and Pn-specific IgG pre-and post- vaccine (day 7 and 30) responses (Figure 6.12/Table 6.13).   
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Figure 6.12. CD19+B-cell subpopulation percentages and relationships to good or impaired/absent responses to PCV-13 vaccination. Good responses are classed as patients that reach 
WHO threshold ( 0.35 µg/mL) to >8 out of 12 Pn serotypes and impaired/absent responses are classed as patients that do not reach WHO  threshold and have protection against <8 out 
of 12 Pn serotypes. The percentage of B-cell populations are depicted as box and whisker (minimum to maximum) plots. Mann-Whitney U non-parametrical tests were performed at all 
time points where p< 0.05 is considered significant. 
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Table 6.13. Association between CD19+ B-cell populations and vaccine responses at pre- and post-vaccination (day 7 and 30)  
(according to WHO threshold (0.35 µg/mL) and > 8 out of 12 Pn serotypes protected) 
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6.3.4.3 Do baseline B-cell populations predict total immunoglobulin (IgG, IgA, and IgM) 
responses to PCV-13? 
Very weak to strong correlations were found between baseline CD19+ B-cell subpopulations 
and total IgG, IgA, and IgM (day 7 and 30) antibody responses (Table 6.14).  
Transitional B-cells correlate strongly with total IgG antibody levels at day 7 post-
vaccination (r=0.74, p=0.0174) and moderately at day 30 post-vaccination (r=0.54, p=0.1139). 
Exhausted B-cells were found to correlate moderately with total IgG at day 30 (r=0.41, 
p=0.2475) and total IgA at day 7 (r=0.47, p=0.1786). Marginal zone B-cells correlated 
moderately with total IgM at day 7 (r= 0.49, p=0.1548) and 30 (r=0.54, p=0.1139) post-
vaccination. Switched memory B-cells also correlated moderately with total IgM at day 7 
(r=0.47, p=0.1786) and 30 (r=0.43, p=0.2182).  
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Table 6.14. Baseline CD19+ B-cell populations can predict total immunoglobulin responses to PCV-13 
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6.4. Discussion 
The impact of HIV-infection and changes to peripheral B-cell populations, total serum IgG, 
IgA, and IgM antibody concentrations, and Pn-specific IgG pre- and post-vaccination with 
PCV-13 at day 7 and 30 were investigated in this chapter.  
Plasmablast populations were increased above normal ranges at baseline and day 7 post-
vaccination with PCV-13; however, there was a reduction from day 7 to day 30 post-
vaccination. Increased plasmablast populations are common in the context of HIV-infection  
(319,120). Interestingly, a significant reduction in the percentage of plasmablasts was seen at 
day 30 post-vaccination, which has not been established in prior pneumococcal conjugate 
vaccination studies in HIV-infection. This suggests that there is an attenuation in vaccine 
responses to conjugate vaccination regarding plasmablast populations. This may be due to 
the small group number and the fact that this is an interim analysis of a small pilot study.  
It was chosen not to correlate CD4, VL, and ethnicity with vaccine responses as it was found 
that CD4 and VL are not robust predictors of pneumococcal vaccine responses (178,320).  
Switched-memory B-cell populations were relatively normal compared to normal healthy 
adult reference ranges at baseline and post-vaccination time points; however, there were 
significant reductions seen from baseline to day 7 and 30 post-vaccination. The depletion of 
memory B-cell populations has been evidenced in previous studies, although not in the 
context of pneumococcal vaccination (124,122,289,292,293,295,321).  
Marginal zone B-cell populations were very low compared to normal reference ranges as 
evidenced in the HIV-infected cohort across all vaccination time points. This is of concern as 
marginal zone B-cells play a major role in the immediate response and clearance of 
encapsulated bacteria, particularly pneumococcus (290) . Other studies (although not in the 
context of pneumococcal vaccination) have also supported my observation that CD27+ B-
cells (including marginal zone populations) are depleted in HIV-infection (295,322–324). 
This may be due to the fact that the splenic marginal zone may have atrophied following 
major disturbances to the germinal centres and marginal zone region even early on in HIV-
infection despite being on ARV treatment (325). Interestingly, total IgM serum antibody 
concentrations following pre- and post-vaccination were similar to normal reference ranges 
with no increase in concentrations following PCV-13 vaccination. This is a novel 
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observation, which would need further exploration in future studies by investigating Pn-
specific IgM concentrations.  
All of the patients in this study had commenced ARV treatment, although due to the low 
number of patients in this interim analysis, correlations were not performed on the duration 
of ARV treatment and impact on changes to CD19+ B-cell populations following 
pneumococcal conjugate vaccination. However, other studies (most notably, the  
International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) Strategic 
Timing of AntiRetroviral Treatment (START)) have suggested that starting early ARV 
treatment (when patients have more than 500 CD4+ T-cell counts per cubic millimetre) is 
beneficial than delaying to commence treatment once CD4+ T-cell counts have reduced to 
350 cells per cubic millimetre (274,324,326,121).  
Furthermore, it was found in the HIV-infected patient cohort that there are increased 
activated B-cell populations pre- and post-vaccination, particularly at day 30 post-
vaccination. There is also the presence of mature activated B-cells and exhausted B-cell 
populations, unique to HIV-infection as discussed previously in section 7.1.2. This reflects 
the notion that there are major disturbances to the peripheral B-cell repertoire in HIV-
infection, which may reconstitute post-ARV treatment; however, as this is not a longitudinal 
study, it cannot be established this from this analysis.  
Another interesting finding was the low numbers of immature transitional B-cells at pre-and 
post-vaccination time points, which also reduced further by day 30 post-vaccination 
suggesting attenuation post-vaccination with PCV-13. This is a novel finding as other 
studies have suggested that there is an increase in immature/transitional cells in HIV-
infection (327,328).  
Limitations of this work presented in this chapter include small group numbers as this is an 
interim analysis; however, these findings may be further elucidated following a final 
analysis including all of the patients that have completed the study. Another limitation of 
this work includes the gating of the transitional B-cell and plasmablast populations in 
section 6.2.6.1.1. These gates have been based on B-cell phenotypes from the EUROclass trial 
in CVID (286); however, both B-cell populations may benefit from using different gating 
strategies to further separate both populations.  Furthermore, it is also planned to run Pn-
specific B-cell ELISPOTs, which will help to identify the effects of HIV-infection and the 
memory B-cell response to pneumococcal conjugate vaccination (79,329). 
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It was also found that pre-existing immunity to pneumococcus is impaired at baseline prior 
to pneumococcal conjugate vaccination, with approximately 90% of the HIV-infected 
patients in this analysis classed as non-responders having < 8 out of 12 Pn serotypes that do 
not obtain WHO threshold values. However, by Day 30 post-vaccination, most patients 
(70%) had achieved WHO threshold protection (> 8 out of 12 Pn serotypes).  
However, total IgG, IgA, and IgM serum antibody concentrations (pre-and post-vaccination) 
are relatively normal compared to normal healthy adult control reference ranges.  The total 
IgM serum antibody concentrations pre- and post-vaccination were also quite surprising 
considering that marginal zone B-cell populations (at all vaccination timepoints) and 
plasmablasts (at day 30 post-vaccination) were severely reduced in this HIV-infected cohort, 
which suggests attenuation of the immune response to pneumococcal conjugate vaccination. 
This would need to be further investigated by quantifying the Pn-specific IgM response at 
all pre- and post-vaccination time points. The total IgM antibody concentrations present at 
baseline, day 7, and day 30 post-vaccination may be due to natural, pre-existing antibody 
and potentially, IgM secreted by marginal zone cells (330–334). 
The total IgA antibody levels appeared to decrease at day 7 and recovered by day 30 post-
vaccination. This is a novel finding as one study suggested that IgA antibody levels peak at 
day 14 post-vaccination and then decline very rapidly (335). Another previous study found 
that monomeric IgA is important in the opsonophagocytic response to pneumococcal 
infections 
Low baseline levels of Pn-specific IgG may be due to impairment and loss of memory B-cell 
subsets and has been documented in HIV-infection (124). This study by Titanji et al. has 
suggested that loss of these essential memory B-cell subsets can lead to impairment and 
maintenance of long-term serological memory responses (to prior infections, colonisation, 
and subsequent vaccination) during HIV-infection (124). Furthermore, chronic 
hyperactivation established in HIV-infection may lead to increased numbers of naïve B-cells, 
susceptible to apoptosis, which may affect the generation of circulating memory B-cell 
populations(288). However, increased numbers of naïve B-cells were not seen in this study, 
although I have evidenced that there is a reduction in switched memory B-cells post-
vaccination from baseline and day 7 to day 30.   
There were no associations found between circulating CD19+B-cell responses and good 
versus impaired/absent responses to pneumococcal conjugate vaccination (PCV-13) at all 
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pre-and post-vaccination time points, but this should be considered carefully since these 
results reflect an interim analysis and may change once all of the patients have completed 
the study. Furthermore, there were not many strong correlations found between circulating 
CD19+B-cells and total IgG and IgM responses except for a strong relationship found 
between transitional B-cells and total IgG serum antibody concentrations at day 7 post-
vaccination and mature activated B-cell responses and total IgM serum antibody 
concentrations at day 30 post-vaccination.  
In a previous study, human transitional B-cells were driven by CpG to terminal differentiate 
into plasmablasts producing Pn-specific IgM; however, my observation is a novel finding 
and will need to be further investigated in future studies (336). 
The relationship between mature activated B-cell responses and total IgM serum antibody 
concentrations at day 30 post-vaccination could be attributed to hypergammaglobulinemia, 
which is well established in HIV infection, even though total IgM concentrations appear to 
be within normal reference ranges compared to healthy adults in my study (272). This 
would need to be examined by quantifying Pn-specific IgM concentrations at all vaccination 
time points in my study.  
Several studies have associated reduced memory B-cell subsets and impaired vaccine 
responses in older individuals and in HIV-infected individuals (124,292,293,295,337,338). 
However, although I have evidenced that there are reduced plasmablasts, switched 
memory, marginal zone, and transitional B-cells post-vaccination, it does not appear to 
influence the quantitative Pn-specific IgG response to PCV-13 in HIV-infection. However, 
this will need to be justified by performing qualitative serum antibody testing in 
opsonophagocytic killing assays once all of the HIV-infected patients have completed my 
pilot study discussed in this chapter.   
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Chapter 7. Summary of findings  
7.1    HIV-infection impacts the response to pneumococcal plain 
polysaccharide, Pneumovax-23® PPV-23, vaccination 
In the AIR study, PPV-23 induced poor responses in HIV-infected individuals compared to 
HIV-negative controls. There was also lack of association between CD4+ T-cell counts, viral 
load (VL), and antiretroviral treatment (ARVs) on pneumococcal vaccine responses, which 
challenges previous thinking that individuals with low CD4+ T-cell counts, high viral loads, 
and delaying ARV treatment can benefit responses to pneumococcal vaccination. These 
findings suggested that HIV-infected patients were at risk of bacterial pneumonia and 
invasive pneumococcal disease even if they had high CD4+ T-cell counts and were already 
on ARV treatment. From these findings, a single dose of PPV-23 appeared to be insufficient 
in the HIV-infected cohort. Thus, it was decided to investigate responses to pneumococcal 
conjugate vaccination with the intent of inducing a sustained protective Pn-specific antibody 
response in the HIV-infected cohort.    
7.2 A single dose of Prevenar-13®, PCV-13, is more immunogenic than 
a single dose of Pneumovax-23®, PPV-23 in HIV-infected patients. 
Low proportions of HIV-infected patients were found to have pre-existing Pn-specific IgG at 
baseline, thus there was a need to vaccinate against pneumococci. A single dose of PCV-13 
was found to be more immunogenic than a single dose of PPV-23 in HIV-infected patients. 
A higher proportion of patients that received a single dose of PCV-13 achieved WHO 
threshold protection against >8 out of 12 pneumococcal serotypes included in the PCV-13 
vaccine compared to those that received a single dose of PPV-23. Furthermore, 
opsonophagocytic (OPKA) titres did not correlate with Pn-specific IgG antibody 
concentrations indicating that the quantity does not relate to the quality of Pn-specific IgG, 
perhaps indicating humoral dysregulation in the context of HIV-infection. Further 
assessment of OPKA titres will need to be taken into consideration with regards to opsonic 
ability of Pn-specific IgG post-vaccination in future studies.  
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7.3 A higher proportion of HIV-infected patients achieve WHO 
threshold protection after two PCV-13 vaccines 
A higher percentage of HIV-infected individuals achieved WHO threshold protection 
against pneumococcal serotypes post-vaccination with two doses of PCV-13. Patients that 
received a single dose of PPV-23 followed by a booster dose of PCV-13 achieved similar 
rates of protection to those who received a single dose of PCV-13. Additionally, patients that 
received a single dose of PPV-23 followed by two booster doses of PCV-13 had similar rates 
of protection compared to those who received two doses of PCV-13. The lower rates of 
threshold protection after receiving a single booster dose of PCV-13 following an initial dose 
of PPV-23 suggest hyporesponsiveness.  However, this study demonstrates the effectiveness 
of boosting and that hyporesponsiveness could be overcome by boosting with PCV-13 in 
HIV-infected adults. 
7.4 A single dose of PCV-13 provides a longer period of WHO 
threshold protection compared to a single dose of PPV-23 
HIV-infected patients in the AIR study were followed for a period of 6 years following 
receipt of their initial pneumococcal vaccine dose. Patients who received an initial dose of 
PCV-13 demonstrated that they could retain WHO threshold protection in > 8 out of 12 Pn 
serotypes for a significantly longer period (2 years) than those whose initial dose was PPV-
23 (<1 year). This is an important finding as patients who are administered a dose of PPV-23 
cannot be given another dose of PPV-23 or PCV-13 within five years of their initial dose due 
to hyporesponsiveness, thus leaving a significant proportion of patients vulnerable to 
pneumococcal infection and or invasive pneumococcal disease. 
7.5 There are differences in IgG subclass responses to PPV-23 and 
PCV-13 vaccination 
I have established novel MIA Pn-specific IgG subclass assays, including the assignment of 
Pn-specific IgG1 and IgG2 antibody concentrations to 007sp from 89SF,  that allow for the 
investigation of pneumococcal vaccine responses. This study challenged the idea that a plain 
polysaccharide response is predominantly IgG2-directed and the conjugate vaccine, IgG1-
directed; patients that received PPV-23 vaccination still produced a strong IgG1 response.  
Furthermore, my study has highlighted that the Pn-specific IgG1 and IgG2 responses are 
equivalent at 4-weeks post- PCV-13 vaccination. Additionally, the Pn-specific IgG3 response 
was evidenced to be higher in the PCV-13 vaccine cohort compared to the PPV-23 vaccine 
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cohort. I have also established that there is a granularity in IgG subclass responses, which is 
essential to understanding the IgG response to different pneumococcal vaccines. This study 
shows that Pn-serotype specific assays demonstrate that responses to individual serotypes 
are widely variable and that this granularity cannot be visualised in combined or 
commercially available serotype assays.  
7.6 HIV-infection impacts the immune response to PCV-13   
7.6.1 Pn-specific IgG antibodies 
Pn-specific IgG antibodies were found to be low at baseline in HIV-infected adults in this 
pilot study (B-cell responses to pneumococcal conjugate vaccination), which provides 
validation for pneumococcal vaccination in the context of HIV-infections. Pn-specific 
antibodies increase slightly at day 7 post-vaccination with a higher proportion of HIV-
infected adults achieving threshold protection rates at day 30 post-vaccination. This analysis 
also shows the significant variations in Pn-serotype and individual responses.  
7.6.2 Total Immunoglobulins (IgG, IgA, and IgM) 
This analysis has shown that there is no evidence of hypergammaglobulinaemia in total 
immunoglobulin antibody concentrations in this HIV-infected cohort. Furthermore, the total 
antibody concentrations do not change with pneumococcal vaccination at day 7 or 30.  
7.6.3 CD19+ B-cell populations associated changes with pneumococcal 
vaccination 
This analysis has found that there were low percentages of marginal zone (MZ) B-cells at 
baseline and following PCV-13 vaccination at day 7 and 30, which is a concern as MZ B-cells 
secrete IgM. Switched memory B-cells decreased post-vaccination from baseline to day 30 
post-vaccination; however, there were no significant decreases in total or Pn-specific IgG at 
day 30 post-vaccination. There was an increased number of plasmablasts at baseline, day 7 
and 30 post-vaccination, which could be due to chronic activation of the immune system in 
the context of HIV-infection. Additionally, activated, mature activated, and exhausted B-
cells were present at baseline and post-vaccination, which confirms previous reports of these 
cell populations in HIV-infected adults. Lastly, transitional B-cells were activated at baseline 
and appeared to decrease by day 30 post-vaccination.  
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7.7 Summary 
This study describes the immune response to pneumococcal vaccination in the context of 
HIV-infection. A variety of immunological methods were employed to assess the quantity 
and quality of Pn-specific antibodies produced in response to vaccination. Vaccine-naïve 
HIV-infected patients have low levels of pre-existing Pn-specific IgG antibody, thus 
vaccination is essential in the prevention of pneumococcal infection and IPD.  It was 
established that PPV-23 induces poor responses in HIV-infected adults, which is not 
associated with CD4 counts, viral load, or ARV treatment. Additionally, the AIR study 
evidenced that PCV-13 induces a robust immune response in HIV-infected patients 
compared to PPV-23. Patients who receive an initial dose of PCV-13 can maintain threshold 
protective antibody concentrations for a longer duration than those who receive an initial 
dose of PPV-23. Furthermore, this study has evidenced that boosting is effective in HIV-
infected adults and can potentially overcome hyporesponsiveness. Additionally, the Pn-
specific antibody response is multi-faceted and IgG subclass responses are important in 
understanding the granularity of the immune response to PPV-23 and PCV-13 vaccination. 
There were perturbations to the CD19+ B-cell compartment in HIV-infected patients at 
baseline because of humoral dysregulation, which was associated with responses to PCV-13 
vaccination. Collectively, these findings should be taken into careful consideration when 
deciding optimal pneumococcal vaccination schedules in HIV-infected patients.  
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